

# Oregon Prescription Drug Affordability Board

350 Winter Street NE, Salem, OR 97309-0405 | 971-374-3724 | [pdab@dcbs.oregon.gov](mailto:pdab@dcbs.oregon.gov) | [dfr.oregon.gov/pdab](http://dfr.oregon.gov/pdab)

## Agenda

Date: August 23, 2023 | Time: 9:30 a.m.

**This agenda is subject to change.**

<b>Meeting name</b>	<b>Prescription Drug Affordability Board</b>	<p><b>Board Members:</b> Chair Akil Patterson; Vice Chair Shelley Bailey; Dr. Daniel Hartung; Dr. Richard Bruno; Amy Burns, Robert Judge (A); Dr. Rebecca Spain (A), John Murray (A)</p> <p>*(A) denotes Alternate Member</p> <p><b>Staff:</b> Ralph Magrish, executive director; Cortnee Whitlock, policy analyst; Stephen Kooyman, project manager; Amanda Claycomb, data analyst, Brekke Berg, data analyst, Melissa Stiles, administrative specialist; Jake Gill, counsel; Pramela Reddi, counsel</p>
<b>Meeting location</b>	Virtual	
<b>Zoom link</b>	<a href="#">Register for the meeting</a>	

Subject	Presenter	Time Allotted
<input type="checkbox"/> Call to order, roll call, and <a href="#">approval of minutes</a>	Chair Patterson	5 minutes
<input type="checkbox"/> Executive director’s program update	Ralph Magrish	5 minutes
<input type="checkbox"/> Presentation by Sen. Ron Wyden, chair of the United States Senate Committee on Finance	Sen. Ron Wyden	20 minutes
<a href="#">Board review and discuss existing policies</a>		
<input type="checkbox"/> * Policies and Procedures		
<input type="checkbox"/> * Delegation	Cortnee Whitlock	20 minutes
<input type="checkbox"/> * Conflict of interest		
<input type="checkbox"/> * Public Comment		
<a href="#">Board review of quarterly reports from Drug Price Transparency program (DPT)</a>		
<input type="checkbox"/> * Review 2022 data	Staff	60 minutes
<input type="checkbox"/> * Review of drugs for affordability review		
<input type="checkbox"/> Announcements	Staff	5 minutes
<input type="checkbox"/> Public comment	Chair Patterson	10 minutes
<input type="checkbox"/> Adjournment	Chair Patterson	2 minutes

## Next meeting

Sept. 20, 2023, at 9:30 a.m.

## Accessibility

Anyone needing assistance due to a disability can contact Melissa Stiles at least 48 hours ahead of the meeting at [pdab@dcbs.oregon.gov](mailto:pdab@dcbs.oregon.gov) or 971-374-3724. advance.

## How to submit public comment

### **Oral testimony**

For oral comments, please submit the PDAB Public Comment Form no later than 24 hours before the PDAB meeting. The form is located on the Oregon Prescription Drug Affordability Board website here: <https://dfr.oregon.gov/pdab/Pages/public-comment.aspx>

### **Written testimony**

For written comments, please submit the PDAB Public Comment Form no later than 72 hours before the PDAB meeting. The form is located on the Oregon Prescription Drug Affordability Board website here: <https://dfr.oregon.gov/pdab/Pages/public-comment.aspx>  
Written comments will be posted to the PDAB website.

## Open and closed sessions

All board meetings except executive sessions are open to the public. Pursuant to ORS 192.660, executive sessions are closed, with the exception of news media and staff. No final actions will be taken in the executive session. When action is necessary, the board will return to an open session.



**Oregon Prescription Drug Affordability Board (PDAB) Meeting**  
**Wednesday, July 19, 2023**  
**Draft Minutes**

**Vice Chair Shelley Bailey** called the meeting to order at 9:34 am and asked for the roll call.

**Board members present:** Vice Chair Shelley Bailey, Dr. Amy Burns, Dr. Richard Bruno, Dr. Daniel Hartung, Robert Judge (alternate), Dr. Rebecca Spain (alternate), John Murray (alternate)

**Board members absent:** Chair Akil Patterson, excused

**Vice Chair Bailey** appointed Robert Judge to vote in today's meeting due to a board member absence.

**Approval of the minutes:** **Vice Chair Shelley Bailey** asked if board members had any changes to the June 21, 2023, minutes on Pages 3-5 in the agenda packet: <https://dfr.oregon.gov/pdab/Documents/20230719-PDAB-document-package.pdf> and there were none. **Dr. Amy Burns** moved to approve the minutes and **Robert Judge** provided a second.

**MOTION by Amy Burns to approve the June 21, 2023 minutes.**

**Board Vote:**

Yea: Richard Bruno, Amy Burns, Daniel Hartung, Robert Judge, Vice Chair Shelley Bailey

Nay: None.

**Motion passed.**

**Board Member John Murray** declared a potential conflict of interest due to his ownership of Murray Drugs Incorporated, three independent pharmacies in Eastern Oregon with pharmacy services contracts with PBMs and insurance companies in Oregon.

**Program update: Executive Director Ralph Magrish** said staff signed a contract with the Program on Regulation, Therapeutics, and Law (PORTAL) at the Harvard Medical School and Brigham & Woman's Hospital to provide technical assistance. The effective date of the contract is today. Ralph and Chair Patterson sent a letter to legislative leadership on July 13<sup>th</sup> requesting an extension to complete drug affordability reviews with recommendations to the Legislature by June 30, 2024. Ralph noted his desire to have all work completed by the end of March 2024. He reviewed the updated timeline on [Page 8](#) of the agenda packet.

**Sarah Bartelmann, Oregon Health Authority Cost Growth Target Program Manager**, said the PDAB, the Drug Price Transparency (DPT) program and Cost Growth Target program share the goal of targeting health care costs and market oversight. She shared [data from recent reports](#). The Oregon goal is for health care spending to grow no more than 3.4 percent per year. The program annually looks at key drivers of healthcare costs, including growth in Medicaid and commercial plans, price, utilization, hospital services, and pharmacy costs. They report the information on their website and hold public hearings. Last year the Cost-Growth Target Committee endorsed the Prescription Drug Affordability Board's recommendations and strategies. She reviewed the cost growth drivers between 2013 and 2019 based on claims, data, administrative claims, data from Oregon's, all-payer, all claims database, shown on [Pages 9-32](#) in the agenda packet. The report identified pharmacy costs as a main driver. Pharmacy costs grew almost 200 percent in the Medicare market and almost 80 percent in the commercial market. The claims data does not include pharmacy rebates. **Amy Burns** asked if this considers the state rebates for Medicaid and Sarah Bartelmann said yes, one reason why Medicaid claims are so much higher. Sarah Bartelmann said the report showed growth every year, even with rebates. Pharmacy costs increased 7.6 percent, well above the 3.4 percent target and the 5 percent national trend. Since 2018, per person spending



has increased about 11.5 percent. The report showed pharmaceutical spending totaled more than \$1 billion by 2021. **Daniel Hartung** asked, on [Slide 16](#), how much of the increase was due to growth in enrollment versus changes in prescription spending. Sarah Bartelmann said most of it was due to utilization and enrollment, particularly for Medicaid. **Daniel Hartung** asked about the non-claim circle on [Slide 16](#). Sarah Bartelmann said it captures money a health plan pays to a provider outside of a claim, including value-based payments for performance and quality incentives.

**Robert Judge** noted [Slide 20](#) shows rebate contribution reducing gross spending by about 20 percent for the Medicare Advantage and commercial markets. He asked what rebate portion payers receive and Sarah Bartelmann said it is unknown. **Robert Judge** asked how this rebate offset data compares with other states and Sarah Bartelmann said Colorado and Massachusetts have seen similar trends. **Shelley Bailey** asked if the 2013-2019 reports reflect market anomalies such as Covid and the new blockbuster drugs to treat Hepatitis C and Sarah Bartelmann said yes. They hope to have a website dashboard for looking up specific data to help sort out big markers like blockbuster drugs. **Shelley Bailey** asked about data lag times and Sarah Bartelmann said the next data submission is due in September. The program will collect data for 2022 in September and publish it in early 2024. **Amy Burns** said rebates tend to suppress the market because of preferring one medication over another and asked if the Cost Growth program would be watching for this. Sarah Bartelmann said yes and agreed that protecting market share is a motivation to offering deep rebates and trying to prevent disruption. She invited the board to attend the [public hearing on September 14](#).

**Senate Bill 192: Ralph Magrish, executive director**, discussed the main achievements of Senate Bill 192 as shown on [Pages 33-40](#) of the agenda packet. This bill contains the board's recommendations. The bill achieves:

- New reporting requirement for pharmacy benefit managers (PBMs) in Oregon.
- The board will develop an implementation plan for upper payment limits, including a methodology, an analysis of resources needed, how it would be enforced, and potential savings to the state.
- Allows a combined fee structure for PDAB and the Drug Price Transparency program.
- Makes alternates full board members.

**Health insurer data template review: Cortnee Whitlock**, policy analyst, reviewed the updated timeline on [Page 42](#) of the agenda packet. **Amanda Claycomb**, research analyst, reviewed the data call template on [Pages 50-60](#) that will be sent out by Department of Consumer and Business Services (DCBS). **Vice Chair Shelley Bailey** asked about adding a basis of cost determination field to request from payers NDC code and 340B information. **Robert Judge** said it is an elective field for pharmacies and not required to pay a claim. It would provide some insight but not for decision making. **Shelley Bailey** said she thinks it is an important data point to be able to observe and would provide helpful information. **Ralph Magrish** said they would consult with the Oregon Health Authority.

**Dr. Rebecca Spain** said she appreciates the columns about step therapy and prior authorization requirements for access on [Page 59](#). She wonders if data is available to add another column for the lag time or delay between prescription submission and actual delivery of drugs. She said it would be nice to know the impediment to access. **Amy Burns** said it would be challenging to determine whether it is a true correlation of prior authorization and dispense date. The board could look at it, but not be able to draw conclusions from it. **Robert Judge** agreed. He also asked when the board would discuss therapeutic alternatives, which are very different from therapeutic equivalents. **Ralph Magrish** said staff will discuss with PORTAL when they meet soon.

**PDAB hearing update: Cortnee Whitlock** provided a summary of the comments from the rulemaking hearing held on June 22, including feedback from BIO and PhRMA. She reviewed [Pages 43-46](#) of the agenda packet.



**Affordability review rule updates:** **Cortnee Whitlock** reviewed the proposed changes in the affordability review rule on [Pages 47-49](#). **Shelley Bailey** asked, since pharmacies do not have to submit a diagnosis code for transactions, how will the board determine when a drug is being used to treat a rare disease and when it is not. **Ralph Magrish** said staff doesn't know specifically how to make that determination but they want to keep it as an option for the board's affordability reviews after consulting with the Department of Justice. **Robert Judge** confirmed medical claims include a diagnosis but not pharmacy claims. **Cortnee Whitlock** reviewed the wording for therapeutic alternatives and asked the board for feedback about BIO's proposed definition provided during the rulemaking hearing. **Robert Judge** asked if there would be a reason not to use the U.S. Department of Human Resources (DHS) definition. **Cortnee Whitlock** said the proposed is based on the DHS definition but not identical. **Rebecca Spain** said she prefers the proposed definition because it is more flexible and at the same time more rigorous by showing how something will be defined equivalent through peer-reviewed studies. **Daniel Hartung** said he is not comfortable with the wording about FDA approved for the same indication because many off-label drugs without FDA approval are used consistent with standard medical practice. **Amy Burns** suggested adding a clause about compendia recognized for off-label use for the same indication, which is line with Medicare. **Dr. Richard Bruno** said he agreed about adding a phrase for off label use and suggested moving the last line up.. Board members proposed amending this section of the rule and agreed it was ready for approval with the following amendments:

- A prescription drug that is designated by the United States Food and Drug Administration (FDA), under 21 U.S.C. 360bb, as a drug for a rare disease or condition is not subject to an affordability review. *Added to section (1)(m)*
- In addition to the criteria in subparagraph (1)(m): A prescription drug approved by the FDA for other indications, in addition to a rare disease or condition, is not exempt from an affordability review for those other indications. *Added to section (2)(n)*
- Therapeutic alternative is to mean a drug product that contains a different therapeutic agent than the drug in question, but is FDA-approved, compendia-recognized as off-label use for the same indication, or has been recommended as consistent with standard medical practice by medical professional association guidelines to have similar therapeutic effects, safety profile, and expected outcome when administered to patients in a therapeutically-equivalent dose. *Revised definition for (2)(c).*

**Approval of the affordability review rule:** **Vice Chair Shelley Bailey** asked for a motion to approve the affordability review rule on [Pages 74-78](#) in the agenda packet with the above amendments. **Dr. Amy Burns** moved to approve the rule and **Richard Bruno** provided a second.

**MOTION by Amy Burns to approve the affordability review rule with amendments.**

**Board Vote:**

Yea: Richard Bruno, Amy Burns, Daniel Hartung, Robert Judge, Vice Chair Shelley Bailey

Nay: None.

**Motion passed.**

**Staff member touch base meetings:** **Cortnee Whitlock** reviewed [Pages 79-83](#) of the agenda packet. There are 46 data points to consider for the affordability review process. Staff and board members will meet one on one for consultation about the data points and bring discussion items back to the public board meetings.

**Public comment:** The vice chair allocated three minutes for public comment. Dharia McGrew, state policy director, PhRMA, provided testimony to the board.

**Adjournment:** The meeting was adjourned at 11:23 a.m. by **Vice Chair Shelley Bailey**.



## Summary of 2023 policy updates

**Title:** Policies and Procedures

**Policy Number:** 01

**Annual Approval Date:** July 20, 2022

- Updated all ORS references with links to online statute
- Section 4: Updated term lengths and language under Senate Bill 192
- Section 8: Updated language to clarify public comments
- Section 9: Updated language for posting PDAB meeting recordings to website
- Section 10: Updated number of board members for quorum and split vote decisions
- Section 15: Section was added for board issued iPads
- Some sections had minor edits
- Added footnotes

**Title:** Board Delegation Policy

**Policy Number:** 02

**Annual Approval Date:** July 20, 2022

- Updated all ORS references with links to online statute
- Section 4: Updated language for posting PDAB meeting recordings to website

**Title:** Conflict of Interest

**Policy Number:** 03

**Annual Approval Date:** August 3, 2022

- Updated all ORS references with links to online statute
- Removed references to alternate members
- Some sections had minor edits

**Title:** Public Comment

**Policy Number:** 04

**Annual Approval Date:** January 18, 2023

- Updated all ORS references with links to online statute
- Section 2: Updated language for submission of written and oral comments



**Title:** Policies and Procedures

**Policy Number:** 01

**Annual Approval Date:** July 20, 2022

**Date Issued:** June 23, 2022

**Dates Reviewed:** June 23, 2022; August 23, 2023

**Amendment Date Approved:** July 20, 2022

## 1. Statutory authority.

The Prescription Drug Affordability Board is convened under [ORS 646A.693 through ORS 646A.697](#). Nothing in this document is intended to be contrary to these, or any, rules, statutes, constitutional provisions, or relevant judicial decisions. To the extent there is any inconsistency, the rules, statutes, Constitution, and judicial decisions govern.

## 2. Purpose.

The Prescription Drug Affordability Board is established by statute to protect residents of Oregon, state and local governments, commercial health plans, health care providers, pharmacies licensed in this state, and other stakeholders within the health care system in this state from the high costs of prescription drugs.

The board is directed to collect and evaluate information concerning the cost of prescription drugs in Oregon; perform affordability reviews of those prescription drugs; study the entire prescription drug distribution and payment system in this state and policies adopted by other states and countries that are designed to lower the list price of prescription drugs; and make recommendations to the legislative assembly to make prescription drugs more affordable in the state.

The board is required to provide reports to the Legislative Assembly on the following schedules:

No later than June 1 of each calendar year, the board shall submit a report to the legislative assembly on the generic drug marketplace.

No later than December 31 of each calendar year, the board shall submit a report to both the Legislative Assembly and the Health Care Cost Growth Target program at the Oregon Health Authority that includes:

- (1) Price trends for the list of drugs provided by Department of Consumer and Business Services (DCBS) to the board;
- (2) The prescription drugs reviewed for affordability reviews; and
- (3) Any recommendations for legislative changes necessary to make prescription drugs more affordable in Oregon.

The board has rulemaking authority to adopt criteria for drug affordability reviews and to provide consultation to DCBS in the adoption of annual fees to be paid by manufacturers to meet the cost of program and board administration costs.

### 3. Board member selection process

Individuals interested in serving on the board may apply through the Oregon Boards and Commissions website.<sup>1</sup> Applicants must be residents of Oregon with expertise in health care economics and clinical medicine. Openings will be communicated to the public through a notice or other consumer alert. The board application process is open to the public at all times.

### 4. Term length and vacancies

~~The board consists of eight members appointed by the Governor under Senate Bill 192 (2023), and who are subject to Senate confirmation. The For the initial board, the governor appointed five members and three alternate members on May 10, 2022, who are subject to Senate confirmation. Term durations for each members will be determined based on election of the board is four years after the initial first appointed board member's terms. chairperson and member interest in term durations. Pending member choice, terms to for the first appointed board will be determined are~~ as follows:

- (1) ~~One Two board~~ members ~~and one alternate~~ shall serve for a term ending December 31, 2024.
- (2) ~~Two Three board~~ members ~~and one alternate~~ shall serve for a term ending December 31, 2025.
- (3) ~~Two Three board~~ members, including the chairperson, ~~and one alternate~~ shall serve for a term ending December 31, 2026.

### 5. Conflict of interest

The board's conflict of interest policy is set forth in the Prescription Drug Affordability Board Policy No. 03.

<sup>1</sup> Boards & Commissions, Office of Oregon Governor Tina Kotek, <https://www.oregon.gov/gov/Pages/board-list.aspx>

## 6. Responsibilities of the chair and vice chair

The members of the board will elect one member to serve as chair and one member to serve as vice chair for the duration of their appointment to the inaugural board. The chair provides leadership for the board, presides over all board meetings, and provides strategic planning to help the board comply with its statutory duties and responsibilities. The vice chair presides over a board meeting in their absence. The chair works with board staff to develop board meeting agendas as set forth in Section 8. The chair also ensures member compliance with the Conflict of Interest Policy No. 03.

## 7. Open records and meetings

The board activities are subject to the Oregon Public Meetings Law, [ORS Chapter 192](#). Consistent with those laws, board activities generally will be conducted in public pursuant to public notice requirements, unless public meetings laws permit particular matters to be discussed in executive session to receive legal advice from the Oregon Department of Justice, to consider trade secret, confidential, or proprietary data that is not otherwise available to the public or other grounds found in [ORS 192.660](#).

The board records are generally subject to the Oregon's Public Records Laws, subject to any exclusions from disclosure contained in [ORS 192.340 through ORS 192.390](#).

## 8. Meetings

The board will hold meetings at least every six weeks. The chair of the board may decide to cancel or postpone a meeting when there are no prescription drugs to review whether as a result of incomplete data or the need for further analysis and no other board business to conduct. The meetings may be referred to as meetings or hearings depending on what types of business the board plans to conduct. The board has discretion to set the time for its meetings. The board may decide to adjourn a meeting or hearing to the next available day because a meeting or hearing is running long or for any other reason. A member can participate in person, by phone, or virtually. Board meetings are broadcast live over the internet, other than executive sessions.

The board will provide the opportunity for public comment at each meeting. Public comment can be submitted in writing or alternatively, given orally during the designated time. Persons giving oral comments should introduce themselves with their name and affiliation, if any. The board is not obligated to respond to comments. The amount of time allocated for public comment will be determined by the chair of the board in consultation with board staff.

Unless otherwise invited to speak or present by the board, persons or organizations wanting to offer public oral comment shall identify themselves no later than 24 hours before the PDAB meeting, prior to the beginning of the comment period through a sign-up process administered by board staff. The board's public comment policy is set forth in the Prescription Drug Affordability Board Policy No. 04.

## 9. Meeting agendas, materials, and ~~notes~~recordings

Board staff will post ~~Board meeting minutes, agendas, and~~ notices of upcoming meetings, meeting agendas, packets, minutes, and recordings on the Prescription Drug Affordability Board website. The meeting agenda will be designed, ~~among other things,~~ to ensure the bBoard meets its statutory obligations. The bBoard cChair in collaboration with the sStaff will prepare a draft agenda and provide it to the members prior to the bBoard meeting or hearing.

## 10. Quorum, decisions, and voting

A majority of the ~~five (5)~~eight (8) person board constitutes a quorum. Five members must be present to have a quorum. Voting will be conducted by a member roll call. Motions to conduct board business should flexibly follow the processes set forth in Robert's Rules of Order (e.g. motion, second, discussion, vote). ORS 174.130 requires a majority of board members to concur for the motion to pass. If a vote ends in a tie, the motion fails.<sup>2</sup>

~~Alternate board appointees will participate in all aspects of board activities, including participation in executive session, however they will not hold voting rights unless otherwise designated by the chair person in a member's absence or declaration of a conflict of interest on the issue or drug product brought to a vote by the board.~~

~~The board chair will select an alternate member for voting privileges if a member is not in attendance or available, or if there is a vacant position until filled. The alternate will uphold the same responsibilities as voting members.~~

~~Alternates will be chosen based on the following criteria:~~

~~(1) an alternate who has a conflict of interest will not be chosen;~~

---

<sup>2</sup> Attorney General's Public Records and Meetings Manual 2019, Appendix K – Parliamentary Procedure, Quorums and Voting. Oregon Department of Justice. <https://www.doj.state.or.us/oregon-department-of-justice/public-records/public-records-and-meetings-law/>

- ~~(2) an alternate who has been present for more of the substantive discussions of the subjects under consideration will be given priority over an alternate who has been absent;~~
- ~~(3) an alternate who can commit to attendance at future meetings if the appointment will continue beyond the current meeting will be given priority over an alternate who cannot; and~~
- ~~(4) priority will be given to an alternate who not been previously designated as a voting member over one who has been previously chosen.~~

~~If, after applying the criteria in (1)–(4), there is no prioritized alternate, alternates will be chosen in alphabetical order by last name.~~

## 11. Executive session

The board may, at any time, retire into executive session to consult with the assigned assistant attorney(s) general at the Oregon Department of Justice or as permitted by [ORS 192.660](#). The board will meet in executive session to discuss trade secret information. The board will not deliberate concerning whether to subject a prescription drug to an affordability review, or otherwise make any final decision of the board in executive session.

Upon reconvening the open meeting at the conclusion of the executive session, all members will maintain the confidentiality of the information discussed and/or legal advice provided in executive session.<sup>3</sup> The board will ensure that electronic recordings of executive sessions are securely stored and will only be disclosed if required under the Oregon Public Records Law, [ORS Chapter 192](#).

## 12. Meeting attendance, absences, and participation

Board members ~~and alternate appointees~~ are expected to make every effort to attend board meetings. Members may participate in a meeting in person, by telephone, or any other means of electronic communication by which all persons participating in the meeting can hear each other at the same time. If a member is unable to attend a meeting, the member must notify the chair and executive director prior to the meeting. Under [ORS 182.010 through ORS 182.020](#), any member of a state board or commission appointed by the governor who fails to attend two consecutive meetings of the board or commission, whether regular, adjourned or special, shall forfeit office unless the member is prevented from attending by the serious illness of a member or the family of the member or for any

---

<sup>3</sup> [Attorney General's Public Records and Meetings Manual 2019, II. Public Meetings, E. Executive \(Closed Sessions\). Oregon Department of Justice. https://www.doj.state.or.us/oregon-department-of-justice/public-records/attorney-generals-public-records-and-meetings-manual/ii-public-meetings/#\\_Toc11743475](#)

other cause that in the judgment of the governor constitutes a valid reason for failing to attend. The governor shall immediately appoint a successor.

### **13. Board members are public representatives**

Members of the board are public representatives, appointed by the governor to protect residents of this state, state and local governments, commercial health plans, health care providers, pharmacies licensed in this state and other stakeholders within the health care system in this state from the high costs of prescription drugs. Members accept appointment to the board with the understanding that they will represent the public interest in their actions and decisions on the board.

### **14. Use of state email accounts**

State email accounts should be used only to send or receive information to or from the board staff. When sending or replying to board staff, members should not reply all so as to avoid a situation of appearance of board business being discussed in a setting that should otherwise be public. If board members receive communications from the public about board business, board member should forward those communications to the PDAB Executive Director Ralph Magrish at [Ralph.M.Magrish@dcbs.oregon.gov](mailto:Ralph.M.Magrish@dcbs.oregon.gov).

### **15. Board Issued iPads**

Board members are provided iPads and should be used only to conduct board business. Board members are to log into their iPads regularly and comply with security procedures and instructions to update systems when notified through email. If a member has an any login issues, the iPad is damaged, or stolen they are to contact DFR Techs or PDAB staff as soon as possible.

Members are to return their iPads to DFR Techs or PDAB staff once their service term ends.

### **15.16. Coordinating with other entities**

The board may, from time to time, coordinate with other boards, commissions, industry, educational institutions, and state agencies where the responsibilities and interests overlap in creating transparency for the cost of prescription drugs and determining the affordability of prescription drugs for Oregon consumers.

### **16.17. Interaction with the media and lobbyists**

Unless otherwise delegated to them by a majority vote of the board, individual board members do not have the authority to speak on behalf of the board. The board operates as a single entity when communicating with external parties. If board members receive media

requests related to their board work and participation, they should notify the PDAB Executive Director Ralph Magrish at [Ralph.M.Magrish@dcbs.oregon.gov](mailto:Ralph.M.Magrish@dcbs.oregon.gov).

#### **17.18. Department of Consumer and Business Services staff**

~~Board Staff from the Department of Consumer and Business Services~~ shall provide support to the board including serving as the recording secretary for the board; coordinating board meeting times, location (virtual or otherwise), materials, and other logistics; compiling information necessary for the board to conduct affordability reviews, administrative rule development, drafting and filing, policy issue brief development, data analysis, and additional tasks as delegated by the board.

The staff may also provide support to the board in preparing policy recommendations to the Legislative Assembly and preparation of annual reports to the Legislative Assembly (pursuant to [ORS 646A.693 through ORS 646A.697](#)).

The ~~Department of Consumer and Business Services-DCBS~~ on behalf of the board, may enter into contracts with qualified, independent third parties for services necessary to carry out the powers and duties of the board. All contractors are required to enter into a nondisclosure agreement to protect trade secret, confidential, or proprietary information.

The board may also delegate particular tasks to ~~the Department of Consumer and Business ServicesDCBS~~ on a case-by-case basis to perform its duties.

#### **18.19. Annual review**

The board will review this policy and the conflict of interest policy at least annually.



**Title:** Board Delegation Policy

**Policy Number:** 02

**Annual Approval Date:** July 20, 2022

**Date Issued:** June 23, 2022

**Dates Reviewed:** June 23, 2022; July 20, 2022; August 23, 2023

### 1. Statutory authority

The Prescription Drug Affordability Board is convened under [ORS 646A.693 through 646A.697](#). Nothing in this document is intended to be contrary to these, or any, statutes, constitutional provisions, or relevant judicial decisions. To the extent there is any inconsistency, the statutes, constitution, and judicial decisions govern.

### 2. Purpose

- a. To clarify when staff within the Department of Consumer and Business Services (DCBS) may perform work on behalf of the Prescription Drug Affordability Board.
- b. To provide guidance to the board regarding their duties and responsibilities with respect to staff.

### 3. Board support

Staff from the Department of Consumer and Business Services shall provide support to the board including serving as the recording secretary for the board; coordinating board meeting times, location (virtual or otherwise), materials, and other logistics; compiling information necessary for the board to conduct affordability reviews, administrative rule development and drafting, policy issue brief development, data analysis, and additional tasks as delegated by the board.

Staff may also provide support to the board in preparing policy recommendations to the Legislative Assembly and preparation of annual reports to the Legislative Assembly pursuant to [ORS 646A.696 through 646A.697](#).

DCBS, with the approval from the board, may enter into contracts with qualified, independent third parties for services necessary to carry out the powers and duties of the board. All third-party contractors are required to agree to contractual provisions that address confidentiality and non-disclosure to protect trade-secret, confidential, or proprietary information. Third party contractors are to disclose any conflict of interests prior to entering into contract agreement and if any conflicts occur under the time of the contract.

The board may also delegate particular tasks to DCBS on a case-by-case basis to perform its duties.

#### 4. Policy statement

The board delegates its authority to Staff to perform the following functions on the Board's behalf. The board may also delegate its authority to staff in other specific policies and procedures, or during meetings through oral direction or by written resolution. The board may elect to perform any of these duties at its discretion, including delegation of any of these duties to an individual board member.

##### Board meetings pursuant to Oregon Public Meetings Law, [ORS Chapter 192](#)

- a. Facilitate public meetings and board executive sessions, including scheduling meetings, arranging meeting platforms and/or locations, and sending calendar invitations and board-related notices.
- b. Provide public notice of board meetings and agenda items on the board website and Oregon Transparency website.
- c. Develop agendas for board meetings in coordination with the board chair.
- d. Serve as the recording secretary for the board and prepare meeting minutes for consideration by the board.
- e. Prepare board materials.
- f. Distribute agenda and materials in support of the board agenda to each board member.
- g. Review meeting materials and agenda items with legal counsel prior to the board meeting.
- h. Record all meetings.
- i. Provide minutes and recordings of board meetings on the board website.
- j. Record and securely store recordings of all executive sessions entered into by the board at board meetings.

##### Contracts

- a. Pursuant to and in compliance with state law and procurement policies, facilitate contracts for work deemed necessary by the board to carry out its powers and duties and ensure contract deliverables requested by the board, if any, are prepared and presented to the board.
- b. The board determines that to necessarily carry out its powers and duties, DCBS is authorized to contract on its behalf for work related to the following:

- i. Data identification, collection, and analysis related to pharmaceutical markets and supply chains, prescription drug pricing, and other state and federal programs related to prescription drug pricing;
- ii. Data, research, analysis, and supporting materials to inform the process for and conducting of affordability reviews;
- iii. Equity and cultural responsiveness related to the Board's activities; and
- iv. Data, research, analysis, and supporting materials for board consideration in identifying potential policy recommendations to the Legislative Assembly and compiling board recommendations.

#### Administration

- a. Serve as the custodian of record for the board in accordance with Oregon Public Records law ([ORS Chapter 192](#)).
- b. Maintain records for the board in accordance with board retention policies and all applicable laws and regulations, including but not limited to securely storing information, documents, and records received by the board and executing the board's destruction policy.
- c. Establish and maintain an electronic mail account for the board for submission of public comment, public inquiries, or submissions of information for board consideration.
- d. Receive and respond to requests related to the board in accordance with any applicable board policies and all applicable laws and regulations and seek assistance of legal counsel in connection with any such request, if necessary.
- e. The executive director or any other staff for the board may accept service on behalf of the board.
- f. Draft and issue correspondence on behalf of the board, including with stakeholders, to communicate board positions and determinations, provide notice of board activities, respond to administrative or ministerial requests made to the board, and/or seek additional information on behalf of the board.
- g. Receive and maintain documents and correspondence addressed or submitted to the board and ensure the board's review of such materials, if necessary.
- h. Draft reports and memoranda pertaining to work completed by or on behalf of the board.
- i. Maintain the board's public webpage and ensure the webpage contains the following:
  - i. Conflicts of interest disclosed to the board pursuant to [ORS 646A.693](#).
  - ii. Reports prepared for the Health Care Cost Growth Target program pursuant to [ORS 646A.696](#).

- iii. Reports prepared for the Legislative Assembly pursuant to [ORS 646.697](#).
- iv. Notice of board meetings and hearings.
- v. All agendas, non-confidential and non-privileged meeting materials, and board-approved meeting minutes.
- vi. List of board members.
- vii. Instructions for submitting materials for the board's consideration.
- viii. Contact information for submitting requests pursuant to Oregon Public Meetings Law, [ORS Chapter 192](#).
- ix. Policies and procedures adopted by the board.
- x. Resolutions, orders, and any other memorialized decisions by the board.
- xi. Findings, reports, and studies conducted by the board, redacted for confidential information as necessary.
- xii. Notices of proposed rulemaking and rulemaking hearing information.
- xiii. Regulations and guidance adopted by the board.
- xiv. List of all prescription drugs the board determines to be unaffordable.
- xv. Any material specifically requested by the board.

#### Support for performance of board duties

- a. Facilitate rulemaking conducted by the board, including but not limited to:
  - i. Draft rules for consideration by the board.
  - ii. Effectuate publication and/or filing of notices of draft proposed regulations approved by the board, and adopted rules in the Oregon Bulletin, on the Oregon Secretary of State's website.
  - iii. Submit requests for advice from Oregon Department of Justice.
  - iv. Compile the official rulemaking record for all rulemaking conducted by the board, including receipt and inclusion of any public comments.
- b. Collect and provide conflicts of interest to the board:
  - i. Distribute conflict of interest forms and coordinate completion of disclosures when required by law.
- c. Draft reports required by [ORS 646A.696](#) and [ORS 646A.697](#), and present drafts to the board for review, amendment, and approval.
- d. Coordinate with legislative staff regarding any legislative hearings or presentations.
- e. Coordinate the secure collection of and access to data and information on behalf of the board pursuant [ORS 646A.694](#), [ORS 646A.696](#), and [ORS 646A.697](#), including by working with other state agencies, stakeholders, and presenting material received to the board, and entering into memoranda of understanding or data use agreements as needed and

approved by the board.

- f. Request notification and copies of any notices of membership withdrawal received by the board pursuant to [ORS 646A.693](#).
- g. Assist in the collection and presentation of data, information, or analysis necessary for the board to perform its duties related to affordability reviews and as may be further specifically addressed in other board policies.



**Title:** Conflict of Interest

**Policy Number:** 03

**Annual Approval Date:** August 3, 2022

**Date Issued:** Aug. 3, 2022

**Dates Reviewed:** Aug. 3, 2022; [August 23, 2023](#)

**Amendment Date Approved:** Aug. 3, 2022

## 1. Purpose

To ensure that the Oregon Prescription Drug Affordability Board conducts business for the benefit of the public and in the absence of personal, financial, or otherwise improper interests. The purpose of this policy is to describe the statutory requirements regarding conflicts of interest.

## 2. ORS Chapter 244

Board members will adhere to the requirements of [ORS Chapter 244](#), the Government Ethics Act, and the Oregon Administrative Rules, [Chapter 199](#), of the Oregon Government Ethics Commission (OGEC), which can be found here:

<https://secure.sos.state.or.us/oard/displayChapterRules.action?selectedChapter=143>

Guidance regarding these laws can be found on the OGEC website:

<https://www.oregon.gov/ogec/Pages/default.aspx>

Board members will disclose, in accordance with subsection 4 of this policy, any potential or actual conflicts of interest as defined in [ORS 244.020\(1\) and \(13\)](#):

(1) “Actual conflict of interest” means any action or any decision or recommendation by a person acting in a capacity as a public official, the effect of which would be to the private pecuniary benefit or detriment of the person or the person’s relative or any business with which the person or a relative of the person is associated unless the pecuniary benefit or detriment arises out of circumstances described in subsection (13) of this section.”

(13) “Potential conflict of interest” means any action or any decision or recommendation by a person acting in a capacity as a public official, the effect of which could be to the private pecuniary benefit or detriment of the person or the person’s relative, or a business with which the person or the person’s relative is associated, unless the pecuniary benefit or detriment arises out of the following:

- (a) An interest or membership in a particular business, industry, occupation or other class required by law as a prerequisite to the holding by the person of the office or position.
- (b) Any action in the person's official capacity which would affect to the same degree a class consisting of all inhabitants of the state, or a smaller class consisting of an industry, occupation or other group including one of which or in which the person, or the person's relative or business with which the person or the person's relative is associated, is a member or is engaged.
- (c) Membership in or membership on the board of directors of a nonprofit corporation that is tax-exempt under section 501(c) of the Internal Revenue Code."

Board members, under [ORS 244.120 \(2\)](#), will also:

- (a) When met with a potential conflict of interest, announce publicly the nature of the potential conflict prior to taking any action as a board member; or
- (b) When met with an actual conflict of interest, announce publicly the nature of the actual conflict and:
  - (A) Except as provided in subparagraph (B) of this paragraph, refrain from participating as a board member in any discussion or debate on the issue out of which the actual conflict arises or from voting on the issue.
  - (B) If the board member's vote is necessary to meet a requirement of a minimum number of votes to take official action, be eligible to vote, but not to participate as a public official in any discussion or debate on the issue out of which the actual conflict arises.

*Please note that if the requirements of recusal under [ORS 646A.693](#) apply, the board member must recuse themselves from the decision, even if the board member would otherwise be allowed to vote under [ORS 244.120\(2\)\(b\)\(B\)](#).*

### 3. ORS 646A.693

Board members will adhere to the requirements of [ORS 646A.693](#) as follows:

#### Recusal

- (a) A member of the board shall recuse ~~the member themselves~~ from decisions related to a prescription drug if the member, or an immediate family member of the member, has received or could receive any of the following:

- (A) A direct financial benefit of any amount deriving from the result or finding of a study, review or determination by or for the board; or
  - (B) A financial benefit from any person that owns, manufactures, or provides prescription drugs, services or items to be reviewed by the board that in the aggregate exceeds \$5,000 per year.
- (b) For the purposes of paragraph (a) of this subsection, a financial benefit includes honoraria, fees, stock, the value of the member's or immediate family member's stock holdings and any direct financial benefit deriving from the result or finding of a study, review or determination by or for the Board.

#### **Disclosure of conflicts of interest**

- (c) A conflict of interest shall be disclosed:
- (A) By the board when hiring board staff;
  - (B) By the governor when appointing members ~~and alternate members~~ to the board; and
  - (C) By the board, when a member of the board is recused in any final decision resulting from a review of a prescription drug.
- (d) A conflict of interest shall be disclosed at the earlier of:
- (A) Prior to the first board meeting after the conflict is identified; or
  - (B) Within five days after the conflict is identified.
- (e) A conflict of interest disclosed under this section shall be posted on the website of the board unless the chair of the board recuses the member from any final decision resulting from a review of a prescription drug.
- (f) A posting under paragraph (e) of this subsection shall include the type, nature and magnitude of the conflict of interest of the member involved.

#### **Gifts**

Members ~~and alternate members~~ of the board, staff, and third parties that contract with the board may not accept any gift or donation of services or property that creates a potential conflict of interest or has the appearance of biasing the work of the board.

#### **4. Procedures for identifying and managing conflicts of interest**

Prior to each board meeting, board members will review the draft agenda and identify any potential or actual conflicts of interest under ~~ORS 646.120~~ or [ORS 244.120](#) or [ORS 646A.693](#) (conflict of interest).

When a board member determines they have a conflict of interest, the board member must inform the board chair and vice-chair, recuse themselves and fill out and submit the conflict of interest form to [pdab@dcbs.oregon.gov](mailto:pdab@dcbs.oregon.gov).

The board member will also notify the board staff to help ensure that the member does not have access to information on matters for which the member must recuse themselves and to ensure the conflict of interest is appropriately posted.

Potential contractors will disclose any prior or current work in the pharmaceutical business sector that could give rise to a potential or actual conflict of interest as defined in [ORS 244.020](#).

Contractors will ensure that qualified personnel selected to perform work for the board have no professional, familial or financial conflict of interest relating to the pharmaceutical business sector. In connection with any particular project or work to be performed, the board reserves the right to reject any proposed personnel. In the event the board rejects the proposed personnel, the contractor will be required to provide other personnel who are acceptable to the board.

## 5. Annual review

The board will review this policy at least annually.



**Title:** Conflict of Interest Form

**Policy Number:** 03

**Annual Approval Date:** August 3, 2022

**Date Issued:** Aug. 3, 2022

**Dates Reviewed:** Aug. 3, 2022; [August 23, 2023](#)

## CONFLICT OF INTEREST FORM

The Prescription Drug Affordability Board (PDAB) asks that you complete this conflict of interest disclosure required ~~ments in~~ by [ORS Chapter 244](#).

This form is due annually ~~when or when~~ a conflict is disclosed by a board member under [ORS 646A.693](#) or when a conflict is disclosed by a contractor under [ORS 244.020](#). You may wish to retain a copy of this form.

**Instructions:** Please fill in the appropriate box. If a conflict of interest is indicated, fill out questions 1 and 2 and include activities occurring currently or during the past year. Return by email to: [pdab@dcbs.oregon.gov](mailto:pdab@dcbs.oregon.gov)

Declaration (check one):

- I confirm that neither I nor any immediate family member nor any business with which I am associated have any personal or business interest in or potential for personal gain from any of the organizations or projects linked to PDAB. I also confirm that the disclosed information is correct and that no other situation of real, potential or apparent conflict of interest is known to me. I undertake to inform the board chair of any conflict or potential conflict of which I become aware immediately following any announcement by the board or the PDAB staff which may concern me. I also undertake to inform the board chair of any change in these circumstances, including – if an issue arises – during the course of my association with PDAB as a board member, board staff, contractors, and assigned assistant attorneys general.
- I confirm that I or my immediate family member have a financial or other interest in the subject/matter of the work in which I will be involved, which may be considered as constituting a real, potential or apparent conflict of interest.  
*If this section is checked please answer the following questions.*

**1. Financial benefit**

If you or an immediate family member (see definition below) have a direct or indirect ownership or investment, or can benefit from any person that owns, manufactures, or provides prescription drugs, please note the name of the source, ownership percentage and any income generated from the ownership or investment interest. Financial benefit includes honoraria, fees, stock, the value of the member’s or immediate family member’s stock holdings and any direct financial benefit deriving from the result or finding of a study, review or determination by or for the board.

Name & address of source	Financial benefit	Received by

**Immediate family member** - Means any person living in the same household as a board member, a staff member, and/or a contractor working on behalf of the board.

Does an income source listed above do business, or could it reasonably be expected to do business, with the public body you wish to serve or over which you may have authority? **Yes**  **No**

Does an income source listed above have a legislative or administrative interest in the public body you wish to serve or over which you may have authority? **Yes**  **No**

**2. Shared business with lobbyist**

If you or a member of your household shared a partnership, joint venture, or similar substantial economic relationship with a paid lobbyist during the immediately preceding calendar year, or were employed by or employed a paid lobbyist during that time, please list the following: Note: owning stock in a publicly-traded company in which the lobbyist also owns stock is not a relationship which requires disclosure.

Name of Lobbyist	Business Name	Business Type

_____	_____
<b>Name</b>	<b>Date</b>
_____	
<b>Signature</b>	
<p style="text-align: center;"><b>Please return by email to: <a href="mailto:pdab@dcbs.oregon.gov">pdab@dcbs.oregon.gov</a></b></p>	

From the Oregon Government Ethics Commission, A Guide for Public Officials can be reviewed at:  
<https://www.oregon.gov/ogec/Documents/2021%20PO%20Guide%20Final%20Adopted.pdf>.



**Title:** Public Comment

**Policy Number:** 04

**Annual Approval Date:** January 18, 2023

**Date Issued:** Aug. 3, 2022

**Dates Reviewed:** Aug. 3, 2022; Aug. 17, 2022; Jan. 18, 2023; [August 23, 2023](#)

**Amendment Date Approved:** Jan. 18, 2023

## 1. Purpose

The opportunity for public comment will be provided at each Prescription Drug Affordability Board (PDAB) meeting according to [ORS 646A.693\(13\)](#).

## 2. Policy Statement

The Prescription Drug Affordability Board welcomes public comment during board meetings. Board members generally will not respond to public comments during a meeting. Public comments may be submitted in writing or given orally during the designated time by completing the PDAB public comment form provided on the PDAB website.

The PDAB public comment form's purpose is to:

- 1) Sign up to provide comments;
- 2) Assist board staff with time allotments for meeting agenda items; and
- 3) Disclose interest or affiliation.

Having an interest or affiliation does not prevent written or oral comments from being provided, but is included on the form for transparency purposes. Prior to the public comment, the board chair will state whether the form has been completed and any interest or affiliation of the speaker.

### Written comments

~~The Board For~~ For written comments, the PDAB public comment form is to be submitted [no later than 72 hours before the PDAB meeting. The form is located on the Oregon Prescription Drug Affordability Board website. Written comments will be posted to the PDAB website.](#)

~~will receive written public comments and the PDAB public comment form through the Prescription Drug Affordability Board at <https://dfr.oregon.gov/pdab/Pages/public-comment.aspx> and the PDAB public comment form through the Prescription Drug Affordability Board at [https://dfr.oregon.gov/pdab/Pages/public-comment.aspx](mailto:pdab@dcbs.oregon.gov) and the PDAB public comment form through the Prescription Drug Affordability Board at [https://dfr.oregon.gov/pdab/Pages/public-comment.aspx](mailto:pdab@dcbs.oregon.gov). The form includes fields for the name, organization and topic item for persons submitting written testimony. Written public comments~~

~~submitted less than 72 hours before a board meeting will be considered at the following meeting. Beginning Jan. 1, 2023, all written public comments will be posted to the PDAB website. Board staff will post these comments online in advance of the meeting date, following submission requirements.~~

### Oral comments

~~Persons~~ For oral comments, the PDAB public comment form is to be submitted no later than 24 hours before the PDAB meeting. The form is located on the Oregon Prescription Drug Affordability Board website. ~~Interested in providing oral public comments may sign up by completing the PDAB public comment form <https://dfr.oregon.gov/pdab/Pages/public-comment.aspx> and emailing it to [pdab@dcbs.oregon.gov](mailto:pdab@dcbs.oregon.gov) no later than 24 hours before the meeting.~~ Individuals who did not sign up before the deadline will have the opportunity to speak at the next meeting ~~after completing the PDAB public comment form~~. Speakers will be called to speak in the order in which they sign up. The board chair will ask the speakers to introduce themselves with their name and affiliation, if any.

The amount of time allocated for oral public comment will be determined by the board chair in consultation with board staff. When there are multiple requests to comment on a particular topic, the board chair may limit or expand the total time for comment or reduce the time allotted for each speaker. Any changes will be announced at the beginning of the public comment agenda item.



Oregon Prescription Drug  
Affordability Board

The following information is the data provided by the Drug Price Transparency program to be used for the board affordability review. PDF documents are provided in this board packet. But please click below to access the data spreadsheets in Excel format:

[Prescription drug data web page](#)

Click on individual spreadsheet links below:

- \* **DPT carrier data 2022**
- \* **2022 CCO Top Costs Claims**
- \* **DPT manufacturer data annual price increase report 2022**
- \* **DPT manufacturer data new specialty drugs report 2022**
- \* **Insulin data analysis 2021 through 2022**

## DPT carrier data

### Data source:

Data pulled from the annual insurance carrier reporting to the Oregon Drug Price Transparency (DPT) program. Data for the year 2022.

### Top 25 list abbreviations and definitions

List abbreviation	List name	List details and notes
GI	Greatest increase	<p>The top 25 drugs causing the greatest increase in total plan spending one year to the next. Carriers are required to report the prescription drugs causing greatest increase in total plan spending from the current experience period to the previous experience period. This list considered total annual spending, including the net impact of any rebates or other price concessions.</p> <p>Drugs were ranked by the drug causing the largest year-over-year increase, when factoring in the impact of rebates and price concessions.</p> <p>Year-over-year increase is reported as the total annual spending from the previous year minus the total annual spending from two years' prior to the reporting year. For example, during the 2023 reporting year, the year-over-year increase was the total annual spend from 2022 minus the total annual spend from 2021.</p>
MC	Most costly	<p>The top 25 most costly drugs reported by prescription drug products, from both pharmacy and medical benefits, contributing the largest cost to total annual spending. This list considered the net impact of any rebates or other price concessions that impacted the total annual spending for the reported experience period. Drugs were ranked by the drug causing the largest cost to total annual spending, when factoring in the impact of rebates and price concessions.</p>
ME	Most expensive	<p>The top 25 drugs that had the highest cost per prescription.</p>
MP	Most prescribed	<p>The top 25 most prescribed drugs reported by the number of claims received. List includes prescription drugs covered under both the pharmacy and medical benefits. Drugs were ranked by the highest number of prescription drug claims.</p>

### Other terms

Term	Definition/ notes
Has orphan designation(s) per FDA	<p>Values were marked in this field based on a list exported from the FDA's orphan drug designations and approvals database: <a href="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm">https://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm</a></p>

DPT carrier data - top drugs to review

Therapy class	Proprietary name(s)	Non-proprietary name	Number of prescriptions	Number of enrollees	Total annual spend	Year over year increase	Average cost per prescription	List type	Total lists	Has orphan designation(s) per FDA	Was the drug listed on the CCO lists
ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS	Vyvanse	Lisdexamfetamine Dimesylate	21,520	4,663	\$7,558,385	\$1,104,457	\$351.23	MC	1	No	Top Costs
ANALGESICS - ANTI-INFLAMMATORY	Enbrel / Enbrel SureClick	Etanercept	4,805	644	\$22,017,823	\$89,696	\$4,582	MC / ME	2	Both Orphan and Non-Orphan	Top Costs
ANALGESICS - ANTI-INFLAMMATORY	Humira / Humira Pediatric Crohns Start / Humira Pen / Humira Pen-CD/UC/HS Starter / Humira Pen-Pediatric UC Start / Humira Pen-Ps/UV/Adol HS Start / Humira Pen-Psor/Uveit Starter	Adalimumab	14,283	1,842	\$75,241,110	\$3,682,844	\$5,268	MC / GI / ME	3	Both Orphan and Non-Orphan	Top Costs / Top Cost Change
ANTICOAGULANTS	Eliquis / Eliquis DVT/PE Starter Pack	Apixaban	15,396	3,574	\$8,812,210	\$1,296,820	\$572.37	MC	1	No	Top Costs / Top Cost Change
ANTIDIABETICS	Trulicity	Dulaglutide	13,176	2,702	\$8,970,087	\$907,047	\$680.79	MC	1	No	Top Costs / Top Cost Change
ANTIDIABETICS	Rybelsus / Ozempic	Semaglutide	16,774	3,657	\$10,581,528	\$3,238,534	\$631	MC / GI	2	No	Top Costs / Top Cost Change
ANTIDIABETICS	Jardiance	Empagliflozin	17,174	4,160	\$7,262,309	\$1,632,440	\$423	MC / GI	2	No	Top Costs / Top Cost Change
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Keytruda	Pembrolizumab	1,611	269	\$28,248,898	\$11,840,653	\$17,535	MC / GI / ME	3	Both Orphan and Non-Orphan	Top Costs / Top Cost Change
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Opdivo	Nivolumab	887	109	\$10,884,240	\$2,274,979	\$12,271	MC / GI / ME	3	Both Orphan and Non-Orphan	Top Costs / Top Cost Change
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Lenalidomide / Revlimid	Lenalidomide	627	122	\$10,432,994	\$2,350,557	\$16,640	MC / GI / ME	3	Orphan Only	Top Costs
ANTIVIRALS	Biktarvy	Bictegravir-Emtricitabine-Tenofovir Alafenamide Fumarate	5,108	978	\$26,988,465	\$1,926,579	\$5,284	MC / GI / ME	3	Orphan Only	Top Costs / Top Cost Change
DERMATOLOGICALS	Tremfya	Guselkumab	708	144	\$4,336,168	\$1,575,599	\$6,125	GI / ME	2	No	Top Cost Change
DERMATOLOGICALS	Skyrizi / Skyrizi Pen	Risankizumab-rzaa	1,199	372	\$15,517,811	\$8,385,287	\$12,942	MC / GI / ME	3	No	Top Cost Change
DERMATOLOGICALS	Stelara	Ustekinumab	2,717	615	\$28,957,943	\$3,077,394	\$10,658	MC / GI / ME	3	No	Top Costs / Top Cost Change
DERMATOLOGICALS	Dupixent	Dupilumab	4,406	577	\$12,665,407	\$3,333,668	\$2,875	MC / GI / ME	3	Both Orphan and Non-Orphan	Top Costs / Top Cost Change
DERMATOLOGICALS	Cosentyx / Cosentyx Sensoready Pen / Cosentyx Sensoready	Secukinumab	4,401	590	\$18,723,855	\$2,560,019	\$4,254	MC / GI / ME	3	No	Top Costs / Top Cost Change
GASTROINTESTINAL AGENTS - MISC.	Entyvio	Vedolizumab	2,038	354	\$17,655,131	\$2,801,800	\$8,663	MC / GI / ME	3	No	Top Costs / Top Cost Change

DPT carrier data - top drugs to review

Therapy class	Proprietary name(s)	Non-proprietary name	Number of prescriptions	Number of enrollees	Total annual spend	Year over year increase	Average cost per prescription	List type	Total lists	Has orphan designation(s) per FDA	Was the drug listed on the CCO lists
GASTROINTESTINAL AGENTS - MISC.	Inflixtra	Infliximab-dyyb	6,209	1,075	\$16,516,923	\$5,489,239	\$2,660	MC / GI / ME	3	No	Top Costs / Top Cost Change
HEMATOLOGICAL AGENTS - MISC.	Ultomiris	Ravulizumab-cwvz	88	19	\$8,640,498	\$2,566,297	\$98,187	MC / GI	2	Orphan Only	No
HEMATOLOGICAL AGENTS - MISC.	Hemlibra	Emicizumab-kxwh	146	13	\$6,574,803	\$2,584,640	\$45,033	MC / GI	2	Orphan Only	Top Costs / Top Cost Change
NEUROMUSCULAR AGENTS	Botox	OnabotulinumtoxinA	5,940	1,873	\$6,673,692	\$710,048	\$1,123.52	MC	1	Both Orphan and Non-Orphan	Top Costs
OPHTHALMIC AGENTS	Eylea	Aflibercept	2,626	471	\$8,222,980	\$1,059,030	\$3,131	MC / ME	2	Both Orphan and Non-Orphan	Top Costs / Top Cost Change
PASSIVE IMMUNIZING AND TREATMENT AGENTS	Gammagard / Gammaked / Gamunex-C	Immune Globulin (Human) IV or Subcutaneous	2,339	129	\$10,747,945	\$4,312,556	\$4,595	MC / GI / ME	3	Both Orphan and Non-Orphan	Top Cost Change
PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC.	Ocrevus	Ocrelizumab	352	164	\$10,932,003	\$1,784,101	\$31,057	MC / GI / ME	3	No	Top Costs

## Top 25 most prescribed drugs

Rank	Therapy class	Proprietary name(s)	Non-proprietary name	Number of prescriptions
1	VACCINES	Afluria Quadrivalent / Fluarix Quadrivalent / Flulaval Quadrivalent / Fluzone Quadrivalent	Influenza Virus Vaccine Split Quadrivalent	221,220
2	THYROID AGENTS	Euthyrox / Levothyroxine Sodium / Levoxyl / Synthroid / Tirosint / Tirosint-SOL	Levothyroxine Sodium	169,336
3	ANTIHYPERTENSIVES	Atorvaliq / Atorvastatin Calcium / Lipitor	Atorvastatin Calcium	166,505
4	ANTIHYPERTENSIVES	Lisinopril / Prinivil / Qbrelis / Zestril	Lisinopril	161,174
5	ADHD/ ANTI-NARCOLEPSY/ ANTI-OBESITY/ANOREXIANTS	Adderall / Adderall XR / Amphetamine-Dextroamphet ER / Amphetamine-Dextroamphetamine / Mydayis	Amphetamine-Dextroamphetamine	156,001
6	ANTIASTHMATIC AND BRONCHODILATOR AGENTS	Albuterol Sulfate / Albuterol Sulfate ER / Albuterol Sulfate HFA / ProAir HFA / ProAir RespiClick / Proventil HFA / Ventolin HFA	Albuterol Sulfate	141,372
7	ANTIDIABETICS	metFORMIN HCl / metFORMIN HCl ER	Metformin HCl	137,692
8	ANTIDEPRESSANTS	buPROPion HCl / buPROPion HCl ER (SR) / buPROPion HCl ER (XL)	Bupropion HCl	126,612
9	VACCINES	Comirnaty / Moderna COVID-19 Vaccine / Pfizer-BioNTech COVID-19 Vacc / Spikevax COVID-19 Vaccine / Pfizer COVID-19 Vac	COVID-19 (SARS-CoV-2) mRNA Virus Vaccine	124,948
10	ANTIDEPRESSANTS	Sertraline HCl / Zoloft	Sertraline HCl	119,432
11	ANTIHYPERTENSIVES	Cozaar / Losartan Potassium	Losartan Potassium	106,741
12	ANTIDEPRESSANTS	Escitalopram Oxalate / Lexapro	Escitalopram Oxalate	97,660
13	CALCIUM CHANNEL BLOCKERS	amLODIPine Bes+SyrSpend SF / amLODIPine Besylate / Norliqva / Norvasc	Amlodipine Besylate	97,624
14	ANALGESICS - OPIOID	HYDROcodone-Acetaminophen	Hydrocodone-Acetaminophen	95,307
15	ANTICONVULSANTS	Fanatrex FusePaq / Gabapentin / Neurontin	Gabapentin	92,474
16	ANTIDEPRESSANTS	FLUoxetine HCl / PROzac	Fluoxetine HCl	81,720
17	ANTIDEPRESSANTS	traZODone HCl	Trazodone HCl	80,668
18	ANALGESICS - OPIOID	Oxaydo / oxyCODONE HCl / oxyCODONE HCl ER / OxyCONTIN	Oxycodone HCl	58,612
19	ULCER DRUGS/ ANTISPASMODICS/ ANTICHOLINERGICS	Omeprazole	Omeprazole	57,520
20	ESTROGENS	Alora / Climara / Divigel / Dotti / Elestrin / Estrace / Estradiol / Estrogel / Evamist / Lyllana / Menostar / Minivelle / Vivelle-Dot	Estradiol	56,181
21	MUSCULOSKELETAL THERAPY AGENTS	Cyclobenzaprine HCl	Cyclobenzaprine HCl	47,774
22	ADHD/ANTI-NARCOLEPSY/ ANTI-OBESITY/ANOREXIANTS	Adhansia XR / Aptensio XR / Concerta / Jornay PM / Methylin / Methylphenidate HCl / Methylphenidate HCl ER / Methylphenidate HCl ER (CD) / Methylphenidate HCl ER (LA) / Methylphenidate HCl ER (OSM) / Methylphenidate HCl ER (XR) / QuilliChew ER / Quillivant XR / Relexxii / Ritalin / Ritalin LA	Methylphenidate HCl	47,349
23	CORTICOSTEROIDS	predniSONE / predniSONE Intensol / Rayos	Prednisone	45,529
24	ANTIEMETICS	Ondansetron / Zuplenz	Ondansetron	43,530
25	BETA BLOCKERS	Kaspargo Sprinkle / Metoprolol Succinate ER / Toprol XL	Metoprolol Succinate	42,765

### Top 25 most costly drugs (highest total annual plan spending)

Rank	Therapy class	Proprietary name(s)	Non-proprietary name	Total annual plan spending
1	ANALGESICS - ANTI-INFLAMMATORY	Humira / Humira Pediatric Crohns Start / Humira Pen / Humira Pen-CD/UC/HS Starter / Humira Pen-Pediatric UC Start / Humira Pen-Ps/UV/Adol HS Start / Humira Pen-Psor/Uveit Starter	Adalimumab	\$75,241,110
2	DERMATOLOGICALS	Stelara	Ustekinumab	\$28,957,943
3	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Keytruda	Pembrolizumab	\$28,248,898
4	ANTIVIRALS	Biktarvy	Bictegravir-Emtricitabine-Tenofovir Alafenamide Fumarate	\$26,988,465
5	ANALGESICS - ANTI-INFLAMMATORY	Enbrel / Enbrel SureClick	Etanercept	\$22,017,823
6	RESPIRATORY AGENTS - MISC.	Trikafta	Elexacaftor-Tezacaftor-Ivacaftor	\$21,559,651
7	DERMATOLOGICALS	Cosentyx / Cosentyx Sensoready Pen / Cosentyx Sensoready	Secukinumab	\$18,723,855
8	GASTROINTESTINAL AGENTS - MISC.	Entyvio	Vedolizumab	\$17,655,131
9	GASTROINTESTINAL AGENTS - MISC.	Inflectra	Infliximab-dyyb	\$16,516,923
10	DERMATOLOGICALS	Skyrizi / Skyrizi Pen	Risankizumab-rzaa	\$15,517,811
11	DERMATOLOGICALS	Dupixent	Dupilumab	\$12,665,407
12	PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC.	Ocrevus	Ocrelizumab	\$10,932,003
13	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Opdivo	Nivolumab	\$10,884,240
14	PASSIVE IMMUNIZING AND TREATMENT AGENTS	Gammagard / Gammaked / Gamunex-C	Immune Globulin (Human) IV or Subcutaneous	\$10,747,945
15	ANTIDIABETICS	Rybelsus / Ozempic	Semaglutide	\$10,581,528
16	MISCELLANEOUS THERAPEUTIC CLASSES	Lenalidomide / Revlimid	Lenalidomide	\$10,432,994
17	ANTIDIABETICS	Trulicity	Dulaglutide	\$8,970,087
18	ANTICOAGULANTS	Eliquis / Eliquis DVT/PE Starter Pack	Apixaban	\$8,812,210
19	HEMATOLOGICAL AGENTS - MISC.	Ultomiris	Ravulizumab-cwvz	\$8,640,498
20	OPHTHALMIC AGENTS	Eylea	Aflibercept	\$8,222,980
21	ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS	Vyvanse	Lisdexamfetamine Dimesylate	\$7,558,385
22	ANTIDIABETICS	Jardiance	Empagliflozin	\$7,262,309
23	VACCINES	Shingrix	Zoster Vaccine Recombinant Adjuvanted	\$6,822,359
24	NEUROMUSCULAR AGENTS	Botox	OnabotulinumtoxinA	\$6,673,692
25	HEMATOLOGICAL AGENTS - MISC.	Hemlibra	Emicizumab-kxwh	\$6,574,803

### Top 25 greatest increase drugs

Rank	Therapy class	Proprietary name(s)	Non-proprietary name	YoY increase
1	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Keytruda	Pembrolizumab	\$11,840,653
2	DERMATOLOGICALS	Skyrizi / Skyrizi Pen	Risankizumab-rzaa	\$8,385,287
3	GASTROINTESTINAL AGENTS - MISC.	Inflectra	Infliximab-dyyb	\$5,489,239
4	RESPIRATORY AGENTS - MISC.	Trikafta	Elexacaftor-Tezacaftor-Ivacaftor	\$4,417,699
5	PASSIVE IMMUNIZING AND TREATMENT AGENTS	Gammagard / Gammaked / Gamunex-C	Immune Globulin (Human) IV or Subcutaneous	\$4,312,556
6	ANALGESICS - ANTI-INFLAMMATORY	Humira / Humira Pediatric Crohns Start / Humira Pen / Humira Pen-CD/UC/HS Starter / Humira Pen-Pediatric UC Start / Humira Pen-Ps/UV/Adol HS Start / Humira Pen-Psor/Uveit Starter	Adalimumab	\$3,682,844
7	DERMATOLOGICALS	Dupilumab	Dupilumab	\$3,333,668
8	ANTIDIABETICS	Rybelsus / Ozempic	Semaglutide	\$3,238,534
9	DERMATOLOGICALS	Stelara	Ustekinumab	\$3,077,394
10	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Adcetris	Brentuximab Vedotin	\$3,020,976
11	GASTROINTESTINAL AGENTS - MISC.	Entyvio	Vedolizumab	\$2,801,800
12	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Darzalex Faspro	Daratumumab-Hyaluronidase-fihj	\$2,735,655
13	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Verzenio	Abemaciclib	\$2,680,808
14	HEMATOLOGICAL AGENTS - MISC.	Hemlibra	Emicizumab-kxwh	\$2,584,640
15	HEMATOLOGICAL AGENTS - MISC.	Ultomiris	Ravulizumab-cwvz	\$2,566,297
16	DERMATOLOGICALS	Cosentyx / Cosentyx Sensoready Pen / Cosentyx Sensoready	Secukinumab	\$2,560,019
17	MISCELLANEOUS THERAPEUTIC CLASSES	Lenalidomide / Revlimid	Lenalidomide	\$2,350,557
18	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Opdivo	Nivolumab	\$2,274,979
19	ANTIVIRALS	Biktarvy	Bictegravir-Emtricitabine-Tenofovir Alafenamide Fumarate	\$1,926,579
20	VACCINES	Pevnar 20	Pneumococcal 20-Valent Conjugate Vaccine	\$1,896,151
21	PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC.	Ocrevus	Ocrelizumab	\$1,784,101
22	HEMATOLOGICAL AGENTS - MISC.	Takhzyro	Lanadelumab-flyo	\$1,742,373
23	ANTIDIABETICS	Jardiance	Empagliflozin	\$1,632,440
24	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Tecentriq	Atezolizumab	\$1,580,794
25	DERMATOLOGICALS	Tremfya	Guselkumab	\$1,575,599

**Top 25 most expensive drugs (highest average cost per prescription)**

Rank	Therapy class	Proprietary name(s)	Non-proprietary name	Total annual plan spending	Number of prescriptions	Average cost per prescription
1	PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC.	Ocrevus	Ocrelizumab	\$10,932,003	352	\$31,057
2	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Keytruda	Pembrolizumab	\$28,248,898	1,611	\$17,535
3	MISCELLANEOUS THERAPEUTIC CLASSES	Lenalidomide / Revlimid	Lenalidomide	\$10,432,994	627	\$16,640
4	DERMATOLOGICALS	Skyrizi / Skyrizi Pen	Risankizumab-rzaa	\$15,517,811	1,199	\$12,942
5	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Opdivo	Nivolumab	\$10,884,240	887	\$12,271
6	DERMATOLOGICALS	Stelara	Ustekinumab	\$28,957,943	2,717	\$10,658
7	GASTROINTESTINAL AGENTS - MISC.	Entyvio	Vedolizumab	\$17,655,131	2,038	\$8,663
8	DERMATOLOGICALS	Tremfya	Guselkumab	\$4,336,168	708	\$6,125
9	ANTIVIRALS	Odefsey	Emtricitabine-Rilpivirine-Tenofovir Alafenamide Fumarate	\$5,822,139	986	\$5,905
10	ANTIVIRALS	Biktarvy	Bictegravir-Emtricitabine-Tenofovir Alafenamide Fumarate	\$26,988,465	5,108	\$5,284
11	ANALGESICS - ANTI-INFLAMMATORY	Humira / Humira Pediatric Crohns Start / Humira Pen / Humira Pen-CD/UC/HS Starter / Humira Pen-Pediatric UC Start / Humira Pen-Ps/UV/Adol HS Start / Humira Pen-Psor/Uveit Starter	Adalimumab	\$75,241,110	14,283	\$5,268
12	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Truxima	Rituximab-abbs	\$4,680,246	903	\$5,183
13	ANTIVIRALS	Genvoya	Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide	\$3,400,080	727	\$4,677
14	PASSIVE IMMUNIZING AND TREATMENT AGENTS	Gammagard / Gammaked / Gamunex-C	Immune Globulin (Human) IV or Subcutaneous	\$10,747,945	2,339	\$4,595
15	ANALGESICS - ANTI-INFLAMMATORY	Enbrel / Enbrel SureClick	Etanercept	\$22,017,823	4,805	\$4,582
16	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Riabni	Rituximab-arxx	\$985,840	217	\$4,543
17	ANTIVIRALS	Triumeq / Triumeq PD	Abacavir-Dolutegravir-Lamivudine	\$4,371,265	1,009	\$4,332
18	DERMATOLOGICALS	Cosentyx / Cosentyx Sensoready Pen / Cosentyx Sensoready	Secukinumab	\$18,723,855	4,401	\$4,254
19	HEMATOPOIETIC AGENTS	Ziextenzo	Pegfilgrastim-bmez	\$1,704,074	454	\$3,753
20	OPHTHALMIC AGENTS	Eylea	Aflibercept	\$8,222,980	2,626	\$3,131
21	ANALGESICS - ANTI-INFLAMMATORY	Otezla	Apremilast	\$3,385,140	1,172	\$2,888
22	DERMATOLOGICALS	Dupilixent	Dupilumab	\$12,665,407	4,406	\$2,875
23	ANALGESICS - ANTI-INFLAMMATORY	Xeljanz / Xeljanz XR	Tofacitinib Citrate	\$5,195,829	1,905	\$2,727
24	GASTROINTESTINAL AGENTS - MISC.	Inflectra	Infliximab-dyyb	\$16,516,923	6,209	\$2,660
25	ANTIASTHMATIC AND BRONCHODILATOR AGENTS	Xolair	Omalizumab	\$5,645,533	2,148	\$2,628

Top 50 Drugs by Claim Count - CCO Only

Rank	Drug	PDL Class	2018	2019	2020	2021	2022
1	ALBUTEROL SULFATE HFA	Beta-Agonists, Inhaled Short-Acting		196,029	251,155	259,894	297,870
2	OMEPRAZOLE	Antacid, Proton Pump Inhibitors	218,037	217,772	241,949	251,609	259,721
3	GABAPENTIN	Antiepileptics, Outpatient	228,059	236,333	241,213	245,490	258,688
4	ATORVASTATIN CALCIUM	Statins & Combos	195,683	210,923	224,398	231,935	234,358
5	LISINAPRIL	Inhibitors of the Renin-Angiotensin-Aldosterone System (RAAS)	222,867	217,111	223,956	226,169	217,520
6	VITAMIN D3	Calcium/Vit D Replacement, Oral	162,548	187,856	202,494	209,928	211,059
7	LEVOTHYROXINE SODIUM	Thyroid Hormone, Oral	190,136	183,417	173,551	173,617	178,525
8	METFORMIN HCL	Diabetes, Miscellaneous Antidiabetic Agents	142,818	135,803	135,395	131,890	127,976
9	IBUPROFEN	Non-Steroidal Anti-Inflammatory Drugs	121,430	135,842	132,017	123,991	126,670
10	AMLODIPINE BESYLATE	Calcium Channel Blockers - Dihydropyridine, Oral	108,146	112,333	116,995	121,287	123,864
11	HYDROCODONE-ACETAMINOPHEN	Opioids, Short-Acting	177,839	145,744	135,661	128,907	122,146
12	CYCLOBENZAPRINE HCL	Muscle Relaxants, Oral	124,017	119,556	116,443	117,541	119,950
13	LOSARTAN POTASSIUM	Inhibitors of the Renin-Angiotensin-Aldosterone System (RAAS)	89,479	93,797	104,651	113,298	115,434
14	HYDROXYZINE HCL	Antihistamines, First Generation	58,689	78,332	90,938	101,527	111,329
15	ONDANSETRON ODT	Antiemetics, Newer	73,333	80,305	80,029	93,617	110,203
16	AMOXICILLIN	STC 22 - Penicillin	112,431	111,420	76,170	71,136	105,088
17	BUPRENORPHINE-NALOXONE	Substance Use Disorders, Opioid & Alcohol	44,084	80,611	99,360	100,022	103,321
18	OXYCODONE HCL	Opioids, Short-Acting	106,638	94,058	98,183	98,848	100,166
19	DEXTROAMPHETAMINE-AMPHETAMINE	ADHD Drugs	57,188	62,503	72,673	84,023	99,091
20	METOPROLOL SUCCINATE	Beta-Blockers, Oral	64,564	67,801	76,371	85,535	89,411
21	MONTELUKAST SODIUM	Miscellaneous Pulmonary Agents	65,667	75,376	85,832	85,286	87,929
22	CLONIDINE HCL	STC 71 - Other Hypotensives	72,967	76,333	80,424	83,465	87,437
23	Ondansetron Hcl Injection	Physician Administered Drug	65,965	80,123	74,962	81,151	86,026
24	DEXTROAMPHETAMINE-AMPHET ER	ADHD Drugs	35,134	37,895	43,236	61,812	84,842
25	Ketorolac Tromethamine Inj	Physician Administered Drug	70,392	78,982	69,293	75,342	83,197
26	PANTOPRAZOLE SODIUM	Antacid, Proton Pump Inhibitors	50,766	56,271	66,632	73,860	81,233
27	METFORMIN HCL ER	Diabetes, Miscellaneous Antidiabetic Agents	47,674	55,248	61,167	69,424	81,147
28	ACETAMINOPHEN	STC 41 - Non-narcotic Analgesics	10,982	55,054	71,021	68,151	78,260
29	PREDNISONE	Glucocorticoids, Oral	72,874	76,262	68,229	65,519	75,413
30	HYDROCHLOROTHIAZIDE	Diuretics, Oral	76,144	73,593	79,768	77,098	73,178
31	CETIRIZINE HCL	Antihistamines, Second Generation	58,062	71,332	67,252	62,798	70,944
32	ASPIRIN EC	Platelet Inhibitors	56,238	78,246	77,658	73,358	69,438
33	PROPRANOLOL HCL	Beta-Blockers, Oral	45,767	51,186	56,438	62,637	67,499
34	Inj Heparin Sodium Per 1000u	Physician Administered Drug	41,988	47,790	50,329	64,262	65,536
35	FAMOTIDINE	Antacid, H2 Antagonists	21,789	27,812	41,132	57,961	63,824
36	MELOXICAM	Non-Steroidal Anti-Inflammatory Drugs	58,591	57,813	56,236	59,470	62,847
37	SPIRONOLACTONE	Diuretics, Oral	43,953	46,527	51,711	56,691	61,307
38	FLUTICASONE PROPIONATE	Nasal Allergy Inhalers	47,546	56,731	52,935	49,498	60,103
39	AMOXICILLIN-CLAVULANATE POTASS	Amoxicillin and Clavulanate, Oral	46,258	47,451	39,786	40,218	60,097
40	DOCUSATE SODIUM	Laxatives, Chronic Constipation	12,395	13,850	13,033	39,033	57,239
41	FUROSEMIDE	Diuretics, Oral	54,399	54,305	57,821	59,632	56,693
42	CLONAZEPAM	Benzodiazepines	59,750	55,012	57,646	56,304	55,589
43	TRIAMCINOLONE ACETONIDE	Steroids, Topical	51,618	52,603	51,308	53,380	55,125
44	PRAZOSIN HCL	STC 71 - Other Hypotensives	44,293	48,447	53,124	54,205	54,938
45	CEPHALEXIN	Cephalosporins (1st Gen), Oral	52,238	53,259	48,930	52,092	54,717
46	TOPIRAMATE	Antiepileptics, Outpatient	46,317	47,035	49,153	51,575	52,809
47	Dexamethasone Sodium Phos	Physician Administered Drug	40,729	46,304	38,473	44,204	50,368
48	Normal Saline Solution Infus	Physician Administered Drug	82,529	89,063	81,650	80,821	49,590
49	Epoetin Alfa, 100 Units Esrd	Physician Administered Drug	29,583	34,518	42,600	49,386	49,582
50	METHYLPHENIDATE ER	ADHD Drugs	46,667	46,497	44,496	43,978	49,435

**Top 50 Drugs by Gross Amount Paid - CCO Only**  
 Rebates not accounted for

Rank	Drug	PDL Class	2018	2019	2020	2021	2022
1	HUMIRA(CF) PEN	Targeted Immune Modulators	\$788,525	\$11,535,888	\$25,429,082	\$34,853,706	\$43,545,462
2	BIKTARVY	HIV	\$3,014,256	\$13,646,598	\$23,137,344	\$28,710,684	\$35,538,241
3	TRIKAFTA	Cystic Fibrosis		\$788,227	\$16,229,586	\$21,677,071	\$27,052,878
4	MAVYRET	Hepatitis C, Direct-Acting Antivirals	\$24,514,502	\$49,664,887	\$37,283,840	\$27,330,819	\$25,246,068
5	STELARA	Targeted Immune Modulators	\$7,764,155	\$10,357,028	\$16,314,849	\$19,816,925	\$24,515,828
6	TRULICITY	Diabetes, GLP-1 Receptor Agonists and GIP Therapies	\$1,916,735	\$5,079,619	\$10,417,101	\$17,653,841	\$22,159,071
7	Inj Pembrolizumab	Physican Administered Drug	\$5,667,099	\$7,620,323	\$10,322,056	\$12,567,729	\$17,315,198
8	ELIQUIS	Anticoagulants, Oral and SQ	\$3,921,221	\$5,879,647	\$9,534,286	\$13,493,230	\$16,970,691
9	BASAGLAR KWIKPEN U-100	Diabetes, Insulins	\$18,514,249	\$20,300,641	\$23,309,541	\$21,318,940	\$16,869,487
10	BUPRENORPHINE-NALOXONE	Substance Use Disorders, Opioid & Alcohol	\$4,407,522	\$7,764,974	\$10,791,753	\$11,182,509	\$12,816,355
11	Inj., Emicizumab-Kxwh 0.5 Mg	Physican Administered Drug	\$597,267	\$6,212,350	\$10,299,389	\$9,393,466	\$12,800,634
12	ENBREL SURECLICK	Targeted Immune Modulators	\$11,715,053	\$9,974,803	\$11,939,525	\$11,440,766	\$11,047,611
13	COSENTYX PEN (2 PENS)	Targeted Immune Modulators	\$3,209,496	\$4,055,721	\$5,671,274	\$8,319,346	\$10,546,630
14	Injection, Inflectra	Physican Administered Drug	\$1,920,914	\$3,152,544	\$5,231,940	\$7,959,309	\$10,455,737
15	ALBUTEROL SULFATE HFA	Beta-Agonists, Inhaled Short-Acting		\$9,173,027	\$10,793,534	\$9,329,189	\$10,022,191
16	Injection, Vedolizumab	Physican Administered Drug	\$2,895,499	\$3,868,401	\$5,780,664	\$7,434,859	\$8,856,139
17	HUMIRA PEN	Targeted Immune Modulators	\$26,482,570	\$17,129,370	\$11,395,163	\$8,948,510	\$7,906,256
18	JARDIANCE	Diabetes, SGLT-2 Inhibitors	\$1,052,459	\$1,897,905	\$4,418,398	\$4,897,188	\$7,828,447
19	Aflibercept Injection	Physican Administered Drug	\$2,104,825	\$3,042,714	\$4,383,293	\$5,989,778	\$7,455,295
20	BUDESONIDE-FORMOTEROL FUMARATE	Corticosteroids/LABA Combination, Inhaled			\$5,770,538	\$6,728,243	\$7,437,198
21	CREON	Pancreatic Enzymes	\$3,387,757	\$4,189,404	\$5,252,955	\$6,288,871	\$7,093,726
22	XARELTO	Anticoagulants, Oral and SQ	\$3,692,137	\$4,381,179	\$5,491,087	\$6,399,688	\$6,873,302
23	Injection, Nivolumab	Physican Administered Drug	\$4,738,260	\$5,497,098	\$4,081,271	\$3,582,408	\$6,536,196
24	TRIUMEQ	HIV	\$8,268,387	\$7,120,498	\$7,308,732	\$6,947,903	\$6,532,597
25	GENVOYA	HIV	\$9,088,231	\$7,825,456	\$7,227,778	\$6,953,668	\$6,271,667
26	OZEMPIC	Diabetes, GLP-1 Receptor Agonists and GIP Therapies	\$49,105	\$350,421	\$962,130	\$2,050,291	\$6,041,690
27	STEGLATRO	Diabetes, SGLT-2 Inhibitors	\$50,500	\$291,466	\$939,682	\$3,757,084	\$5,901,062
28	IBRANCE	Antineoplastics, Newer	\$4,411,937	\$5,166,557	\$6,261,486	\$4,754,850	\$5,862,646
29	Etonogestrel Implant System	Physican Administered Drug	\$4,715,856	\$5,541,933	\$5,203,729	\$5,363,676	\$5,836,481
30	XIFAXAN	Rifamycins	\$4,175,683	\$4,691,847	\$5,448,535	\$5,698,065	\$5,698,675
31	Injection, Ocrelizumab, 1 Mg	Physican Administered Drug	\$1,611,288	\$2,795,579	\$3,781,804	\$5,050,425	\$5,640,641
32	FLOVENT HFA	Corticosteroids, Inhaled	\$7,673,101	\$8,439,863	\$8,568,935	\$7,896,564	\$5,554,535
33	TRELEGY ELLIPTA	LAMA/LABA Combination, Inhalers	\$237,983	\$1,235,827	\$2,499,677	\$4,069,311	\$5,547,915
34	HUMIRA(CF)	Targeted Immune Modulators	\$500,751	\$2,711,434	\$4,357,139	\$4,974,742	\$5,438,526
35	ENTRESTO	Inhibitors of the Renin-Angiotensin-Aldosterone System (RAAS)	\$439,024	\$874,175	\$1,948,998	\$3,261,138	\$5,383,574
36	Injection, OnabotulinumtoxinA	Physican Administered Drug	\$2,700,363	\$3,056,087	\$3,422,454	\$4,513,678	\$5,340,386
37	VICTOZA 3-PAK	Diabetes, GLP-1 Receptor Agonists and GIP Therapies	\$3,350,631	\$4,692,996	\$5,393,535	\$5,536,498	\$5,285,687
38	DESCOVY	HIV	\$4,001,502	\$3,581,452	\$4,030,785	\$4,434,308	\$5,182,110
39	FLUTICASONE-SALMETEROL	Corticosteroids/LABA Combination, Inhaled	\$527,337	\$2,407,247	\$3,371,850	\$4,189,338	\$5,076,689
40	UPTRAVI	Pulmonary Arterial Hypertension Oral and Inhaled Drugs	\$1,489,139	\$1,386,377	\$2,804,589	\$4,361,405	\$5,004,841
41	VYVANSE	ADHD Drugs	\$3,425,613	\$3,382,476	\$3,764,782	\$4,190,725	\$4,907,356
42	Mirena, 52 Mg	Physican Administered Drug	\$4,883,571	\$4,871,803	\$4,734,191	\$5,152,050	\$4,861,168
43	REVLIMID	STC 30 - Antineoplastic	\$4,439,158	\$4,572,492	\$4,743,701	\$5,863,215	\$4,718,426
44	ODEFSEY	HIV	\$3,593,791	\$3,679,695	\$4,045,399	\$4,463,065	\$4,643,490
45	QVAR REDIHALER	Corticosteroids, Inhaled	\$3,473,942	\$5,151,172	\$5,722,999	\$5,229,087	\$4,586,861
46	Factor VIII Recombinant Nos	Physican Administered Drug	\$7,499,246	\$4,507,370	\$3,452,504	\$3,248,740	\$4,567,067
47	Methadone Oral 5mg	Physican Administered Drug	\$2,681,900	\$4,046,564	\$4,230,297	\$4,783,638	\$4,522,339
48	NORDITROPIN FLEXPRO	Growth Hormones	\$2,190,853	\$2,993,974	\$3,695,845	\$4,042,428	\$4,393,819
49	DUPIXENT PEN	Targeted Immune Modulators for Asthma and Atopic Dermatitis			\$155,079	\$1,705,686	\$4,386,219
50	SUBLOCADE	Substance Use Disorders, Opioid & Alcohol	\$34,412	\$444,640	\$2,077,132	\$2,963,807	\$4,276,042

**Top 50 Drugs by Greatest Increase in Share of Total Cost - 2021 to 2022 - CCO Only**

Rebates not accounted for

		Annual Total CCO Cost:		2021	2022		
				\$997,492,680	\$1,095,947,359		
Rank	PDL_FriendlyName	DrugName	2021	2022	Absolute Change in Spending	Change in Spending as % of 2022 Total CCO Cost	
1	Targeted Immune Modulators	HUMIRA(CF) PEN	\$34,853,706	\$43,545,462	\$8,691,756	0.7931%	
2	HIV	BIKTARVY	\$28,710,684	\$35,538,241	\$6,827,557	0.6230%	
3	Cystic Fibrosis	TRIKAFTA	\$21,677,071	\$27,052,878	\$5,375,806	0.4905%	
4	Physican Administered Drug	Inj Pembrolizumab	\$12,567,729	\$17,315,198	\$4,747,470	0.4332%	
5	Targeted Immune Modulators	STELARA	\$19,816,925	\$24,515,828	\$4,698,902	0.4288%	
6	Diabetes, GLP-1 Receptor Agonists and GIP Therapies	TRULICITY	\$17,653,841	\$22,159,071	\$4,505,230	0.4111%	
7	Diabetes, GLP-1 Receptor Agonists and GIP Therapies	OZEMPIC	\$2,050,291	\$6,041,690	\$3,991,399	0.3642%	
8	Anticoagulants, Oral and SQ	ELIQUIS	\$13,493,230	\$16,970,691	\$3,477,462	0.3173%	
9	Physican Administered Drug	Inj., Emicizumab-Kxwh 0.5 Mg	\$9,393,466	\$12,800,634	\$3,407,168	0.3109%	
10	Diabetes, Insulins	INSULIN GLARGINE-YFGN	\$129,121	\$3,216,262	\$3,087,141	0.2817%	
11	Physican Administered Drug	Injection, Nivolumab	\$3,582,408	\$6,536,196	\$2,953,788	0.2695%	
12	Diabetes, SGLT-2 Inhibitors	JARDIANCE	\$4,897,188	\$7,828,447	\$2,931,259	0.2675%	
13	Targeted Immune Modulators	SKYRIZI PEN	\$504,553	\$3,361,425	\$2,856,872	0.2607%	
14	Tobacco Smoking Cessation	VARENICLINE TARTRATE	\$1,506,758	\$4,224,423	\$2,717,665	0.2480%	
15	Targeted Immune Modulators for Asthma and Atopic Dermatitis	DUPIXENT PEN	\$1,705,686	\$4,386,219	\$2,680,533	0.2446%	
16	Antineoplastics, Newer	VERZENIO	\$1,543,580	\$4,118,286	\$2,574,706	0.2349%	
17	Physican Administered Drug	Injection, Inflectra	\$7,959,309	\$10,455,737	\$2,496,428	0.2278%	
18	Targeted Immune Modulators	COSENTYX PEN (2 PENS)	\$8,319,346	\$10,546,630	\$2,227,284	0.2032%	
19	Diabetes, SGLT-2 Inhibitors	STEGLATRO	\$3,757,084	\$5,901,062	\$2,143,978	0.1956%	
20	Inhibitors of the Renin-Angiotensin-Aldosterone System (RAAS)	ENTRESTO	\$3,261,138	\$5,383,574	\$2,122,436	0.1937%	
21	Physican Administered Drug	Inj Golodirsen 10 Mg	\$215,424	\$2,145,181	\$1,929,757	0.1761%	
22	Diabetes, SGLT-2 Inhibitors	FARXIGA	\$1,286,778	\$3,067,938	\$1,781,160	0.1625%	
23	Substance Use Disorders, Opioid & Alcohol	BUPRENORPHINE-NALOXONE	\$11,182,509	\$12,816,355	\$1,633,846	0.1491%	
24	LAMA/LABA Combination, Inhalers	TRELEGY ELLIPTA	\$4,069,311	\$5,547,915	\$1,478,604	0.1349%	
25	Physican Administered Drug	Aflibercept Injection	\$5,989,778	\$7,455,295	\$1,465,517	0.1337%	
26	Physican Administered Drug	Injection, Vedolizumab	\$7,434,859	\$8,856,139	\$1,421,280	0.1297%	
27	Opioid Reversal Agents	NALOXONE HCL	\$5,808	\$1,386,362	\$1,380,554	0.1260%	
28	Multiple Sclerosis	KESIMPTA PEN	\$186,200	\$1,325,980	\$1,139,780	0.1210%	
29	Physican Administered Drug	Factor VIII Recombinant Nos	\$3,248,740	\$4,567,067	\$1,318,327	0.1203%	
30	Substance Use Disorders, Opioid & Alcohol	SUBLOCADE	\$2,963,807	\$4,276,042	\$1,312,235	0.1197%	
31	Physican Administered Drug	Gammagard Liquid Injection	\$2,631,793	\$3,844,470	\$1,212,677	0.1107%	
32	Pulmonary Arterial Hypertension Oral and Inhaled Drugs	OPSUMIT	\$2,608,068	\$3,800,500	\$1,192,432	0.1088%	
33	Physican Administered Drug	Inj, Atezolizumab,10 Mg	\$1,935,911	\$3,113,220	\$1,177,309	0.1074%	
34	STC 47 - Sedative Non-barbiturate	XYWAV	\$535,658	\$1,700,633	\$1,164,975	0.1063%	
35	Antineoplastics, Newer	CABOMETYX	\$1,118,772	\$2,235,036	\$1,116,264	0.1019%	
36	Antineoplastics, Newer	IBRANCE	\$4,754,850	\$5,862,646	\$1,107,795	0.1011%	
37	Physican Administered Drug	Daratumumab, Hyaluronidase	\$1,407,554	\$2,463,980	\$1,056,426	0.0964%	
38	Targeted Immune Modulators	TREMFYA	\$1,555,015	\$2,529,233	\$974,217	0.0889%	
39	Pulmonary Arterial Hypertension Oral and Inhaled Drugs	ORENITRAM ER	\$953,945	\$1,919,750	\$965,804	0.0881%	
40	Physican Administered Drug	Eculizumab Injection	\$1,195,961	\$2,153,059	\$957,098	0.0873%	
41	Antiepileptics, Outpatient	EPIDIOLEX	\$2,636,341	\$3,570,797	\$934,456	0.0853%	
42	STC 00 - Medical Supplies	DEXCOM G6 SENSOR	\$2,261,843	\$3,194,005	\$932,162	0.0851%	
43	Diabetes, Insulins	SEMGLEE (YFGN) PEN	\$64,453	\$969,771	\$905,318	0.0826%	
44	Physican Administered Drug	Buprenorph Xr 100 Mg Or Less	\$1,255,841	\$2,144,787	\$888,946	0.0811%	
45	Corticosteroids/LABA Combination, Inhaled	FLUTICASONONE-SALMETEROL	\$4,189,338	\$5,076,689	\$887,352	0.0810%	
46	STC 39 - Diagnostics	FLOWFLEX COVID-19 AG HOME TEST	\$28	\$884,375	\$884,348	0.0807%	
47	Targeted Immune Modulators	SKYRIZI	\$574,099	\$1,456,848	\$882,748	0.0805%	
48	Duchenne Muscular Dystrophy	EMFLAZA	\$1,446,276	\$2,327,412	\$881,135	0.0804%	
49	STC 90 - Biologicals	PFIZER COVID (12Y UP) VAC(EUA)	\$240	\$854,924	\$854,684	0.0780%	
50	Physican Administered Drug	Gamunex-C/Gammaked	\$1,447,127	\$2,289,684	\$842,556	0.0769%	

## Manufacturer Data - Annual Price Increase Filings for 2022

### Background:

Under ORS 646A.689 manufacturers are required to report annually prescription drugs with a price of \$100 or more for a one month supply (or course of treatment less than one month) with a net price increase of 10 percent or more.

Drugs reported to the Oregon Drug Price Transparency (DPT) program with price increases in 2022 were reviewed and ranked by the greatest increase, most costly, and most expensive.

### Data Sources Utilized:

Manufacturer data reported to iReg as part of the 2022 annual rate increase filings. Items marked trade secret (TS) by the manufacturer have been redacted from this report.

Medi-span price history data was also reviewed to calculate the Average Wholesale Acquisition Cost (AWAC) and for data validation and correction as needed.

### Definitions:

Acronym	Term	Definition - how it was calculated
TS	Trade secret	The value was flagged as trade secret in iReg and has been excluded from this data set.
	Date on market	The date a given drug is first available to buy/sell in the U.S.
AWAC	Average wholesale acquisition cost	The time-weighted price average for the year 2022. Price history was reviewed in Medi-span by the Oregon DPT data analyst. Each price listed in 2022 was multiplied by the number of days spent at said price and divided by the number days of the year, then the results were for each price were added together to obtain the AWAC.
	Beginning WAC 2022	The Wholesale Acquisition Cost (WAC) reported in iReg for January 1, 2022.
	Beginning WAC 2023	The WAC listed in Medi-span at the beginning of January 2023 if the change to pricing occurred within 4 days of the end of calendar year 2022, or the December 31st WAC reported in iReg if there was not a price increase within 4 days of the end of the calendar year 2022.
	Introductory Price	The price the drug on the date of its date on market.
	Price per unit	Calculated by: AWAC / (Package Size x Package Quantity)
NIP	Net increase percentage	The percent the WAC increased from the beginning of 2022 to the beginning of 2023. Calculated by: (Beginning WAC 2023 - Beginning WAC 2022) / Beginning WAC 2022
GI	Greatest increase	Drugs with the greatest net increase percentage.
MC	Most costly	Drugs with the greatest AWAC for 2022.
ME	Most expensive	Drugs with the highest price per unit for 2022.
	Has orphan indications	Reviewed drugs for any orphan designations in the FDA Orphan Designation Database, if none were found, the drug was listed as "No". If an approved orphan designation was listed for the drug, the FDA label(s) for the drug were reviewed to determine if the drug was approved for any other indications in addition to the orphan designation. If the orphan designation was the only approved use, the drug was listed as "Orphan only". If the indications for the drug included both orphan and non-orphan approved indications, the drug was marked as "both".

### Data Limitations:

While price per unit gives a general idea of the costs associated with the drug, it may not fully capture the cost of a course of treatment.

NDC	Trade name / proprietary name	Chemical name / non-proprietary name	Therapeutic class	Manufacturer	Date on market	2022 Calculated AWAC	Beginning WAC 2022	Beginning WAC 2023	Introductory price	Drug dosage	Package quantity	Package size	Price per unit	Net Increase percentage	Rank GI	Rank MC	Rank ME	Has orphan indications
76310002201	Proleukin	Aldesleukin	Antineoplastics and Adjunctive Therapies	Clinigen, INC.	6/5/1992	\$5,168.17	\$4,683.60	\$5,551.47	\$4,683.60	.4 dose(s) per package	1	1	\$5,168.17	19%	47	11	2	Orphan Only
42291096218	Yuvafem	Estradiol	Vaginal and Related Products	Avkare, INC (Aka Avpak)	12/15/2016	\$124.77	\$119.72	\$140.67	\$279.33	Yuvafem should be administered intravaginally using the supplied applicator: 1 insert daily for 2 weeks, followed by 1 insert twice weekly	1	18	\$6.93	17%	48	76	49	No
42192010406	Sodium Sulfacetamide and Sulfur	Sodium Sulfacetamide and Sulfur	Dermatologicals	Acella Pharmaceuticals LLC	4/28/2008	\$753.35	\$659.94	\$757.91	\$63.57	liberally applied once daily to affected area	1	170.1	\$4.43	15%	53	32	58	No
46287002410	Potassium Phosphates	Monobasic Potassium Phosphate and Dibasic Potassium Phosphate	Minerals & Electrolytes	CMP Pharma, INC.	3/1/2020	\$139.32	\$131.00	\$299.00	\$131.00	1 dose per package	10	15	\$0.93	128%	1	71	76	No
42192010316	BP Cleansing Wash	Sodium Sulfacetamide and Sulfur	Dermatologicals	Acella Pharmaceuticals LLC	2/11/2008	\$697.01	\$610.58	\$701.23	\$99.90	liberally applied once daily to affected area	1	473	\$1.47	15%	50	36	70	No
42192011270	Salicylic Acid	Salicylic Acid	Dermatologicals	Acella Pharmaceuticals LLC	11/11/2009	\$176.70	\$154.79	\$177.77	\$123.10	Unless otherwise directed by a prescribing physician, Salicylic Acid 6% Foam should be applied topically to the affected area twice a day. Salicylic Acid 6% Foam should be rubbed into the skin until it is completely absorbed. Salicylic Acid 6% Foam should be shaken vigorously before each application and inverted to administer.	1	70	\$2.52	15%	52	65	65	No
42192011515	Urea Hydrating Topical	Urea	Dermatologicals	Acella Pharmaceuticals LLC	5/21/2010	\$256.74	\$224.91	\$258.30	\$168.30	apply to cover affected area twice per day	1	150	\$1.71	15%	51	60	68	No
42192014301	Sodium Sulfacetamide 10% and Sulfur 5% Emollient Foam	Sulfacetamide Sodium and Sulfur	Dermatologicals	Acella Pharmaceuticals LLC	1/2/2013	\$428.80	\$375.64	\$431.40	\$150.93	apply to cover affected area	1	100	\$4.29	15%	55	45	59	No
68001035937	Gemcitabine	Gemcitabine	Antineoplastics and Adjunctive Therapies	Amerisource Health Services, LLC	9/25/2018	\$105.60	\$82.07	\$105.60	\$105.60	2mg/20ml	1	20	\$5.28	29%	15	81	54	No
68001044226	Cyclophosphamide	Cyclophosphamide	Antineoplastics and Adjunctive Therapies	Amerisource Health Services, LLC	3/12/2021	\$366.25	\$329.63	\$366.25	\$366.25	500mg/25ml	1	1	\$366.25	11%	61	52	11	No
68001044327	Cyclophosphamide	Cyclophosphamide	Antineoplastics and Adjunctive Therapies	Amerisource Health Services, LLC	3/12/2021	\$732.50	\$659.25	\$732.50	\$732.50	1mg/50ml	1	1	\$732.50	11%	59	34	6	No
68001044432	Cyclophosphamide	Cyclophosphamide	Antineoplastics and Adjunctive Therapies	Amerisource Health Services, LLC	3/12/2021	\$1,465.00	\$1,318.50	\$1,465.00	\$1,465.00	2G/100ml	1	1	\$1,465.00	11%	59	21	4	No
62584081201	Oxazepam	Oxazepam	Antianxiety Agents	Amerisource Health Services, LLC	12/12/2007	\$235.02	\$198.75	\$238.50	\$238.50	10mg	1	100	\$2.35	20%	26	62	66	No
62584081301	Oxazepam	Oxazepam	Antianxiety Agents	Amerisource Health Services, LLC	12/12/2007	\$258.64	\$218.73	\$262.48	\$262.48	15mg	1	100	\$2.59	20%	25	59	64	No
62584081401	Oxazepam	Oxazepam	Antianxiety Agents	Amerisource Health Services, LLC	12/12/2007	\$287.10	\$242.80	\$291.36	\$291.36	30mg	1	100	\$2.87	20%	26	58	63	No
60687049301	Verapamil Hydrochloride	Verapamil Hcl	Calcium Channel Blockers	Amerisource Health Services, LLC	6/25/2020	\$133.36	\$110.88	\$140.80	\$140.80	120mg	1	100	\$1.33	27%	18	73	74	No
60687050401	Verapamil Hydrochloride	Verapamil Hcl	Calcium Channel Blockers	Amerisource Health Services, LLC	7/16/2020	\$142.82	\$118.75	\$150.81	\$150.81	180mg	1	100	\$1.43	27%	17	69	72	No
62584015901	Demeclocycline Hydrochloride	Demeclocycline Hydrochloride	Tetracyclines	Amerisource Health Services, LLC	11/30/2010	\$677.79	\$630.46	\$693.51	\$693.51	150mg	1	100	\$6.78	10%	69	38	52	No
60687020601	Diltiazem Hydrochloride	Diltiazem Hydrochloride	Calcium Channel Blockers	Amerisource Health Services, LLC	1/26/2017	\$143.17	\$39.00	\$80.55	\$80.55	180mg	1	100	\$1.43	107%	2	68	71	No
60687022901	Loperamide Hydrochloride	Loperamide Hydrochloride	Antidiarrheal/Probiotic Agents	Amerisource Health Services, LLC	1/10/2017	\$377.53	\$67.06	\$85.00	\$85.00	2mg	1	100	\$3.78	27%	19	51	60	No
60687040825	Mesalamine	Mesalamine	Gastrointestinal Agents - Misc.	Amerisource Health Services, LLC	4/17/2019	\$754.68	\$314.10	\$410.00	\$410.00	800mg	1	30	\$25.16	31%	14	31	34	No
42192014360	Sodium Sulfacetamide 10% and Sulfur 5% Emollient Foam	Sulfacetamide Sodium and Sulfur	Dermatologicals	Acella Pharmaceuticals LLC	1/2/2013	\$321.60	\$281.72	\$323.55	\$113.20	Apply small amount to affected area	1	60	\$5.36	15%	49	56	53	No
42192071401	Ciclopirox	Ciclopirox	Dermatologicals	Acella Pharmaceuticals LLC	9/12/2011	\$360.73	\$316.00	\$362.91	\$138.45	apply small amount once daily	1	34.6	\$10.43	15%	54	53	46	No
60793060210	Bicillin C-R 900/300	Penicillin G Benzathine and Penicillin G Procaine	Penicillins	Pfizer	1/1/2013	\$1,543.62	\$1,509.57	\$1,660.53	\$506.36	A single injection of Bicillin C-R 900/300	10	2	\$77.18	10%	75	19	29	No
60793060010	Bicillin CR	Penicillin G Benzathine and Penicillin G Procaine	Penicillins	Pfizer	1/1/2013	\$1,585.26	\$1,509.57	\$1,660.53	\$486.46	2,400,000 units (recommended in adults and pediatric patients over 60 lbs)	10	2	\$79.26	10%	75	17	27	No
60793060110	Bicillin CR	Penicillin G Benzathine and Penicillin G Procaine	Penicillins	Pfizer	1/1/2013	\$1,585.26	\$1,509.57	\$1,660.53	\$486.46	2,400,000 units (recommended in adults and pediatric patients over 60 lbs)	10	2	\$79.26	10%	75	17	27	No
60793070210	Bicillin L-A	Penicillin G Benzathine	Penicillins	Pfizer	1/1/2013	\$4,075.14	\$3,880.58	\$4,268.64	\$1,250.51	max dose is 2,400,000 units at 7 day intervals for 3 doses for the treatment of late syphilis (tertiary and neurosyphilis)	10	4	\$101.88	10%	80	14	26	No
00409337301	Corlofam	Fenoldopam Mesylate	Antihypertensives	Pfizer	9/5/2015	\$434.33	\$413.59	\$454.95	\$179.05	max dose is 0.0016mg/kg/min	1	1	\$434.33	10%	73	44	8	No
00409337302	Corlofam	Fenoldopam Mesylate	Antihypertensives	Pfizer	9/5/2015	\$688.66	\$827.19	\$909.91	\$358.09	max dose is 0.0016mg/kg/min	1	2	\$434.33	10%	78	28	7	No
00009027101	Depo-Estradiol	Estradiol Cypionate	Estrogens	Pfizer	3/6/2003	\$133.74	\$127.35	\$140.09	\$22.32	max dose is 5mg every 3 weeks	1	5	\$26.75	10%	63	72	33	No
00409741803	LMD in Dextrose	Dextran 40	Hematological Agents - Misc.	Pfizer	9/5/2015	\$351.95	\$351.95	\$387.15	\$299.76	max dose is 20mL per kg of body weight	12	500	\$0.06	10%	66	55	80	No
00069019602	Fragmin	Dalteparin Sodium	Anticoagulants	Pfizer	2/20/2015	\$746.42	\$453.67	\$499.04	\$354.50	5000 IU once per day	10	0.2	\$238.21	10%	68	43	18	No
00069020602	Fragmin	Dalteparin Sodium	Anticoagulants	Pfizer	2/20/2015	\$714.70	\$680.58	\$748.64	\$531.80	7500 IU for the extended treatment of symptomatic venous thromboembolism	10	0.3	\$238.23	10%	72	35	16	No
00069022002	Fragmin	Dalteparin Sodium	Anticoagulants	Pfizer	2/20/2015	\$1,191.12	\$1,134.25	\$1,247.68	\$886.30	12500 IU for the extended treatment of symptomatic venous thromboembolism	10	0.5	\$238.22	10%	70	25	17	No
00793013010	Penicillin G Procaine	Penicillin G Procaine	Penicillins	Pfizer	1/1/2013	\$398.80	\$379.76	\$417.74	\$169.39	max dose is 3500000 units per day for 10 days	10	1	\$39.88	10%	67	47	31	No
00409490014	Sodium Bicarbonate	Sodium Bicarbonate	Minerals & Electrolytes	Pfizer	5/20/2020	\$169.39	\$161.26	\$177.39	\$140.50	max dose is 5 mEq/kg (5mL/kg)	10	10	\$1.69	10%	65	66	69	No
00409553414	Sodium Bicarbonate	Sodium Bicarbonate	Minerals & Electrolytes	Pfizer	5/21/2020	\$131.16	\$124.86	\$137.35	\$108.10	max dose is 5 mEq/kg (10mL/kg)	10	10	\$1.31	10%	64	74	75	No
64896069501	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	1/2/2013	\$358.86	\$303.72	\$364.16	\$145.00	5MG	1	100	\$3.59	20%	36	54	61	No
64896069513	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	4/17/2013	\$215.30	\$182.22	\$218.48	\$87.01	5MG	1	60	\$3.59	20%	40	63	62	No
64896069601	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	1/2/2013	\$523.94	\$443.44	\$531.68	\$211.72	7.5MG	1	100	\$5.24	20%	41	42	56	No
64896069613	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	4/17/2013	\$314.37	\$266.06	\$319.01	\$127.03	7.5MG	1	60	\$5.24	20%	28	57	55	No
64896069701	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	1/2/2013	\$689.09	\$583.21	\$699.27	\$278.45	10MG	1	100	\$6.89	20%	34	37	51	No
64896069713	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	4/17/2013	\$413.46	\$349.93	\$419.57	\$167.07	10MG	1	60	\$6.89	20%	29	46	50	No
64896069801	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	1/2/2013	\$955.58	\$808.75	\$969.69	\$386.15	15MG	1	100	\$9.56	20%	38	27	48	No
64896069813	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	4/17/2013	\$573.36	\$485.26	\$581.83	\$231.69	15MG	1	60	\$9.56	20%	31	40	47	No
64896069901	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	1/2/2013	\$1,222.17	\$1,034.38	\$1,240.22	\$493.86	20MG	1	100	\$12.22	20%	39	24	45	No
64896069913	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	4/17/2013	\$733.31	\$620.63	\$744.14	\$296.32	20MG	1	60	\$12.22	20%	30	33	44	No
64896070001	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	1/2/2013	\$1,428.09	\$1,488.82	\$1,785.10	\$710.84	30MG	1	100	\$14.28	20%	33	22	39	No
64896070013	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	4/17/2013	\$1,055.48	\$893.30	\$1,071.07	\$426.50	30MG	1	60	\$17.59	20%	32	26	37	No
64896070101	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	1/2/2013	\$2,296.09	\$1,943.28	\$2,329.99	\$927.82	40MG	1	100	\$22.96	20%	37	16	36	No
64896070113	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	4/17/2013	\$1,377.66	\$1,165.97	\$1,398.00	\$556.69	40MG	1	60	\$22.96	20%	35	23	35	No
65162011511	Hydrocodone Bitartrate and Acetaminophen	Hydrocodone Bitartrate and Acetaminophen	Analgesics - Opioid	Amneal Pharmaceuticals	1/24/2017	\$121.73	\$120.00	\$210.00	\$120.00	325MG	1	1000	\$0.12	75%	4	77	79	No
00069023201	Fragmin	Dalteparin Sodium	Anticoagulants	Pfizer	2/20/2015	\$819.22	\$779.90	\$857.89	\$609.42	max dose is 18,000 IU daily	1	3.8	\$215.58	10%	81	30	20	No
00409155554	Hextend	Hetastarch	Hematological Agents - Misc.	Pfizer	9/5/2015	\$864.28	\$864.28	\$950.71	\$680.40	The amount usually administered is 500 to 1000 mL. Doses of more than 1500 mL per day for the typical 70 kg patient (approximately 20 mL per kg of body weight) are usually not required. Assume the usual dose is 500mL and the max dose is 1500mL, according to the NDC strength.	12	500	\$0.14	10%	74	29	78	No
00409663714	Sodium Bicarbonate	Sodium Bicarbonate	Minerals & Electrolytes	Pfizer	5/20/2020	\$125.10	\$119.10	\$131.10	\$105.60	max dose is 5 mEq/kg (5mL/kg)	10	50	\$0.25	10%	62	75	77	No

NDC	Trade name / proprietary name	Chemical name / non-proprietary name	Therapeutic class	Manufacturer	Date on market	2022 Calculated AWAC	Beginning WAC 2022	Beginning WAC 2023	Introductory price	Drug dosage	Package quantity	Package size	Price per unit	Net Increase percentage	Rank GI	Rank MC	Rank ME	Has orphan indications
00409963305	Verapamil Hydrochloride	Verapamil Hydrochloride	Calcium Channel Blockers	Pfizer	9/5/2015	\$582.96	\$554.98	\$610.48	\$480.50	max dose is 20mg	10	4	\$14.57	10%	71	39	38	No
44206053211	Cytogam	Human Cytomegalovirus Immune Globulin	Passive Immunizing and Treatment Agents	Kamada INC.	12/4/1998	\$1,481.42	\$1,412.22	\$1,756.85	\$1,412.22	150 mg Ig/kg	1	50	\$29.63	24%	20	20	32	Orphan Only
52427065830	Loreev XR	Lorazepam	Antianxiety Agents	Almatica Pharma INC.	9/20/2021	\$397.00	\$285.00	\$425.00	\$285.00	The recommended once daily dosage of LOREEV XR is equal to the total daily dose of lorazepam tablets. For example, the recommended dosage for patients who have been receiving lorazepam tablets at a dosage of 1 mg three times daily is LOREEV XR 3 mg once daily in the morning	1	30	\$13.23	49%	6	48	40	No
52427066330	Loreev XR	Lorazepam	Antianxiety Agents	Almatica Pharma INC.	9/20/2021	\$397.00	\$285.00	\$425.00	\$285.00	The recommended once daily dosage of LOREEV XR is equal to the total daily dose of lorazepam tablets. For example, the recommended dosage for patients who have been receiving lorazepam tablets at a dosage of 1 mg three times daily is LOREEV XR 3 mg once daily in the morning	1	30	\$13.23	49%	6	48	40	No
52427066730	Loreev XR	Lorazepam	Antianxiety Agents	Almatica Pharma INC.	9/20/2021	\$397.00	\$285.00	\$425.00	\$285.00	The recommended once daily dosage of LOREEV XR is equal to the total daily dose of lorazepam tablets. For example, the recommended dosage for patients who have been receiving lorazepam tablets at a dosage of 1 mg three times daily is LOREEV XR 3 mg once daily in the morning	1	30	\$13.23	49%	6	48	40	No
63090010030	Nuplazid	Pimavanserin Tartrate	Antipsychotics/Antimanic Agents	Acadia Pharmaceuticals INC.	7/16/2018	\$4,293.58	\$3,980.00	\$4,565.00	\$2,778.00	10mg, 30 tablets	1	30	\$143.12	15%	56	12	21	No
63090034030	Nuplazid	Pimavanserin Tartrate	Antipsychotics/Antimanic Agents	Acadia Pharmaceuticals INC.	7/16/2018	\$4,293.58	\$3,980.00	\$4,565.00	\$2,778.00	34 mg, 30 capsules	1	30	\$143.12	15%	56	12	21	No
55292081155	Cosmegen	Dactinomycin	Antineoplastics and Adjunctive Therapies	Recordati Rare Diseases, INC.	11/1/2013	\$2,468.77	\$2,248.68	\$2,473.55	\$621.63	Solution Reconstituted 0.5 MG	1	1	\$2,468.77	10%	79	15	3	No
16252054001	Isradipine	Isradipine	Calcium Channel Blockers	Teva	1/1/2010	\$207.96	\$141.71	\$211.00	\$141.71	5MG	1	100	\$2.08	49%	10	64	67	No
16252053901	Isradipine	Isradipine	Calcium Channel Blockers	Teva	1/1/2010	\$142.22	\$96.90	\$144.30	\$96.90	2.5MG	1	100	\$1.42	49%	9	70	73	No
00093360882	Fluticasone Propionate and Salmeterol	Fluticasone Propionate and Salmeterol	Antiasthmatic and Bronchodilator Agents	Teva	4/28/2017	\$114.81	\$95.40	\$117.00	\$90.00	113/14MCG	1	1	\$114.81	23%	21	78	23	No
00093360982	Fluticasone Propionate and Salmeterol	Fluticasone Propionate and Salmeterol	Antiasthmatic and Bronchodilator Agents	Teva	4/28/2017	\$114.81	\$95.40	\$117.00	\$90.00	232/14MCG	1	1	\$114.81	23%	21	78	23	No
00093360782	Fluticasone Propionate and Salmeterol	Fluticasone Propionate and Salmeterol	Antiasthmatic and Bronchodilator Agents	Teva	4/28/2017	\$114.81	\$95.40	\$117.00	\$90.00	55-14MCG	1	1	\$114.81	23%	21	78	23	No
00264959420	Lidocaine Hydrochloride and Dextrose	Lidocaine Hydrochloride Anhydrous and Dextrose Monohydrate	Antiarrhythmics	B Braun Medical INC	5/1/1992	\$152.98	\$136.95	\$175.20	TS	TS	24	250	\$0.03	28%	16	67	81	No
00517250210	Caffeine and Sodium Benzoate	Caffeine and Sodium Benzoate	ADHD/Anti-Narcolepsy/Anti-Obesity/Aorexians	American Regent INC	1/1/1987	\$248.14	\$230.90	\$257.50	\$150.00	\$128.75	10	2	\$12.41	12%	58	61	43	No
69866103008	Maci	Autologous Cultured Chondrocytes	Musculoskeletal Therapy Agents	Vericel Corporation	6/27/2017	\$83,190.02	\$62,548.00	\$104,504.00	\$47,750.00	2 BAG in 1 BOX > 1 BOTTLE, PLASTIC in 1 BAG (69866-1030-7) > 1 IMPLANT in 1 BOTTLE, PLASTIC (69866-1030-6)	1	2	\$41,595.01	67%	5	1	1	No
71090000101	Keveyis	Dichlorphenamide	Diuretics	Xeris Pharmaceuticals	4/1/2017	\$28,363.24	\$24,963.28	\$30,150.67	\$13,650.00	Initiate dosing at 50 mg by mouth once or twice daily. The dosage may be increased or decreased based on individual response, at weekly intervals (or sooner in case of adverse reaction). The minimum recommended total daily dosage is 50 mg, and the maximum recommended total daily dosage is 200 mg.	1	100	\$283.63	21%	24	2	15	No
52856050101	Emflaza	Deflazacort	Corticosteroids	PTC Therapeutics INC	5/1/2017	\$7,467.43	\$6,597.06	\$7,859.50	\$4,361.00	6mg/kg - weight based dosing by patient	1	100	\$74.67	19%	46	9	30	Orphan Only
52856050203	Emflaza	Deflazacort	Corticosteroids	PTC Therapeutics INC	5/1/2017	\$6,720.86	\$5,937.50	\$7,073.73	\$3,925.00	18mg/kg - weight based dosing by patient	1	30	\$224.03	19%	44	10	19	Orphan Only
52856050303	Emflaza	Deflazacort	Corticosteroids	PTC Therapeutics INC	5/1/2017	\$11,202.01	\$9,896.33	\$11,790.16	\$6,542.00	30mg/kg - weight based dosing by patient	1	30	\$373.40	19%	42	7	10	Orphan Only
52856050403	Emflaza	Deflazacort	Corticosteroids	PTC Therapeutics INC	5/1/2017	\$12,967.59	\$11,456.13	\$13,648.45	\$7,290.00	36mg/kg - weight based dosing by patient	1	30	\$432.25	19%	43	6	9	Orphan Only
52856050522	Emflaza	Deflazacort	Corticosteroids	PTC Therapeutics INC	5/1/2017	\$17,526.98	\$4,346.10	\$5,177.79	\$3,634.93	22.75mg/mL/kg - weight based dosing by patient	1	13	\$1,348.23	19%	45	5	5	Orphan Only
73116021556	Copiktra	Duvelisib	Antineoplastics and Adjunctive Therapies	Secura Bio, INC	9/24/2018	\$18,441.46	\$16,446.15	\$24,020.76	\$11,800.00	25 mg administered as oral capsules twice daily (BID) with or without food. A cycle consists of 28 days	1	56	\$329.31	46%	11	3	13	Orphan Only
71779011502	Copiktra	Duvelisib	Antineoplastics and Adjunctive Therapies	Secura Bio, INC	9/24/2018	\$18,441.46	\$16,446.15	\$24,020.76	\$11,800.00	25 mg administered as oral capsules twice daily (BID) with or without food. A cycle consists of 28 days	1	56	\$329.31	46%	11	3	13	Orphan Only
71779011503	Copiktra	Duvelisib	Antineoplastics and Adjunctive Therapies	Secura Bio, INC	9/24/2018	\$9,220.74	\$8,223.08	\$12,010.38	\$5,900.00	25 mg administered as oral capsules twice daily (BID) with or without food. A cycle consists of 28 days	1	28	\$329.31	46%	13	8	12	Orphan Only
51267089099	Contrave	Naltrexone Hydrochloride and Bupropion Hydrochloride	ADHD/Anti-Narcolepsy/Anti-Obesity/Aorexians	Currax Pharmaceuticals LLC	9/1/2014	\$571.45	\$303.60	\$625.20	\$198.17	Tablet	1	120	\$4.76	106%	3	41	57	No

Drugs ranked by greatest increase

NDC	Trade name / proprietary name	Chemical name / non-proprietary name	Therapeutic class	Manufacturer	2022 Calculated AWAC	Price per unit	Beginning WAC 2022	Beginning WAC 2023	Net increase percentage	Rank GI	Has orphan indications
46287002410	Potassium Phosphates	Monobasic Potassium Phosphate and Dibasic Potassium Phosphate	Minerals & Electrolytes	CMP Pharma, INC.	\$139.32	\$0.93	\$131.00	\$299.00	128%	1	No
60687020601	Diltiazem Hydrochloride	Diltiazem Hydrochloride	Calcium Channel Blockers	Amerisource Health Services, LLC	\$143.17	\$1.43	\$39.00	\$80.55	107%	2	No
51267089099	Contrave	Naltrexone Hydrochloride and Bupropion Hydrochloride	ADHD/Anti-Narcolepsy/Anti-Obesity/Anorexiant	Currax Pharmaceuticals LLC	\$571.45	\$4.76	\$303.60	\$625.20	106%	3	No
65162011511	Hydrocodone Bitartrate and Acetaminophen	Hydrocodone Bitartrate and Acetaminophen	Analgesics - Opioid	Amneal Pharmaceuticals	\$121.73	\$0.12	\$120.00	\$210.00	75%	4	No
69866103008	Maci	Autologous Cultured Chondrocytes	Musculoskeletal Therapy Agents	Vericel Corporation	\$83,190.02	\$41,595.01	\$62,548.00	\$104,504.00	67%	5	No
52427065830	Loreev XR	Lorazepam	Antianxiety Agents	Almatica Pharma INC.	\$397.00	\$13.23	\$285.00	\$425.00	49%	6	No
52427066330	Loreev XR	Lorazepam	Antianxiety Agents	Almatica Pharma INC.	\$397.00	\$13.23	\$285.00	\$425.00	49%	6	No
52427066730	Loreev XR	Lorazepam	Antianxiety Agents	Almatica Pharma INC.	\$397.00	\$13.23	\$285.00	\$425.00	49%	6	No
16252053901	Isradipine	Isradipine	Calcium Channel Blockers	Teva	\$142.22	\$1.42	\$96.90	\$144.30	49%	9	No
16252054001	Isradipine	Isradipine	Calcium Channel Blockers	Teva	\$207.96	\$2.08	\$141.71	\$211.00	49%	10	No
73116021556	Copiktra	Duvelisib	Antineoplastics and Adjunctive Therapies	Secura Bio, INC	\$18,441.46	\$329.31	\$16,446.15	\$24,020.76	46%	11	Orphan Only
71779011502	Copiktra	Duvelisib	Antineoplastics and Adjunctive Therapies	Secura Bio, INC	\$18,441.46	\$329.31	\$16,446.15	\$24,020.76	46%	11	Orphan Only
71779011503	Copiktra	Duvelisib	Antineoplastics and Adjunctive Therapies	Secura Bio, INC	\$9,220.74	\$329.31	\$8,223.08	\$12,010.38	46%	13	Orphan Only
60687040825	Mesalamine	Mesalamine	Gastrointestinal Agents - Misc.	Amerisource Health Services, LLC	\$754.68	\$25.16	\$314.10	\$410.00	31%	14	No
68001035937	Gemcitabine	Gemcitabine	Antineoplastics and Adjunctive Therapies	Amerisource Health Services, LLC	\$105.60	\$5.28	\$82.07	\$105.60	29%	15	No
00264959420	Lidocaine Hydrochloride and Dextrose	Lidocaine Hydrochloride Anhydrous and Dextrose Monohydrate	Antiarrhythmics	B Braun Medical INC	\$152.98	\$0.03	\$136.95	\$175.20	28%	16	No
60687050401	Verapamil Hydrochloride	Verapamil Hcl	Calcium Channel Blockers	Amerisource Health Services, LLC	\$142.82	\$1.43	\$118.75	\$150.81	27%	17	No
60687049301	Verapamil Hydrochloride	Verapamil Hcl	Calcium Channel Blockers	Amerisource Health Services, LLC	\$133.36	\$1.33	\$110.88	\$140.80	27%	18	No
60687022901	Loperamide Hydrochloride	Loperamide Hydrochloride	Antidiarrheal/Probiotic Agents	Amerisource Health Services, LLC	\$377.53	\$3.78	\$67.06	\$85.00	27%	19	No
44206053211	Cytogam	Human Cytomegalovirus Immune Globulin	Passive Immunizing and Treatment Agents	Kamada INC.	\$1,481.42	\$29.63	\$1,412.22	\$1,756.85	24%	20	Orphan Only
00093360882	Fluticasone Propionate and Salmeterol	Fluticasone Propionate and Salmeterol	Antiasthmatic and Bronchodilator Agents	Teva	\$114.81	\$114.81	\$95.40	\$117.00	23%	21	No
00093360982	Fluticasone Propionate and Salmeterol	Fluticasone Propionate and Salmeterol	Antiasthmatic and Bronchodilator Agents	Teva	\$114.81	\$114.81	\$95.40	\$117.00	23%	21	No
00093360782	Fluticasone Propionate and Salmeterol	Fluticasone Propionate and Salmeterol	Antiasthmatic and Bronchodilator Agents	Teva	\$114.81	\$114.81	\$95.40	\$117.00	23%	21	No
71090000101	Keveyis	Dichlorphenamide	Diuretics	Xeris Pharmaceuticals	\$28,363.24	\$283.63	\$24,963.28	\$30,150.67	21%	24	No
62584081301	Oxazepam	Oxazepam	Antianxiety Agents	Amerisource Health Services, LLC	\$258.64	\$2.59	\$218.73	\$262.48	20%	25	No
62584081201	Oxazepam	Oxazepam	Antianxiety Agents	Amerisource Health Services, LLC	\$235.02	\$2.35	\$198.75	\$238.50	20%	26	No
62584081401	Oxazepam	Oxazepam	Antianxiety Agents	Amerisource Health Services, LLC	\$287.10	\$2.87	\$242.80	\$291.36	20%	26	No
64896069613	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$314.37	\$5.24	\$266.06	\$319.01	20%	28	No
64896069713	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$413.46	\$6.89	\$349.93	\$419.57	20%	29	No
64896069913	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$733.31	\$12.22	\$620.63	\$744.14	20%	30	No
64896069813	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$573.36	\$9.56	\$485.26	\$581.83	20%	31	No
64896070013	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$1,055.48	\$17.59	\$893.30	\$1,071.07	20%	32	No
64896070001	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$1,428.09	\$14.28	\$1,488.82	\$1,785.10	20%	33	No
64896069701	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$689.09	\$6.89	\$583.21	\$699.27	20%	34	No
64896070113	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$1,377.66	\$22.96	\$1,165.97	\$1,398.00	20%	35	No
64896069501	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$358.86	\$3.59	\$303.72	\$364.16	20%	36	No
64896070101	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$2,296.09	\$22.96	\$1,943.28	\$2,329.99	20%	37	No
64896069801	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$955.58	\$9.56	\$808.75	\$969.69	20%	38	No
64896069901	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$1,222.17	\$12.22	\$1,034.38	\$1,240.22	20%	39	No
64896069513	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$215.30	\$3.59	\$182.22	\$218.48	20%	40	No
64896069601	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$523.94	\$5.24	\$443.44	\$531.68	20%	41	No
52856050303	Emflaza	Deflazacort	Corticosteroids	PTC Therapeutics INC	\$11,202.01	\$373.40	\$9,896.33	\$11,790.16	19%	42	Orphan Only

NDC	Trade name / proprietary name	Chemical name / non-proprietary name	Therapeutic class	Manufacturer	2022 Calculated AWAC	Price per unit	Beginning WAC 2022	Beginning WAC 2023	Net increase percentage	Rank GI	Has orphan indications
52856050403	Emflaza	Deflazacort	Corticosteroids	PTC Therapeutics INC	\$12,967.59	\$432.25	\$11,456.13	\$13,648.45	19%	43	Orphan Only
52856050203	Emflaza	Deflazacort	Corticosteroids	PTC Therapeutics INC	\$6,720.86	\$224.03	\$5,937.50	\$7,073.73	19%	44	Orphan Only
52856050522	Emflaza	Deflazacort	Corticosteroids	PTC Therapeutics INC	\$17,526.98	\$1,348.23	\$4,346.10	\$5,177.79	19%	45	Orphan Only
52856050101	Emflaza	Deflazacort	Corticosteroids	PTC Therapeutics INC	\$7,467.43	\$74.67	\$6,597.06	\$7,859.50	19%	46	Orphan Only
76310002201	Proleukin	Aldesleukin	Antineoplastics and Adjunctive Therapies	Clinigen, INC.	\$5,168.17	\$5,168.17	\$4,683.60	\$5,551.47	19%	47	Orphan Only
42291096218	Yuvafem	Estradiol	Vaginal and Related Products	Avkare, INC (Aka Avpak)	\$124.77	\$6.93	\$119.72	\$140.67	17%	48	No
42192014360	Sodium Sulfacetamide 10% and Sulfur 5% Emollient Foam	Sulfacetamide Sodium and Sulfur	Dermatologicals	Acella Pharmaceuticals LLC	\$321.60	\$5.36	\$281.72	\$323.55	15%	49	No
42192010316	BP Cleansing Wash	Sodium Sulfacetamide and Sulfur	Dermatologicals	Acella Pharmaceuticals LLC	\$697.01	\$1.47	\$610.58	\$701.23	15%	50	No
42192011515	Urea Hydrating Topical	Urea	Dermatologicals	Acella Pharmaceuticals LLC	\$256.74	\$1.71	\$224.91	\$258.30	15%	51	No
42192011270	Salicylic Acid	Salicylic Acid	Dermatologicals	Acella Pharmaceuticals LLC	\$176.70	\$2.52	\$154.79	\$177.77	15%	52	No
42192010406	Sodium Sulfacetamide and Sulfur	Sodium Sulfacetamide and Sulfur	Dermatologicals	Acella Pharmaceuticals LLC	\$753.35	\$4.43	\$659.94	\$757.91	15%	53	No
42192071401	Ciclopirox	Ciclopirox	Dermatologicals	Acella Pharmaceuticals LLC	\$360.73	\$10.43	\$316.00	\$362.91	15%	54	No
42192014301	Sodium Sulfacetamide 10% and Sulfur 5% Emollient Foam	Sulfacetamide Sodium and Sulfur	Dermatologicals	Acella Pharmaceuticals LLC	\$428.80	\$4.29	\$375.64	\$431.40	15%	55	No
63090010030	Nuplazid	Pimavanserin Tartrate	Antipsychotics/Antimanic Agents	Acadia Pharmaceuticals INC.	\$4,293.58	\$143.12	\$3,980.00	\$4,565.00	15%	56	No
63090034030	Nuplazid	Pimavanserin Tartrate	Antipsychotics/Antimanic Agents	Acadia Pharmaceuticals INC.	\$4,293.58	\$143.12	\$3,980.00	\$4,565.00	15%	56	No
00517250210	Caffeine and Sodium Benzoate	Caffeine and Sodium Benzoate	ADHD/Anti-Narcolepsy/Anti-Obesity/Anorexiant	American Regent INC	\$248.14	\$12.41	\$230.90	\$257.50	12%	58	No
68001044327	Cyclophosphamide	Cyclophosphamide	Antineoplastics and Adjunctive Therapies	Amerisource Health Services, LLC	\$732.50	\$732.50	\$659.25	\$732.50	11%	59	No
68001044432	Cyclophosphamide	Cyclophosphamide	Antineoplastics and Adjunctive Therapies	Amerisource Health Services, LLC	\$1,465.00	\$1,465.00	\$1,318.50	\$1,465.00	11%	59	No
68001044226	Cyclophosphamide	Cyclophosphamide	Antineoplastics and Adjunctive Therapies	Amerisource Health Services, LLC	\$366.25	\$366.25	\$329.63	\$366.25	11%	61	No
00409663714	Sodium Bicarbonate	Sodium Bicarbonate	Minerals & Electrolytes	Pfizer	\$125.10	\$0.25	\$119.10	\$131.10	10%	62	No
00009027101	Depo-Estradiol	Estradiol Cypionate	Estrogens	Pfizer	\$133.74	\$26.75	\$127.35	\$140.09	10%	63	No
00409553414	Sodium Bicarbonate	Sodium Bicarbonate	Minerals & Electrolytes	Pfizer	\$131.16	\$1.31	\$124.86	\$137.35	10%	64	No
00409490014	Sodium Bicarbonate	Sodium Bicarbonate	Minerals & Electrolytes	Pfizer	\$169.39	\$1.69	\$161.26	\$177.39	10%	65	No
00409741803	LMD in Dextrose	Dextran 40	Hematological Agents - Misc.	Pfizer	\$351.95	\$0.06	\$351.95	\$387.15	10%	66	No
60793013010	Penicillin G Procaine	Penicillin G Procaine	Penicillins	Pfizer	\$398.80	\$39.88	\$379.76	\$417.74	10%	67	No
00069019602	Fragmin	Dalteparin Sodium	Anticoagulants	Pfizer	\$476.42	\$238.21	\$453.67	\$499.04	10%	68	No
62584015901	Demeclocycline Hydrochloride	Demeclocycline Hydrochloride	Tetracyclines	Amerisource Health Services, LLC	\$677.79	\$6.78	\$630.46	\$693.51	10%	69	No
00069022002	Fragmin	Dalteparin Sodium	Anticoagulants	Pfizer	\$1,191.12	\$238.22	\$1,134.25	\$1,247.68	10%	70	No
00409963305	Verapamil Hydrochloride	Verapamil Hydrochloride	Calcium Channel Blockers	Pfizer	\$582.96	\$14.57	\$554.98	\$610.48	10%	71	No
00069020602	Fragmin	Dalteparin Sodium	Anticoagulants	Pfizer	\$714.70	\$238.23	\$680.58	\$748.64	10%	72	No
00409337301	Corlopan	Fenoldopam Mesylate	Antihypertensives	Pfizer	\$434.33	\$434.33	\$413.59	\$454.95	10%	73	No
00409155554	Hextend	Hetastarch	Hematological Agents - Misc.	Pfizer	\$864.28	\$0.14	\$864.28	\$950.71	10%	74	No
60793060210	Bicillin C-R 900/300	Penicillin G Benzathine and Penicillin G Procaine	Penicillins	Pfizer	\$1,543.62	\$77.18	\$1,509.57	\$1,660.53	10%	75	No
60793060010	Bicillin CR	Penicillin G Benzathine and Penicillin G Procaine	Penicillins	Pfizer	\$1,585.26	\$79.26	\$1,509.57	\$1,660.53	10%	75	No
60793060110	Bicillin CR	Penicillin G Benzathine and Penicillin G Procaine	Penicillins	Pfizer	\$1,585.26	\$79.26	\$1,509.57	\$1,660.53	10%	75	No
00409337302	Corlopan	Fenoldopam Mesylate	Antihypertensives	Pfizer	\$868.66	\$434.33	\$827.19	\$909.91	10%	78	No
55292081155	Cosmegen	Dactinomycin	Antineoplastics and Adjunctive Therapies	Recordati Rare Diseases, INC.	\$2,468.77	\$2,468.77	\$2,248.68	\$2,473.55	10%	79	No
60793070210	Bicillin L-A	Penicillin G Benzathine	Penicillins	Pfizer	\$4,075.14	\$101.88	\$3,880.58	\$4,268.64	10%	80	No
00069023201	Fragmin	Dalteparin Sodium	Anticoagulants	Pfizer	\$819.22	\$215.58	\$779.90	\$857.89	10%	81	No

Drugs ranked by most costly (highest 2022 calculated AWAC)

NDC	Trade name / proprietary name	Chemical name / non-proprietary name	Therapeutic class	Manufacturer	2022 Calculated AWAC	Price per unit	Beginning WAC 2022	Beginning WAC 2023	Net increase percentage	Rank MC	Has orphan indications
69866103008	Maci	Autologous Cultured Chondrocytes	Musculoskeletal Therapy Agents	Vericel Corporation	\$83,190.02	\$41,595.01	\$62,548.00	\$104,504.00	67%	1	No
71090000101	Keveysi	Dichlorphenamide	Diuretics	Xeris Pharmaceuticals	\$28,363.24	\$283.63	\$24,963.28	\$30,150.67	21%	2	No
73116021556	Copiktra	Duvelisib	Antineoplastics and Adjunctive Therapies	Secura Bio, INC	\$18,441.46	\$329.31	\$16,446.15	\$24,020.76	46%	3	Orphan Only
71779011502	Copiktra	Duvelisib	Antineoplastics and Adjunctive Therapies	Secura Bio, INC	\$18,441.46	\$329.31	\$16,446.15	\$24,020.76	46%	3	Orphan Only
52856050522	Emflaza	Deflazacort	Corticosteroids	PTC Therapeutics INC	\$17,526.98	\$1,348.23	\$4,346.10	\$5,177.79	19%	5	Orphan Only
52856050403	Emflaza	Deflazacort	Corticosteroids	PTC Therapeutics INC	\$12,967.59	\$432.25	\$11,456.13	\$13,648.45	19%	6	Orphan Only
52856050303	Emflaza	Deflazacort	Corticosteroids	PTC Therapeutics INC	\$11,202.01	\$373.40	\$9,896.33	\$11,790.16	19%	7	Orphan Only
71779011503	Copiktra	Duvelisib	Antineoplastics and Adjunctive Therapies	Secura Bio, INC	\$9,220.74	\$329.31	\$8,223.08	\$12,010.38	46%	8	Orphan Only
52856050101	Emflaza	Deflazacort	Corticosteroids	PTC Therapeutics INC	\$7,467.43	\$74.67	\$6,597.06	\$7,859.50	19%	9	Orphan Only
52856050203	Emflaza	Deflazacort	Corticosteroids	PTC Therapeutics INC	\$6,720.86	\$224.03	\$5,937.50	\$7,073.73	19%	10	Orphan Only
76310002201	Proleukin	Aldesleukin	Antineoplastics and Adjunctive Therapies	Clinigen, INC.	\$5,168.17	\$5,168.17	\$4,683.60	\$5,551.47	19%	11	Orphan Only
63090010030	Nuplazid	Pimavanserin Tartrate	Antipsychotics/Antimanic Agents	Acadia Pharmaceuticals INC.	\$4,293.58	\$143.12	\$3,980.00	\$4,565.00	15%	12	No
63090034030	Nuplazid	Pimavanserin Tartrate	Antipsychotics/Antimanic Agents	Acadia Pharmaceuticals INC.	\$4,293.58	\$143.12	\$3,980.00	\$4,565.00	15%	12	No
60793070210	Bicillin L-A	Penicillin G Benzathine	Penicillins	Pfizer	\$4,075.14	\$101.88	\$3,880.58	\$4,268.64	10%	14	No
55292081155	Cosmegen	Dactinomycin	Antineoplastics and Adjunctive Therapies	Recordati Rare Diseases, INC.	\$2,468.77	\$2,468.77	\$2,248.68	\$2,473.55	10%	15	No
64896070101	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$2,296.09	\$22.96	\$1,943.28	\$2,329.99	20%	16	No
60793060010	Bicillin CR	Penicillin G Benzathine and Penicillin G Procaine	Penicillins	Pfizer	\$1,585.26	\$79.26	\$1,509.57	\$1,660.53	10%	17	No
60793060110	Bicillin CR	Penicillin G Benzathine and Penicillin G Procaine	Penicillins	Pfizer	\$1,585.26	\$79.26	\$1,509.57	\$1,660.53	10%	17	No
60793060210	Bicillin C-R 900/300	Penicillin G Benzathine and Penicillin G Procaine	Penicillins	Pfizer	\$1,543.62	\$77.18	\$1,509.57	\$1,660.53	10%	19	No
44206053211	Cytogam	Human Cytomegalovirus Immune Globulin	Passive Immunizing and Treatment Agents	Kamada INC.	\$1,481.42	\$29.63	\$1,412.22	\$1,756.85	24%	20	Orphan Only
68001044432	Cyclophosphamide	Cyclophosphamide	Antineoplastics and Adjunctive Therapies	Amerisource Health Services, LLC	\$1,465.00	\$1,465.00	\$1,318.50	\$1,465.00	11%	21	No
64896070001	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$1,428.09	\$14.28	\$1,488.82	\$1,785.10	20%	22	No
64896070113	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$1,377.66	\$22.96	\$1,165.97	\$1,398.00	20%	23	No
64896069901	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$1,222.17	\$12.22	\$1,034.38	\$1,240.22	20%	24	No
00069022002	Fragmin	Dalteparin Sodium	Anticoagulants	Pfizer	\$1,191.12	\$238.22	\$1,134.25	\$1,247.68	10%	25	No
64896070013	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$1,055.48	\$17.59	\$893.30	\$1,071.07	20%	26	No
64896069801	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$955.58	\$9.56	\$808.75	\$969.69	20%	27	No
00409337302	Corlopam	Fenoldopam Mesylate	Antihypertensives	Pfizer	\$868.66	\$434.33	\$827.19	\$909.91	10%	28	No
00409155554	Hextend	Hetastarch	Hematological Agents - Misc.	Pfizer	\$864.28	\$0.14	\$864.28	\$950.71	10%	29	No
00069023201	Fragmin	Dalteparin Sodium	Anticoagulants	Pfizer	\$819.22	\$215.58	\$779.90	\$857.89	10%	30	No
60687040825	Mesalamine	Mesalamine	Gastrointestinal Agents - Misc.	Amerisource Health Services, LLC	\$754.68	\$25.16	\$314.10	\$410.00	31%	31	No
42192010406	Sodium Sulfacetamide and Sulfur	Sodium Sulfacetamide and Sulfur	Dermatologicals	Acella Pharmaceuticals LLC	\$753.35	\$4.43	\$659.94	\$757.91	15%	32	No
64896069913	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$733.31	\$12.22	\$620.63	\$744.14	20%	33	No
68001044327	Cyclophosphamide	Cyclophosphamide	Antineoplastics and Adjunctive Therapies	Amerisource Health Services, LLC	\$732.50	\$732.50	\$659.25	\$732.50	11%	34	No
00069020602	Fragmin	Dalteparin Sodium	Anticoagulants	Pfizer	\$714.70	\$238.23	\$680.58	\$748.64	10%	35	No
42192010316	BP Cleansing Wash	Sodium Sulfacetamide and Sulfur	Dermatologicals	Acella Pharmaceuticals LLC	\$697.01	\$1.47	\$610.58	\$701.23	15%	36	No
64896069701	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$689.09	\$6.89	\$583.21	\$699.27	20%	37	No
62584015901	Demeclocycline Hydrochloride	Demeclocycline Hydrochloride	Tetracyclines	Amerisource Health Services, LLC	\$677.79	\$6.78	\$630.46	\$693.51	10%	38	No
00409963305	Verapamil Hydrochloride	Verapamil Hydrochloride	Calcium Channel Blockers	Pfizer	\$582.96	\$14.57	\$554.98	\$610.48	10%	39	No
64896069813	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$573.36	\$9.56	\$485.26	\$581.83	20%	40	No
51267089099	Contrave	Naltrexone Hydrochloride and Bupropion Hydrochloride	ADHD/Anti-Narcolepsy/Anti-Obesity/Anorexiant	Currax Pharmaceuticals LLC	\$571.45	\$4.76	\$303.60	\$625.20	106%	41	No
64896069601	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$523.94	\$5.24	\$443.44	\$531.68	20%	42	No
00069019602	Fragmin	Dalteparin Sodium	Anticoagulants	Pfizer	\$476.42	\$238.21	\$453.67	\$499.04	10%	43	No
00409337301	Corlopam	Fenoldopam Mesylate	Antihypertensives	Pfizer	\$434.33	\$434.33	\$413.59	\$454.95	10%	44	No

NDC	Trade name / proprietary name	Chemical name / non-proprietary name	Therapeutic class	Manufacturer	2022 Calculated AWAC	Price per unit	Beginning WAC 2022	Beginning WAC 2023	Net increase percentage	Rank MC	Has orphan indications
42192014301	Sodium Sulfacetamide 10% and Sulfur 5% Emollient Foam	Sulfacetamide Sodium and Sulfur	Dermatologicals	Acella Pharmaceuticals LLC	\$428.80	\$4.29	\$375.64	\$431.40	15%	45	No
64896069713	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$413.46	\$6.89	\$349.93	\$419.57	20%	46	No
60793013010	Penicillin G Procaine	Penicillin G Procaine	Penicillins	Pfizer	\$398.80	\$39.88	\$379.76	\$417.74	10%	47	No
52427065830	Loreev XR	Lorazepam	Antianxiety Agents	Almatica Pharma INC.	\$397.00	\$13.23	\$285.00	\$425.00	49%	48	No
52427066330	Loreev XR	Lorazepam	Antianxiety Agents	Almatica Pharma INC.	\$397.00	\$13.23	\$285.00	\$425.00	49%	48	No
52427066730	Loreev XR	Lorazepam	Antianxiety Agents	Almatica Pharma INC.	\$397.00	\$13.23	\$285.00	\$425.00	49%	48	No
60687022901	Loperamide Hydrochloride	Loperamide Hydrochloride	Antidiarrheal/Probiotic Agents	Amerisource Health Services, LLC	\$377.53	\$3.78	\$67.06	\$85.00	27%	51	No
68001044226	Cyclophosphamide	Cyclophosphamide	Antineoplastics and Adjunctive Therapies	Amerisource Health Services, LLC	\$366.25	\$366.25	\$329.63	\$366.25	11%	52	No
42192071401	Ciclopirox	Ciclopirox	Dermatologicals	Acella Pharmaceuticals LLC	\$360.73	\$10.43	\$316.00	\$362.91	15%	53	No
64896069501	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$358.86	\$3.59	\$303.72	\$364.16	20%	54	No
00409741803	LMD in Dextrose	Dextran 40	Hematological Agents - Misc.	Pfizer	\$351.95	\$0.06	\$351.95	\$387.15	10%	55	No
42192014360	Sodium Sulfacetamide 10% and Sulfur 5% Emollient Foam	Sulfacetamide Sodium and Sulfur	Dermatologicals	Acella Pharmaceuticals LLC	\$321.60	\$5.36	\$281.72	\$323.55	15%	56	No
64896069613	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$314.37	\$5.24	\$266.06	\$319.01	20%	57	No
62584081401	Oxazepam	Oxazepam	Antianxiety Agents	Amerisource Health Services, LLC	\$287.10	\$2.87	\$242.80	\$291.36	20%	58	No
62584081301	Oxazepam	Oxazepam	Antianxiety Agents	Amerisource Health Services, LLC	\$258.64	\$2.59	\$218.73	\$262.48	20%	59	No
42192011515	Urea Hydrating Topical	Urea	Dermatologicals	Acella Pharmaceuticals LLC	\$256.74	\$1.71	\$224.91	\$258.30	15%	60	No
00517250210	Caffeine and Sodium Benzoate	Caffeine and Sodium Benzoate	ADHD/Anti-Narcolepsy/Anti-Obesity/Anorexiant	American Regent INC	\$248.14	\$12.41	\$230.90	\$257.50	12%	61	No
62584081201	Oxazepam	Oxazepam	Antianxiety Agents	Amerisource Health Services, LLC	\$235.02	\$2.35	\$198.75	\$238.50	20%	62	No
64896069513	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$215.30	\$3.59	\$182.22	\$218.48	20%	63	No
16252054001	Isradipine	Isradipine	Calcium Channel Blockers	Teva	\$207.96	\$2.08	\$141.71	\$211.00	49%	64	No
42192011270	Salicylic Acid	Salicylic Acid	Dermatologicals	Acella Pharmaceuticals LLC	\$176.70	\$2.52	\$154.79	\$177.77	15%	65	No
00409490014	Sodium Bicarbonate	Sodium Bicarbonate	Minerals & Electrolytes	Pfizer	\$169.39	\$1.69	\$161.26	\$177.39	10%	66	No
00264959420	Lidocaine Hydrochloride and Dextrose	Lidocaine Hydrochloride Anhydrous and Dextrose Monohydrate	Antiarrhythmics	B Braun Medical INC	\$152.98	\$0.03	\$136.95	\$175.20	28%	67	No
60687020601	Diltiazem Hydrochloride	Diltiazem Hydrochloride	Calcium Channel Blockers	Amerisource Health Services, LLC	\$143.17	\$1.43	\$39.00	\$80.55	107%	68	No
60687050401	Verapamil Hydrochloride	Verapamil Hcl	Calcium Channel Blockers	Amerisource Health Services, LLC	\$142.82	\$1.43	\$118.75	\$150.81	27%	69	No
16252053901	Isradipine	Isradipine	Calcium Channel Blockers	Teva	\$142.22	\$1.42	\$96.90	\$144.30	49%	70	No
46287002410	Potassium Phosphates	Monobasic Potassium Phosphate and Dibasic Potassium Phosphate	Minerals & Electrolytes	CMP Pharma, INC.	\$139.32	\$0.93	\$131.00	\$299.00	128%	71	No
00009027101	Depo-Estradiol	Estradiol Cypionate	Estrogens	Pfizer	\$133.74	\$26.75	\$127.35	\$140.09	10%	72	No
60687049301	Verapamil Hydrochloride	Verapamil Hcl	Calcium Channel Blockers	Amerisource Health Services, LLC	\$133.36	\$1.33	\$110.88	\$140.80	27%	73	No
00409553414	Sodium Bicarbonate	Sodium Bicarbonate	Minerals & Electrolytes	Pfizer	\$131.16	\$1.31	\$124.86	\$137.35	10%	74	No
00409663714	Sodium Bicarbonate	Sodium Bicarbonate	Minerals & Electrolytes	Pfizer	\$125.10	\$0.25	\$119.10	\$131.10	10%	75	No
42291096218	Yuvafem	Estradiol	Vaginal and Related Products	Avkare, INC (Aka Avpak)	\$124.77	\$6.93	\$119.72	\$140.67	17%	76	No
65162011511	Hydrocodone Bitartrate and Acetaminophen	Hydrocodone Bitartrate and Acetaminophen	Analgesics - Opioid	Amneal Pharmaceuticals	\$121.73	\$0.12	\$120.00	\$210.00	75%	77	No
00093360882	Fluticasone Propionate and Salmeterol	Fluticasone Propionate and Salmeterol	Antiasthmatic and Bronchodilator Agents	Teva	\$114.81	\$114.81	\$95.40	\$117.00	23%	78	No
00093360982	Fluticasone Propionate and Salmeterol	Fluticasone Propionate and Salmeterol	Antiasthmatic and Bronchodilator Agents	Teva	\$114.81	\$114.81	\$95.40	\$117.00	23%	78	No
00093360782	Fluticasone Propionate and Salmeterol	Fluticasone Propionate and Salmeterol	Antiasthmatic and Bronchodilator Agents	Teva	\$114.81	\$114.81	\$95.40	\$117.00	23%	78	No
68001035937	Gemcitabine	Gemcitabine	Antineoplastics and Adjunctive Therapies	Amerisource Health Services, LLC	\$105.60	\$5.28	\$82.07	\$105.60	29%	81	No

Drugs ranked by most expensive (highest cost per unit)

NDC	Trade name / proprietary name	Chemical name / non-proprietary name	Therapeutic class	Manufacturer	2022 Calculated AWAC	Price per unit	Beginning WAC 2022	Beginning WAC 2023	Net increase percentage	Rank ME	Has orphan indications
69866103008	Maci	Autologous Cultured Chondrocytes	Musculoskeletal Therapy Agents	Vericel Corporation	\$83,190.02	\$41,595.01	\$62,548.00	\$104,504.00	67%	1	No
76310002201	Proleukin	Aldesleukin	Antineoplastics and Adjunctive Therapies	Clinigen, INC.	\$5,168.17	\$5,168.17	\$4,683.60	\$5,551.47	19%	2	Orphan Only
55292081155	Cosmegen	Dactinomycin	Antineoplastics and Adjunctive Therapies	Recordati Rare Diseases, INC.	\$2,468.77	\$2,468.77	\$2,248.68	\$2,473.55	10%	3	No
68001044432	Cyclophosphamide	Cyclophosphamide	Antineoplastics and Adjunctive Therapies	Amerisource Health Services, LLC	\$1,465.00	\$1,465.00	\$1,318.50	\$1,465.00	11%	4	No
52856050522	Emflaza	Deflazacort	Corticosteroids	PTC Therapeutics INC	\$17,526.98	\$1,348.23	\$4,346.10	\$5,177.79	19%	5	Orphan Only
68001044327	Cyclophosphamide	Cyclophosphamide	Antineoplastics and Adjunctive Therapies	Amerisource Health Services, LLC	\$732.50	\$732.50	\$659.25	\$732.50	11%	6	No
00409337302	Corlopan	Fenoldopam Mesylate	Antihypertensives	Pfizer	\$868.66	\$434.33	\$827.19	\$909.91	10%	7	No
00409337301	Corlopan	Fenoldopam Mesylate	Antihypertensives	Pfizer	\$434.33	\$434.33	\$413.59	\$454.95	10%	8	No
52856050403	Emflaza	Deflazacort	Corticosteroids	PTC Therapeutics INC	\$12,967.59	\$432.25	\$11,456.13	\$13,648.45	19%	9	Orphan Only
52856050303	Emflaza	Deflazacort	Corticosteroids	PTC Therapeutics INC	\$11,202.01	\$373.40	\$9,896.33	\$11,790.16	19%	10	Orphan Only
68001044226	Cyclophosphamide	Cyclophosphamide	Antineoplastics and Adjunctive Therapies	Amerisource Health Services, LLC	\$366.25	\$366.25	\$329.63	\$366.25	11%	11	No
71779011503	Copiktra	Duvelisib	Antineoplastics and Adjunctive Therapies	Secura Bio, INC	\$9,220.74	\$329.31	\$8,223.08	\$12,010.38	46%	12	Orphan Only
73116021556	Copiktra	Duvelisib	Antineoplastics and Adjunctive Therapies	Secura Bio, INC	\$18,441.46	\$329.31	\$16,446.15	\$24,020.76	46%	13	Orphan Only
71779011502	Copiktra	Duvelisib	Antineoplastics and Adjunctive Therapies	Secura Bio, INC	\$18,441.46	\$329.31	\$16,446.15	\$24,020.76	46%	13	Orphan Only
71090000101	Keveyis	Dichlorphenamide	Diuretics	Xeris Pharmaceuticals	\$28,363.24	\$283.63	\$24,963.28	\$30,150.67	21%	15	No
00069020602	Fragmin	Dalteparin Sodium	Anticoagulants	Pfizer	\$714.70	\$238.23	\$680.58	\$748.64	10%	16	No
00069022002	Fragmin	Dalteparin Sodium	Anticoagulants	Pfizer	\$1,191.12	\$238.22	\$1,134.25	\$1,247.68	10%	17	No
00069019602	Fragmin	Dalteparin Sodium	Anticoagulants	Pfizer	\$476.42	\$238.21	\$453.67	\$499.04	10%	18	No
52856050203	Emflaza	Deflazacort	Corticosteroids	PTC Therapeutics INC	\$6,720.86	\$224.03	\$5,937.50	\$7,073.73	19%	19	Orphan Only
00069023201	Fragmin	Dalteparin Sodium	Anticoagulants	Pfizer	\$819.22	\$215.58	\$779.90	\$857.89	10%	20	No
63090010030	Nuplazid	Pimavanserin Tartrate	Antipsychotics/Antimanic Agents	Acadia Pharmaceuticals INC.	\$4,293.58	\$143.12	\$3,980.00	\$4,565.00	15%	21	No
63090034030	Nuplazid	Pimavanserin Tartrate	Antipsychotics/Antimanic Agents	Acadia Pharmaceuticals INC.	\$4,293.58	\$143.12	\$3,980.00	\$4,565.00	15%	21	No
00093360882	Fluticasone Propionate and Salmeterol	Fluticasone Propionate and Salmeterol	Antiasthmatic and Bronchodilator Agents	Teva	\$114.81	\$114.81	\$95.40	\$117.00	23%	23	No
00093360982	Fluticasone Propionate and Salmeterol	Fluticasone Propionate and Salmeterol	Antiasthmatic and Bronchodilator Agents	Teva	\$114.81	\$114.81	\$95.40	\$117.00	23%	23	No
00093360782	Fluticasone Propionate and Salmeterol	Fluticasone Propionate and Salmeterol	Antiasthmatic and Bronchodilator Agents	Teva	\$114.81	\$114.81	\$95.40	\$117.00	23%	23	No
60793070210	Bicillin L-A	Penicillin G Benzathine	Penicillins	Pfizer	\$4,075.14	\$101.88	\$3,880.58	\$4,268.64	10%	26	No
60793060010	Bicillin CR	Penicillin G Benzathine and Penicillin G Procaine	Penicillins	Pfizer	\$1,585.26	\$79.26	\$1,509.57	\$1,660.53	10%	27	No
60793060110	Bicillin CR	Penicillin G Benzathine and Penicillin G Procaine	Penicillins	Pfizer	\$1,585.26	\$79.26	\$1,509.57	\$1,660.53	10%	27	No
60793060210	Bicillin C-R 900/300	Penicillin G Benzathine and Penicillin G Procaine	Penicillins	Pfizer	\$1,543.62	\$77.18	\$1,509.57	\$1,660.53	10%	29	No
52856050101	Emflaza	Deflazacort	Corticosteroids	PTC Therapeutics INC	\$7,467.43	\$74.67	\$6,597.06	\$7,859.50	19%	30	Orphan Only
60793013010	Penicillin G Procaine	Penicillin G Procaine	Penicillins	Pfizer	\$398.80	\$39.88	\$379.76	\$417.74	10%	31	No
44206053211	Cytogam	Human Cytomegalovirus Immune Globulin	Passive Immunizing and Treatment Agents	Kamada INC.	\$1,481.42	\$29.63	\$1,412.22	\$1,756.85	24%	32	Orphan Only
00009027101	Depo-Estradiol	Estradiol Cypionate	Estrogens	Pfizer	\$133.74	\$26.75	\$127.35	\$140.09	10%	33	No
60687040825	Mesalamine	Mesalamine	Gastrointestinal Agents - Misc.	Amerisource Health Services, LLC	\$754.68	\$25.16	\$314.10	\$410.00	31%	34	No
64896070113	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$1,377.66	\$22.96	\$1,165.97	\$1,398.00	20%	35	No
64896070101	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$2,296.09	\$22.96	\$1,943.28	\$2,329.99	20%	36	No
64896070013	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$1,055.48	\$17.59	\$893.30	\$1,071.07	20%	37	No
00409963305	Verapamil Hydrochloride	Verapamil Hydrochloride	Calcium Channel Blockers	Pfizer	\$582.96	\$14.57	\$554.98	\$610.48	10%	38	No
64896070001	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$1,428.09	\$14.28	\$1,488.82	\$1,785.10	20%	39	No
52427065830	Loreev XR	Lorazepam	Antianxiety Agents	Almatica Pharma INC.	\$397.00	\$13.23	\$285.00	\$425.00	49%	40	No
52427066330	Loreev XR	Lorazepam	Antianxiety Agents	Almatica Pharma INC.	\$397.00	\$13.23	\$285.00	\$425.00	49%	40	No
52427066730	Loreev XR	Lorazepam	Antianxiety Agents	Almatica Pharma INC.	\$397.00	\$13.23	\$285.00	\$425.00	49%	40	No

NDC	Trade name / proprietary name	Chemical name / non-proprietary name	Therapeutic class	Manufacturer	2022 Calculated AWAC	Price per unit	Beginning WAC 2022	Beginning WAC 2023	Net increase percentage	Rank ME	Has orphan indications
00517250210	Caffeine and Sodium Benzoate	Caffeine and Sodium Benzoate	ADHD/Anti-Narcolepsy/Anti-Obesity/Anorexiant	American Regent INC	\$248.14	\$12.41	\$230.90	\$257.50	12%	43	No
64896069913	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$733.31	\$12.22	\$620.63	\$744.14	20%	44	No
64896069901	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$1,222.17	\$12.22	\$1,034.38	\$1,240.22	20%	45	No
42192071401	Ciclopirox	Ciclopirox	Dermatologicals	Acella Pharmaceuticals LLC	\$360.73	\$10.43	\$316.00	\$362.91	15%	46	No
64896069813	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$573.36	\$9.56	\$485.26	\$581.83	20%	47	No
64896069801	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$955.58	\$9.56	\$808.75	\$969.69	20%	48	No
42291096218	Yuvaferm	Estradiol	Vaginal and Related Products	Avkare, INC (Aka Avpak)	\$124.77	\$6.93	\$119.72	\$140.67	17%	49	No
64896069713	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$413.46	\$6.89	\$349.93	\$419.57	20%	50	No
64896069701	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$689.09	\$6.89	\$583.21	\$699.27	20%	51	No
62584015901	Demeclocycline Hydrochloride	Demeclocycline Hydrochloride	Tetracyclines	Amerisource Health Services, LLC	\$677.79	\$6.78	\$630.46	\$693.51	10%	52	No
42192014360	Sodium Sulfacetamide 10% and Sulfur 5% Emollient Foam	Sulfacetamide Sodium and Sulfur	Dermatologicals	Acella Pharmaceuticals LLC	\$321.60	\$5.36	\$281.72	\$323.55	15%	53	No
68001035937	Gemcitabine	Gemcitabine	Antineoplastics and Adjunctive Therapies	Amerisource Health Services, LLC	\$105.60	\$5.28	\$82.07	\$105.60	29%	54	No
64896069613	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$314.37	\$5.24	\$266.06	\$319.01	20%	55	No
64896069601	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$523.94	\$5.24	\$443.44	\$531.68	20%	56	No
51267089099	Contrave	Naltrexone Hydrochloride and Bupropion Hydrochloride	ADHD/Anti-Narcolepsy/Anti-Obesity/Anorexiant	Currax Pharmaceuticals LLC	\$571.45	\$4.76	\$303.60	\$625.20	106%	57	No
42192010406	Sodium Sulfacetamide and Sulfur	Sodium Sulfacetamide and Sulfur	Dermatologicals	Acella Pharmaceuticals LLC	\$753.35	\$4.43	\$659.94	\$757.91	15%	58	No
42192014301	Sodium Sulfacetamide 10% and Sulfur 5% Emollient Foam	Sulfacetamide Sodium and Sulfur	Dermatologicals	Acella Pharmaceuticals LLC	\$428.80	\$4.29	\$375.64	\$431.40	15%	59	No
60687022901	Loperamide Hydrochloride	Loperamide Hydrochloride	Antidiarrheal/Probiotic Agents	Amerisource Health Services, LLC	\$377.53	\$3.78	\$67.06	\$85.00	27%	60	No
64896069501	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$358.86	\$3.59	\$303.72	\$364.16	20%	61	No
64896069513	Oxymorphone HCl ER	Oxymorphone HCL	Analgesics - Opioid	Amneal Pharmaceuticals	\$215.30	\$3.59	\$182.22	\$218.48	20%	62	No
62584081401	Oxazepam	Oxazepam	Antianxiety Agents	Amerisource Health Services, LLC	\$287.10	\$2.87	\$242.80	\$291.36	20%	63	No
62584081301	Oxazepam	Oxazepam	Antianxiety Agents	Amerisource Health Services, LLC	\$258.64	\$2.59	\$218.73	\$262.48	20%	64	No
42192011270	Salicylic Acid	Salicylic Acid	Dermatologicals	Acella Pharmaceuticals LLC	\$176.70	\$2.52	\$154.79	\$177.77	15%	65	No
62584081201	Oxazepam	Oxazepam	Antianxiety Agents	Amerisource Health Services, LLC	\$235.02	\$2.35	\$198.75	\$238.50	20%	66	No
16252054001	Isradipine	Isradipine	Calcium Channel Blockers	Teva	\$207.96	\$2.08	\$141.71	\$211.00	49%	67	No
42192011515	Urea Hydrating Topical	Urea	Dermatologicals	Acella Pharmaceuticals LLC	\$256.74	\$1.71	\$224.91	\$258.30	15%	68	No
00409490014	Sodium Bicarbonate	Sodium Bicarbonate	Minerals & Electrolytes	Pfizer	\$169.39	\$1.69	\$161.26	\$177.39	10%	69	No
42192010316	BP Cleansing Wash	Sodium Sulfacetamide and Sulfur	Dermatologicals	Acella Pharmaceuticals LLC	\$697.01	\$1.47	\$610.58	\$701.23	15%	70	No
60687020601	Diltiazem Hydrochloride	Diltiazem Hydrochloride	Calcium Channel Blockers	Amerisource Health Services, LLC	\$143.17	\$1.43	\$39.00	\$80.55	107%	71	No
60687050401	Verapamil Hydrochloride	Verapamil Hcl	Calcium Channel Blockers	Amerisource Health Services, LLC	\$142.82	\$1.43	\$118.75	\$150.81	27%	72	No
16252053901	Isradipine	Isradipine	Calcium Channel Blockers	Teva	\$142.22	\$1.42	\$96.90	\$144.30	49%	73	No
60687049301	Verapamil Hydrochloride	Verapamil Hcl	Calcium Channel Blockers	Amerisource Health Services, LLC	\$133.36	\$1.33	\$110.88	\$140.80	27%	74	No
00409553414	Sodium Bicarbonate	Sodium Bicarbonate	Minerals & Electrolytes	Pfizer	\$131.16	\$1.31	\$124.86	\$137.35	10%	75	No
46287002410	Potassium Phosphates	Monobasic Potassium Phosphate and Dibasic Potassium Phosphate	Minerals & Electrolytes	CMP Pharma, INC.	\$139.32	\$0.93	\$131.00	\$299.00	128%	76	No
00409663714	Sodium Bicarbonate	Sodium Bicarbonate	Minerals & Electrolytes	Pfizer	\$125.10	\$0.25	\$119.10	\$131.10	10%	77	No
00409155554	Hextend	Hetastarch	Hematological Agents - Misc.	Pfizer	\$864.28	\$0.14	\$864.28	\$950.71	10%	78	No
65162011511	Hydrocodone Bitartrate and Acetaminophen	Hydrocodone Bitartrate and Acetaminophen	Analgesics - Opioid	Amneal Pharmaceuticals	\$121.73	\$0.12	\$120.00	\$210.00	75%	79	No
00409741803	LMD in Dextrose	Dextran 40	Hematological Agents - Misc.	Pfizer	\$351.95	\$0.06	\$351.95	\$387.15	10%	80	No
00264959420	Lidocaine Hydrochloride and Dextrose	Lidocaine Hydrochloride Anhydrous and Dextrose Monohydrate	Antiarrhythmics	B Braun Medical INC	\$152.98	\$0.03	\$136.95	\$175.20	28%	81	No

## Manufacturer Data - New Specialty Drug Filings for 2022

### Background:

Under ORS 646A.689, Manufacturers are required to report new prescription specialty drugs for sale in the United States within 30 days of introduction. Specialty drugs are defined as "a drug for sale in the United States at a price that exceeds the threshold established by the Centers for Medicare and Medicaid Services for specialty drugs in the Medicare Part D program".

### Data sources utilized:

Data reported by the manufacturer to the Oregon Drug Price Transparency (DPT) program in iReg.

Items marked as trade secret (TS) in this report were flagged by the manufacturer as trade secret in iReg and have been redacted from this report.

Package quantity and size information was pulled from Medi-span. If no match on the NDC was found, these fields were left blank for the drug.

### Data timeframe:

New specialty drugs filed from 1/1/2022 to 12/31/2022

Definitions:	
Drug price:	The package cost for the NDC as reported by the manufacturer in iReg.
FDA priority:	Whether the United States Food and Drug Administration granted the new prescription drug a breakthrough therapy designation or a priority review.
Patients per month:	The manufacturer's estimate of the average number of patients who will be prescribed the new prescription drug each month.
Price per unit	Calculated by: Drug price / (Package Size x Package Quantity)

**Manufacturers reporting:** 151

**NDCs reported:** 367

NDC	Trade name	Chemical name	Manufacturer name	Drug price	Drug dosage	FDA priority	Patients per month	Package quantity	Package size	Price per unit
23155064941	Bicnu	Carmustine	HERITAGE PHARMACEUTICALS INC DBA AVET PHARMACEUTICALS INC	\$2,637.39	1 Vial - 100 MG Powder	No	500	1	1	\$2,637.39
50222034602	Adbry	Tralokinumab	LEO PHARMA INC	\$1,674.40	The recommended dosage of Adbry is an initial dose of 600 mg (four 150 mg injections), followed by 300 mg (two 150 mg injections) administered every other week. A dosage of 300 mg every 4 weeks may be considered for patients below 100 kg who achieve clear or almost clear skin after 16 weeks of treatment.	No	1	2	1	\$837.20
50222034604	Adbry	Tralokinumab	LEO PHARMA INC	\$3,348.80	The recommended dosage of Adbry is an initial dose of 600 mg (four 150 mg injections), followed by 300 mg (two 150 mg injections) administered every other week. A dosage of 300 mg every 4 weeks may be considered for patients below 100 kg who achieve clear or almost clear skin after 16 weeks of treatment.	No	1	4	1	\$837.20
71258002201	PYLARIFY	piflufolastat F 18	PROGENICS PHARMACEUTICALS INC	\$4,738.00	80 mCi/mL	Yes	590			
23155079041	Bicnu	Carmustine for Injection	HERITAGE PHARMACEUTICALS INC DBA AVET PHARMACEUTICALS INC	\$1,226.00	1 Vial - 100 MG Powder	No	500	1	1	\$1,226.00
79378011001	LIVMARLI	maralixibat	MIRUM PHARMACEUTICALS	\$46,500.00	9.5 mg/mL	Yes	1	1	30	\$1,550.00
62559027583	Nebivolol Tablets 2.5mg 2300ct	Nebivolol	ANI PHARMACEUTICALS INC	\$6,478.33	2.5 mg 2300ct	No	630	1	2300	\$2.82
73536050001	BESREMi	Ropeginterferon alfa-2b-njft	PHARMAESSENTIA USA CORPORATION	\$6,988.00	500 mcg/mL	Yes	4	1	1	\$6,988.00
00078100060	LEQVIO	Inclisiran	NOVARTIS	\$3,250.00	284 mg/1.5 mL	No	TS	1	1.5	\$2,166.67
68135008236	VOXZOGO	vosoritide	BIOMARIN PHARMACEUTICAL	\$8,990.00	0.4 mg per vial	Yes	TS	10	1	\$899.00
68135011966	VOXZOGO	vosoritide	BIOMARIN PHARMACEUTICAL	\$8,990.00	0.56 mg per vial	Yes	TS	10	1	\$899.00
68135018193	VOXZOGO	vosoritide	BIOMARIN PHARMACEUTICAL	\$8,990.00	1.2 mg per vial	Yes	TS	10	1	\$899.00
72786011103	Oxbryta Tablets for Oral Suspension	voxelotor	GLOBAL BLOOD THERAPEUTICS, INC.	\$10,417.00	600-1500mg (weight based dose) orally once daily	Yes	100	1	90	\$115.74
00093766256	ERLOTINIB HCL TABLETS EQ 25MG 30	ERLOTINIB HCL TABLETS EQ 25MG 30	TEVA	\$1,673.68	25MG	No	119	1	30	\$55.79
00480372056	PYRIMETHAMINE TABLETS 25MG 30	PYRIMETHAMINE TABLETS 25MG 30	TEVA	\$7,695.00	25MG	Yes	103	1	30	\$256.50
00480372001	PYRIMETHAMINE TABLETS 25MG 100	PYRIMETHAMINE TABLETS 25MG 100	TEVA	\$25,650.00	25MG	Yes	103	1	100	\$256.50
42806075760	Sulfadiazine 500mg USP 60 Tab	Sulfadiazine	EPIC PHARMA LLC	\$961.76	TABLET	No	TS	1	60	\$16.03
62559027671	Nebivolol Tablets 5mg 1100ct	Nebivolol	ANI PHARMACEUTICALS INC	\$3,098.33	Initial dose: 5 mg orally once a day Dose adjustment: Titrate dose at 2-week intervals up to 40 mg once a day as needed. Maximum dose: 40 mg per day	No	290	1	1100	\$2.82
62559027705	Nebivolol Tablets 10mg 500ct	Nebivolol	ANI PHARMACEUTICALS INC	\$1,408.33	Initial dose: 5 mg orally once a day Dose adjustment: Titrate dose at 2-week intervals up to 40 mg once a day as needed. Maximum dose: 40 mg per day	No	130	1	500	\$2.82
62559027805	Nebivolol Tablets 20mg 500ct	Nebivolol	ANI PHARMACEUTICALS INC	\$1,408.33	Initial dose: 5 mg orally once a day Dose adjustment: Titrate dose at 2-week intervals up to 40 mg once a day as needed. Maximum dose: 40 mg per day	No	660	1	500	\$2.82
62559030690	Lipofen Capsules 150mg	fenofibrate	ANI PHARMACEUTICALS INC	\$783.10	The dose of LIPOFEN is 150 mg once daily	No	250	1	90	\$8.70

NDC	Trade name	Chemical name	Manufacturer name	Drug price	Drug dosage	FDA priority	Patients per month	Package quantity	Package size	Price per unit
62559086015	CORTROPHIN GEL	Repository Corticotropin	ANI PHARMACEUTICALS INC	\$31,851.00	Standard tests for verification of adrenal responsiveness to corticotropin may utilize as much as 80 units as a single injection or one or more injections of a lesser dosage. Verification tests should be performed prior to treatment with corticotropins. The test should utilize the route(s) of administration proposed for treatment. Following verification dosage should be individualized according to the disease under treatment and the general medical condition of each patient. Frequency and dose	No	80	1	5	\$6,370.20
50742052110	Cyclophosphamide Injection	Cyclophosphamide	INGENUS PHARMACEUTICALS, LLC	\$1,465.00	WAC price of 1 vial 1465.00. Course of treatment = 1.15 vials.	No	15,000	1	10	\$146.50
49884055601	Isosorbide dinitrate Tablets	Isosorbide dinitrate Tablets	PAR PHARMACEUTICAL	\$1,335.37	40mg	No	1	1	100	\$13.35
71863011460	Carglumic acid	Carglumic acid	ETON PHARMACEUTICALS, INC.	\$10,921.80	Tablets for oral suspension: 200 mg, functionally scored. (3)	No	10	1	60	\$182.03
00093819928	SUNITINIB MALATE CAPSULES 12.5MG 28	SUNITINIB MALATE CAPSULES 12.5MG 28	TEVA	\$4,889.07	12.5MG	Yes	1,057	1	28	\$174.61
00093822428	SUNITINIB MALATE CAPSULES 25MG 28	SUNITINIB MALATE CAPSULES 25MG 28	TEVA	\$9,778.16	25MG	Yes	1,057	1	28	\$349.22
00093822928	SUNITINIB MALATE CAPSULES 37.5MG 28	SUNITINIB MALATE CAPSULES 37.5MG 28	TEVA	\$14,667.25	37.5MG	Yes	1,057	1	28	\$523.83
00093823128	SUNITINIB MALATE CAPSULES 50MG 28	SUNITINIB MALATE CAPSULES 50MG 28	TEVA	\$17,022.40	50MG	Yes	1,057	1	28	\$607.94
70573009902	Ryplazim	plasminogen, human-tvmh	KEDRION BIOPHARMA INC	\$2,064.00	68.8 mg per vial	No	40	1	1	\$2,064.00
73475304105	VYVGART™	efgartigimod alfa-fcab	ARGENX US, INC.	\$5,950.00	1200 mg per infusion	No	1	1	20	\$297.50
50228033410	Ethacrynic Acid Tablets USP 25 mg	Ethacrynic Acid Tablets USP 25 mg	SCIEGEN PHARMACEUTICALS INC	\$997.88	25 mg	No	300,000	1	100	\$9.98
00143939210	Remifentanil HCl	Remifentanil HCl	HIKMA PHARMACEUTICALS	\$1,225.00	Remifentanil HCl 2mg/5mL per vial. Remifentanil HCl should be administered at an infusion rate of 0.5 to 1mcg/kg/min.	No	1	10	1	\$122.50
69097087067	Lanreotide Injection 120mg/0.5ml	Lanreotide Injection 120mg/0.5ml	CIPLA USA, INC	\$8,892.66	120mg Every Four Weeks	No	11,600	1	0.5	\$17,785.32
72786011102	Oxbryta	voxelotor	GLOBAL BLOOD THERAPEUTICS, INC.	\$10,417.00	600-1500mg (weight based dose) orally once daily	Yes	100	1	60	\$173.62
00378667828	Sunitinib Malate 12.5mg Oral Capsule	Sunitinib Malate 12.5mg Oral Capsule	MYLAN PHARMACEUTICALS INC	\$4,883.64	The dosage differs based on patient and therefore may vary. See Section 2 "DOSAGE AND ADMINISTRATION" of the attached prescribing information for specific dosage information.	No	83,020	1	28	\$174.42
00378667928	Sunitinib Malate 25mg Oral Capsule	Sunitinib Malate 25mg Oral Capsule	MYLAN PHARMACEUTICALS INC	\$9,767.30	The dosage differs based on patient and therefore may vary. See Section 2 "DOSAGE AND ADMINISTRATION" of the attached prescribing information for specific dosage information.	No	83,020	1	28	\$348.83
00378668128	Sunitinib Malate 37.5mg Oral Capsule	Sunitinib Malate 37.5mg Oral Capsule	MYLAN PHARMACEUTICALS INC	\$14,650.95	The dosage differs based on patient and therefore may vary. See Section 2 "DOSAGE AND ADMINISTRATION" of the attached prescribing information for specific dosage information.	No	83,020	1	28	\$523.25
00378668028	Sunitinib Malate 50mg Oral Capsule	Sunitinib Malate 50mg Oral Capsule	MYLAN PHARMACEUTICALS INC	\$17,003.48	The dosage differs based on patient and therefore may vary. See Section 2 "DOSAGE AND ADMINISTRATION" of the attached prescribing information for specific dosage information.	No	83,020	1	28	\$607.27
55513011201	TEZSPIRE	tezepelumab-ekko	AMGEN	\$3,633.00	210 mg/1.91 mL (110 mg/mL) prefilled syringe	Yes	880	1	1.91	\$1,902.09

NDC	Trade name	Chemical name	Manufacturer name	Drug price	Drug dosage	FDA priority	Patients per month	Package quantity	Package size	Price per unit
70121168007	Carboprost Tromethamine	Carboprost Tromethamine Injection, USP 250 mcg/mL 10 x 1 mL single dose vials	AMNEAL PHARMACEUTICALS	\$3,189.90	Please refer to dosing and administration section of the full Prescribing Information found on our corporate website and/or DailyMed.	No	1	10	1	\$318.99
70710128701	Vigabatrin 500mg Tabs	Vigabatrin	ZYDUS PHARMACEUTICALS USA INC	\$10,511.89	As noted in Product Insert. Zydus is not responsible for the dosage prescribed to patients and does not suggest any specific dosage amounts.	No	1	1	100	\$105.12
69800025001	ASCENIV	Immune globulin intravenous, human – slra 10% Liquid	ADMA BIOLOGICS, INC.	\$4,545.00	.11111 dose(s) per package	No	38	1	50	\$90.90
49702026423	APRETUDE 600 mg/3 mL Kit	cabotegravir extended-release injectable suspension 600 mg/3 mL	VIIV HEALTHCARE	\$3,700.00	APRETUDE 600 mg/3 mL Kit is a single-dose vial of 600 mg/3 mL (200 mg/mL) of cabotegravir extended-release injectable suspension. Recommended dosing schedule is to initiate APRETUDE 600 mg/3 mL injection given 1 month apart for 2 consecutive months on the last day of an oral lead-in, if used, or within 3 days and continue with the injection every 2 months thereafter. \$3,700 is the wholesale acquisition cost for APRETUDE 600 mg/3mL Kit.	Yes	1,200,000	1	3	\$1,233.33
00074231030	RINVOQ	upadacitinib	ABBVIE INC.	\$5,671.26	30 mg	Yes	1,000	1	30	\$189.04
49884028302	Everolimus	Everolimus	PAR PHARMACEUTICAL	\$1,780.45	1 mg	No	1	1	60	\$29.67
72065000301	RECORLEV	levoketoconazole	XERIS PHARMACEUTICALS	\$13,500.00	150 mg twice daily (or 15,000 mg for a bottle)	No	12	1	50	\$270.00
81749000401	TARPEYO™	Budesonide	CALLIDITAS THERAPEUTICS US INC.	\$14,160.00	16 mg administered once daily (480 mg for a 30-day supply)	Yes	4,000	1	120	\$118.00
00054071119	Deferiprone	Deferiprone	HIKMA PHARMACEUTICALS	\$6,975.58	Deferiprone Tablets 1000mg, recommended daily dosage is 3 tablets a day.	No	1	1	50	\$139.51
24470092360	Chlorzoxazone Tablet USP	Chlorzoxazone Tablet USP	CINTEX SERVICES, LLC	\$1,194.40	60ct 250mg tablets in one bottle. 4 tablets per day	No	5,250	1	60	\$19.91
29033021401	Carisoprodol Tablet	Carisoprodol Tablet	NOSTRUM LABORATORIES, INC.	\$808.85	100ct 350mg oral tablets, course of treatment is 3 per day for 21 days.	No	2,700	1	100	\$8.09
69097093498	Lanthanum Carbonate Chew Tabs 500 mg 90's	Lanthanum Carbonate Chew Tabs 500 mg 90's	CIPLA USA, INC	\$971.48	The recommended initial total daily dose of lanthanum carbonate chewable tablets are 1,500 mg in divided doses. Titrate every 2 to 3 weeks based on serum phosphate level.	Yes	50,225	2	45	\$10.79
69097093598	Lanthanum Carbonate Chew Tabs 750mg 90's	Lanthanum Carbonate Chew Tabs 750mg 90's	CIPLA USA, INC	\$971.48	The recommended initial total daily dose of lanthanum carbonate chewable tablets are 1,500 mg in divided doses. Titrate every 2 to 3 weeks based on serum phosphate level.	Yes	50,225	6	15	\$10.79
69097093698	Lanthanum Carbonate Chew Tabs 1000mg 90's	Lanthanum Carbonate Chew Tabs 1000mg 90's	CIPLA USA, INC	\$971.48	The recommended initial total daily dose of lanthanum carbonate chewable tablets are 1,500 mg in divided doses. Titrate every 2 to 3 weeks based on serum phosphate level.	Yes	50,225	9	10	\$10.79
00517102025	Vasopressin 20 units/mL 1mL Vial, PKG. OF 25	Vasopressin	AMERICAN REGENT INC	\$3,951.00	Vial	No	83,333	25	1	\$158.04
00069175130	TALZENNA®	talazoparib	PFIZER	\$16,231.76	1 mg per day x 30 days	Yes	3,500	1	30	\$541.06
00069150130	TALZENNA®	talazoparib	PFIZER	\$16,231.76	1 mg per day x 30 days	Yes	3,500	1	30	\$541.06
70121156807	Releuko (filgrastim-ayow)	Releuko (filgrastim-ayow) 300 mcg/0.5 mL Injection 10 Single-dose Prefilled Syringes	AMNEAL PHARMACEUTICALS	\$2,280.00	Please refer to dosing and administration section of the full Prescribing Information found on our corporate website and/or DailyMed.	No	2,867	10	0.5	\$456.00
70121156907	Releuko (filgrastim-ayow)	Releuko (filgrastim-ayow) 300 mcg/0.5 mL Injection 10 Single-dose Prefilled Syringes	AMNEAL PHARMACEUTICALS	\$2,280.00	Please refer to dosing and administration section of the full Prescribing Information found on our corporate website and/or DailyMed.	No	8,667	10	1	\$228.00

NDC	Trade name	Chemical name	Manufacturer name	Drug price	Drug dosage	FDA priority	Patients per month	Package quantity	Package size	Price per unit
70121157007	Releuko (filgrastim-ayow)	Releuko (filgrastim-ayow) 480 mcg/0.8 mL Injection 10 Single-dose Prefilled Syringes	AMNEAL PHARMACEUTICALS	\$3,648.00	Please refer to dosing and administration section of the full Prescribing Information found on our corporate website and/or DailyMed.	No	3,641	10	0.8	\$456.00
70121157107	Releuko (filgrastim-ayow)	Releuko (filgrastim-ayow) 480 mcg/1.6 mL (300 mcg/mL) Injection 10 x 1.6mL Single-dose Vials	AMNEAL PHARMACEUTICALS	\$3,648.00	Please refer to dosing and administration section of the full Prescribing Information found on our corporate website and/or DailyMed.	No	29,560	10	1.6	\$228.00
42023023710	Vasopressin (Vasopressin Injection, USP) 0.2units/mL 10vl	Vasopressin Injection	PAR PHARMACEUTICAL	\$2,123.77	0.2units/mL	No	1	10	100	\$2.12
42023021910	Vasopressin (Vasopressin Injection, USP) 0.4units/mL 10vl	Vasopressin Injection	PAR PHARMACEUTICAL	\$4,247.54	0.4units/mL	No	1	10	100	\$4.25
43598008525	Vasopressin Injection, USP 20u/mL 1mL SDV 25s	Vasopressin	DR. REDDY'S LABORATORIES, INC	\$3,951.20	Pack of 25 of 20u/mL	No	230,000	25	1	\$158.05
75854060203	Balcoltra	levonorgestrel and ethinyl estradiol kit	AVION PHARMACEUTICALS, LLC	\$734.99	Balcoltra is dispensed in a blister card [see How Supplied/Storage and Handling (16)]. Balcoltra may be started using either a Day 1 start or a Sunday start. For the first cycle of a Sunday Start regimen, an additional method of contraception should be used until after the first 07 consecutive days of administration.	No	11,000	3	28	\$8.75
80446040101	KIMMTRAK	TEBENTAFUSP	IMMUNOCORE COMMERCIAL LLC	\$18,760.00		1 Yes	30	1	0.5	\$37,520.00
50242009601	Vabysmo 6mg/0.05ml Vial	faricimab-svoa	GENENTECH INC	\$2,190.00	Vabysmo 6mg/0.05ml Vial	No	TS	1	0.05	\$43,800.00
00069023530	CIBINQO®	abrocitinib	PFIZER	\$4,914.00	200 mg per day max x 30 days	Yes	1,200,000	1	30	\$163.80
00069033530	CIBINQO®	abrocitinib	PFIZER	\$4,914.00	200 mg per day max x 30 days	Yes	1,200,000	1	30	\$163.80
00069043530	CIBINQO®	abrocitinib	PFIZER	\$4,914.00	200 mg per day max x 30 days	Yes	1,200,000	1	30	\$163.80
63323092688	ROMIDEPSIN	ROMIDEPSIN	FRESENIUS KABI USA LLC	TS	TS	No	TS	1	1	
59651043601	Digoxin Tablets USP 62.5 mcg (0.0625mg) - 100/Bottle	Digoxin	AUROBINDO PHARMA USA	\$1,152.00	Tab	No	60	1	100	\$11.52
80203034701	ENJAYMO	sutimimab	BIOVERATIV US LLC	\$1,800.00	The recommended dosage of ENJAYMO for patients with CAD is based on body weight. For patients weighing 39 kg to less than 75 kg, the recommended dose is 6,500 mg and for patients weighing 75 kg or more, the recommended dose is 7,500 mg. Administer ENJAYMO intravenously weekly for the first two weeks, with administration every two weeks thereafter. Administer ENJAYMO at the recommended dosage regimen time points, or within two days of these time points.	Yes	500	1	22	\$81.82
80803015350	FYARRO	Sirolimus	AADI BIOSCIENCE, INC.	\$6,785.00	1 Vial	Yes	TS	1	1	\$6,785.00
71334020505	PYRUKYND	Mitapivat	AGIOS PHARMACEUTICAL INC.	\$25,760.00	5mg 14ct blister card x 4	Yes	13	4	14	\$460.00
71334021020	PYRUKYND	Mitapivat	AGIOS PHARMACEUTICAL INC.	\$25,760.00	20mg 14ct blister card x 4	Yes	13	4	14	\$460.00
71334021550	PYRUKYND	Mitapivat	AGIOS PHARMACEUTICAL INC.	\$25,760.00	50mg 14ct blister card x 4	Yes	13	4	14	\$460.00
71334022011	PYRUKYND	Mitapivat	AGIOS PHARMACEUTICAL INC.	\$3,220.00	5mg 7ct blister card x 1	Yes	13	1	7	\$460.00
71334022512	PYRUKYND	Mitapivat	AGIOS PHARMACEUTICAL INC.	\$6,440.00	20mg 7ct blister card x 1, 5mg 7ct blister card x 1	Yes	13	2	7	\$460.00
71334023013	PYRUKYND	Mitapivat	AGIOS PHARMACEUTICAL INC.	\$6,440.00	50mg 7ct blister card x 1, 20mg 7ct blister card x 1	Yes	13	2	7	\$460.00

NDC	Trade name	Chemical name	Manufacturer name	Drug price	Drug dosage	FDA priority	Patients per month	Package quantity	Package size	Price per unit
55292032020	Isturisa 1 MG	OSILODROSTAT PHOSPHATE	RECORDATI RARE DISEASES, INC.	\$2,517.90	Tablet form, 1 mg, 20 tablets. Initiate dosage at 2 mg orally twice daily, with or without food. Titrate dosage by 1 to 2 mg twice daily, no more frequently than every 2 weeks based on rate of cortisol changes, individual tolerability and improvement in signs and symptoms. Maximum recommended dosage is 30 mg twice daily	Yes	260	1	20	\$125.90
55292041005	Cystadrops	cysteamine ophthalmic solution	RECORDATI RARE DISEASES, INC.	\$1,837.50	Ophthalmic solution containing 3.8 mg/mL of cysteamine (0.37%).	No	277	1	5	\$367.50
52817072005	Apomorphine Hydrochloride	Apomorphine Hydrochloride	TRUPHARMA LLC	\$5,207.85	30mg/3mL	No	1	5	3	\$347.19
55292032060	Isturisa 1 MG	OSILODROSTAT PHOSPHATE	RECORDATI RARE DISEASES, INC.	\$7,553.70	Tablet form, 1 mg, 60 tablets	Yes	260	1	60	\$125.90
55292032120	Isturisa 5 mg	OSILODROSTAT PHOSPHATE	RECORDATI RARE DISEASES, INC.	\$8,652.00	Tablet form, 5 mg, 20 tablets.	Yes	260	1	20	\$432.60
55292032160	Isturisa 5 mg	OSILODROSTAT PHOSPHATE	RECORDATI RARE DISEASES, INC.	\$25,956.00	Tablet form, 5 mg, 60 tablets.	Yes	260	1	60	\$432.60
55292032220	Isturisa 10 mg	OSILODROSTAT PHOSPHATE	RECORDATI RARE DISEASES, INC.	\$10,274.25	Tablet form, 10 mg, 20 tablets.	Yes	260	1	20	\$513.71
55292032260	Isturisa 10 mg	OSILODROSTAT PHOSPHATE	RECORDATI RARE DISEASES, INC.	\$30,822.75	Tablet form, 10 mg, 60 tablets	Yes	260	1	60	\$513.71
00480124328	LLENALIDOMIDE CAPSULE 10MG 28	LLENALIDOMIDE CAPSULE 10MG 28	TEVA	\$20,157.36	10MG	No	10,310	1	28	\$719.91
00480124421	LLENALIDOMIDE CAPSULE 15MG 21	LLENALIDOMIDE CAPSULE 15MG 21	TEVA	\$15,118.04	15MG	No	10,310	1	21	\$719.91
00480124621	LLENALIDOMIDE CAPSULE 25MG 21	LLENALIDOMIDE CAPSULE 25MG 21	TEVA	\$15,118.04	25MG	No	10,310	1	21	\$719.91
00480124228	LLENALIDOMIDE CAPSULE 5MG 28	LLENALIDOMIDE CAPSULE 5MG 28	TEVA	\$20,157.36	5MG	No	10,310	1	28	\$719.91
57894011101	CARVYKTI™	ciltacabtagene autoleucel	JANSSEN BIOTECH	\$465,000.00	0.5-1.0×10 <sup>6</sup> CAR+ viable T-cells per kg of body wt, with a ma dose of 1×10 <sup>8</sup> CAR+ viable T-cells, 5% DMSO	Yes	TS	1	1	\$465,000.00
57894011102	CARVYKTI™	ciltacabtagene autoleucel	JANSSEN BIOTECH	\$465,000.00	0.5-1.0×10 <sup>6</sup> CAR+ viable T-cells per kg of body wt, with a ma dose of 1×10 <sup>8</sup> CAR+ viable T-cells, 5% DMSO	Yes	TS	1	1	\$465,000.00
69238229801	Oxycodone ER	Oxycodone ER Tablet 40MG, 100	AMNEAL PHARMACEUTICALS	\$1,284.25	Please refer to dosing and administration section of the full Prescribing Information found on our corporate website and/or DailyMed.	No	1	1	100	\$12.84
69238230001	Oxycodone ER	Oxycodone ER Tablet 80MG, 100	AMNEAL PHARMACEUTICALS	\$2,240.96	Please refer to dosing and administration section of the full Prescribing Information found on our corporate website and/or DailyMed.	No	1	1	100	\$22.41
24979071051	Paclitaxel	Paclitaxel Protein-Bound Particles for Injectable Suspension 100mg, vial	TWI PHARMACEUTICALS, USA	\$1,422.05	Approximately 5 vials per course based on a 2609 mg/m <sup>2</sup> dose	No	2,666	1	1	\$1,422.05
72482010012	VONJO	pacritinib	CTI BIOPHARMA CORP	\$19,500.00	60 dose(s) per package	Yes	50	1	120	\$162.50
49884076854	Tolvaptan Tablets 15mg 10	Tolvaptan Tablets 15mg 10	PAR PHARMACEUTICAL	\$3,302.04	15mg	No	1	1	10	\$330.20
49884077054	Tolvaptan Tablets 30mg 10	Tolvaptan Tablets 30mg 10	PAR PHARMACEUTICAL	\$3,496.50	30mg	No	1	1	10	\$349.65
00003712511	OPDUALAG	nivolumab and relatlimab	BRISTOL-MYERS SQUIBB, INC	\$13,694.27	Recommended Dosage: Adult patients and pediatric patients 12 years of age or older who weigh at least 40 kg: 480 mg nivolumab and 160 mg relatlimab intravenously every 4 weeks as an intravenous infusion over 30 minutes	Yes	180	1	20	\$684.71
60687062814	Potassium Chloride Oral Solution	Potassium Chloride Oral Solution	AMERISOURCE HEALTH SERVICES, LLC	\$1,065.84	40mEq/30mL	No	100	40	30	\$0.89
60505623004	Paclitaxel	Paclitaxel	APOTEX CORP	\$1,441.01	20ML	No	62,000	1	1	\$1,441.01
73154005060	IBSRELA	tenapanor	ARDELYX, INC.	\$1,500.00	50 mg BID	No	1	1	60	\$25.00
00074104328	RINVOQ	upadacitinib	ABBVIE INC.	\$10,586.35	45 mg	Yes	600	1	28	\$378.08
00480943589	Diclofenac Potassium Caps 25mg 120	Diclofenac Potassium Caps 25mg 120	TEVA	\$1,609.11	25mg	No	1,243	1	120	\$13.41
69339015917	Itraconazole Oral Solution	Itraconazole Oral Solution	DASH PHARMACEUTICALS, LLC	\$979.30	10mL OD	No	105	40	10	\$2.45
68040071338	IMPOYZ® External Cream	Clobetasol propionate 0.025%	PRIMUS PHARMACEUTICALS INC	\$1,235.00	2 consecutive weeks of treatment per course.	No	1,200	1	100	\$12.35
00078103502	Vijoice	alpelisib	NOVARTIS	\$32,500.00	250 mg	Yes	43	1	56	\$580.36
00078102884	Vijoice	alpelisib	NOVARTIS	\$32,500.00	125 mg	Yes	TS	1	28	\$1,160.71
00078102184	Vijoice	alpelisib	NOVARTIS	\$32,500.00	50 mg	Yes	TS	1	28	\$1,160.71
60505605004	Bortezomib for Injection	Bortezomib for Injection	APOTEX CORP	\$913.71	7	No	TS	1	1	\$913.71
10122050201	Revcovi	elapegedemase-lvlr	CHIESI USA, INC.	\$11,245.59	2.4 mg/1.5 mL (1.6 mg/mL)	Yes	47	1	1.5	\$7,497.06

NDC	Trade name	Chemical name	Manufacturer name	Drug price	Drug dosage	FDA priority	Patients per month	Package quantity	Package size	Price per unit
55150036610	Arsenic Trioxide Injection, 12mg/6ml SDV - 10s	ARSENIC TRIOXIDE	EUGIA US LLC (FKA AUROMEDICS PHARMA LLC)	\$5,253.50	12 mg/6 mL (2 mg/mL) arsenic trioxide in single-dose vial	No	80	10	6	\$87.56
60505040603	Diclofenac Sodium Solution	Diclofenac Sodium Solution	APOTEX CORP	\$1,616.82	20mg	No	250,000	1	112	\$14.44
74725010025	Illuccix (Kit for the preparation of Ga-68 gozetotide produced from a cyclotron and purified via GE FASTlab™ or Eckert & Ziegler GalliaPharm® Ge 68/Ga-68 generator )	kit for the preparation of gallium Ga-68 gozetotide	TELEX PHARMACEUTICALS US INC.	\$4,700.00	5mci	No	2,650	1	1	\$4,700.00
74725010064	Illuccix (Kit for the preparation of Ga-68 produced from an IRE Galli Eo® Ge 68/Ga-68 generator)	kit for the preparation of gallium Ga-68 gozetotide	TELEX PHARMACEUTICALS US INC.	\$4,700.00	5mci	No	2,650	1	1	\$4,700.00
73473030660	Clindamycin Phosphate & Tretinoin Gel, 1.2%/0.025%	Clindamycin Phosphate & Tretinoin Gel, 1.2%/0.025%	SOLARIS PHARMA CORP	\$678.74	1 tube	No	650	1	60	\$11.31
43598047060	Posaconazole DR Tabs 100mg US 60s Bottle	Posaconazole	DR. REDDY'S LABORATORIES, INC	\$970.00	100 mg, 60s	No	23,000	1	60	\$16.17
69238208806	Bexarotene 1% Topical Gel 60g	Bexarotene 1%	AMNEAL PHARMACEUTICALS	\$23,268.93	Please refer to dosing and administration section of the full Prescribing Information found on our corporate website and/or DailyMed.	No	66	1	60	\$387.82
69448001463	CAMCEVI	LEUPROLIDE MESYLATE	ACCORD BIOPHARMA, INC.	\$3,900.00	INJECTION, EMULSION	No	74,000	1	1	\$3,900.00
73625011111	Camzyos	mavacamten	BRISTOL-MYERS SQUIBB, INC	\$7,356.16	2.5 MG	Yes	200	1	30	\$245.21
73625011211	Camzyos	mavacamten	BRISTOL-MYERS SQUIBB, INC	\$7,356.16	5 MG	Yes	200	1	30	\$245.21
73625011311	Camzyos	mavacamten	BRISTOL-MYERS SQUIBB, INC	\$7,356.16	10 MG	Yes	200	1	30	\$245.21
73625011411	Camzyos	mavacamten	BRISTOL-MYERS SQUIBB, INC	\$7,356.16	15 MG	Yes	200	1	30	\$245.21
00781808532	PIRFENIDONE	PIRFENIDONE	SANDOZ INC	\$9,130.57	1 bottle containing 270 tablets, 267 mg each, with a child-resistant closure	No	1,500	1	270	\$33.82
00781808692	PIRFENIDONE	PIRFENIDONE	SANDOZ INC	\$9,130.57	1 bottle containing 90 tablets, 801mg each, with a child-resistant closure	No	1,500	1	90	\$101.45
50742048401	Bortezomib Injection 3.5mg/vial	Bortezomib Injection 3.5mg/vial	INGENUS PHARMACEUTICALS, LLC	\$800.00	1 vial	No	34,470	1	1	\$800.00
70257041687	Lyvispah	Lyvispah (Baclofen) Oral Granules 20mg, 90ct	AMNEAL PHARMACEUTICALS	\$1,650.00	Please refer to dosing and administration section of the full Prescribing Information found on our corporate website and/or DailyMed.	No	50	1	90	\$18.33
70710165501	Pemetrexed Injection 500mg/1ml Vial	Pemetrexed	ZYDUS PHARMACEUTICALS USA INC	\$990.93	As noted in Product Insert. Zydus is not responsible for the dosage prescribed to patients and does not suggest any specific dosage amounts. For this product, Zydus has calculated the course of treatment at 2 vials, however, the dosing depends patient to patient.	No	1	1	1	\$990.93
70710167401	Pemetrexed Injection 1000mg/1ml Vial	Pemetrexed	ZYDUS PHARMACEUTICALS USA INC	\$1,882.77	As noted in Product Insert. Zydus is not responsible for the dosage prescribed to patients and does not suggest any specific dosage amounts. For this product, Zydus has calculated the course of treatment dosage at 1 vial, however, the dosing depends patient to patient.	No	1	1	1	\$1,882.77
62332065560	Formoterol Fumarate Inhalation Solution, 20mcg, 120ML	Formoterol Fumarate	ALEMBIC PHARMACEUTICALS INC	\$963.78	one 20 mcg unit-dose vial administered twice daily (morning and evening) by nebulization.	No	32,000	60	2	\$8.03
49702025837	TRIUMEQ PD	abacavir 60 mg; dolutegravir 5 mg; lamivudine 30 mg	VIIV HEALTHCARE	\$1,001.72	TRIUMEQ PD is a fixed dose combination of abacavir, dolutegravir and lamivudine in a dispersible tablet formulation for the treatment of pediatric patients weighing 10 kgs to <25 kgs with human immunodeficiency virus type 1 (HIV-1). \$1,001.72 is the wholesale acquisition cost for the TRIUMEQ PD Kit containing a 90-count bottle and a 40 mL dosing cup.	Yes	1,900	1	90	\$11.13

NDC	Trade name	Chemical name	Manufacturer name	Drug price	Drug dosage	FDA priority	Patients per month	Package quantity	Package size	Price per unit
59385005506	Elyxib	Celecoxib	BIODELIVERY SCIENCES INTERNATIONAL	\$810.00	120mg/per day	No	250	6	4.8	\$28.13
65086000112	Verkazia	cyclosporine 0.1%	SANTEN USA	\$1,465.00	cyclosporine 0.1%	No	10,000	1	120	\$12.21
00517038105	PROVAYBLUE® (methylene blue) injection USP, 0.5% 50 mg/10 mL (5 mg/mL), PKG. OF 5	Methylene Blue	AMERICAN REGENT INC	\$1,823.00	Vial	No	439,060	5	10	\$36.46
00003375614	Opdivo	nivolumab	BRISTOL-MYERS SQUIBB, INC	\$3,526.61	120 mg/12 mL (10 mg/mL) vial, Opdivo is a clear to opalescent, colorless to pale-yellow solution in a single-dose vial. OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody. Administer by intravenous infusion after dilution based upon recommended infusion rate for each indication.	Yes	460	1	12	\$293.88
00480361087	PIRFENIDONE 267MG TABLETS 270	PIRFENIDONE 267MG TABLETS 270	TEVA	\$7,147.41	267MG	Yes	4,708	1	270	\$26.47
00480361198	PIRFENIDONE 801MG TABLETS 90	PIRFENIDONE 801MG TABLETS 90	TEVA	\$7,147.41	801MG	Yes	4,708	1	90	\$79.42
00002150680	Mounjaro	tirzepatide injection	LILLY USA, LLC	\$974.33	2.5 mg/0.5 mL once weekly	Yes	34,500,000	4	0.5	\$487.17
60505606600	Pemetrexed for Injection 500 mg Vial	Pemetrexed	APOTEX CORP	\$2,140.39		3 No	16,572	1	1	\$2,140.39
59651035308	Diclofenac Potassium Capsules 25 mg - 120/Bottle	Diclofenac Potassium	AUROBINDO PHARMA USA	\$1,054.50	Tab	No	60	1	120	\$8.79
70010005140	Valganciclovir Hydrochloride	Valganciclovir Hydrochloride	GRANULES PHARMACEUTICALS INC.	\$800.26	Maximum dose of 900 mg should be administered.	No	100	1	88	\$9.09
50742034101	Pemetrexed Injection 500mg Vial	Pemetrexed	INGENUS PHARMACEUTICALS, LLC	\$800.00	1 vial	No	1,200	1	1	\$800.00
00143939310	Remifentanil HCl	Remifentanil HCl	HIKMA PHARMACEUTICALS	\$2,600.00	5mg/per vial; Remifentanil HCl should be administered at an infusion rate of 0.5 to 1mcg/kg/min.	No	1	10	1	\$260.00
42291087001	Tretinoin	Tretinoin	AVKARE, INC (AKA AVPAK)	\$2,523.35	Adults - 45mg per day	No	100	1	100	\$25.23
65219038030	Allopurinol Sodium	Allopurinol Sodium	FRESENIUS KABI USA LLC	TS	TS	No	TS	1	1	
81672505101	VTAMA (tapinarof) cream, 1%	Tapinarof	DERMAVANT SCIENCES, INC.	\$1,235.00	Cream, 1%; 1 gram of VTAMA cream contains 10 mg of tapinarof	No	38,000	1	60	\$20.58
43598038711	Pemetrexed for Injection 500mg, 1 Vial	Pemetrexed	DR. REDDY'S LABORATORIES, INC	\$793.00	500 mg, 1 vial	No	541,000	1	1	\$793.00
63323013410	PEMETrexed	PEMETrexed Disodium	FRESENIUS KABI USA LLC	TS	TS	No	65,666	1	1	
63323045050	PEMETrexed	PEMETrexed Disodium	FRESENIUS KABI USA LLC	TS	TS	No	65,666	1	1	
00002149580	Mounjaro	tirzepatide injection	LILLY USA, LLC	\$974.33	5 mg/0.5 mL once weekly	Yes	34,500,000	4	0.5	\$487.17
00002148480	Mounjaro	tirzepatide injection	LILLY USA, LLC	\$974.33	7.5 mg/0.5 mL once weekly	Yes	34,500,000	4	0.5	\$487.17
00002147180	Mounjaro	tirzepatide injection	LILLY USA, LLC	\$974.33	10 mg/0.5 mL once weekly	Yes	34,500,000	4	0.5	\$487.17
00002146080	Mounjaro	tirzepatide injection	LILLY USA, LLC	\$974.33	12.5 mg/0.5 mL once weekly	Yes	34,500,000	4	0.5	\$487.17
00002145780	Mounjaro	tirzepatide injection	LILLY USA, LLC	\$974.33	15 mg/0.5 mL once weekly	Yes	34,500,000	4	0.5	\$487.17
59353006512	Korsuva	Difelikefalin	VIFOR (INTERNATIONAL) INC.	\$1,800.00	0.5 mcg/kg dry body weight	Yes	2,000	12	1.3	\$115.38
11994001720	DEFINITY RT	PERFLUTREN LIPID MICROSPHERE INJ	LANTHEUS MEDICAL IMAGING, INC	\$5,977.28	6.52 mg/mL	No	185	20	2	\$149.43
60505606800	Pemetrexed for Injection 750 mg Vial	Pemetrexed	APOTEX CORP	\$3,210.59		3 No	16,572	1	1	\$3,210.59
60505606700	Pemetrexed for Injection 1000 mg Vial	Pemetrexed	APOTEX CORP	\$4,280.78		2 No	16,572	1	1	\$4,280.78
68462088260	Abiraterone Acetate Tablets 500 mg, 120	Abiraterone Acetate Tablets 500 mg, 120	GLENMARK PHARMACEUTICALS INC., USA	\$4,219.54	1000 mg orally once daily	No	1	1	60	\$70.33
55150038301	Pemetrexed for injection, USP SDV, 1000mg/vial - 1s	Pemetrexed	EUGIA US LLC (FKA AUROMEDICS PHARMA LLC)	\$1,000.00	1000mg/vial	No	1,000	1	1	\$1,000.00
00480451401	PEMETREXED INJECTION 500 MG/20 ML 1	PEMETREXED INJECTION 500 MG/20 ML 1	TEVA	\$3,424.67	500 MG / 20 ML	No	116	1	20	\$171.23
00480451501	PEMETREXED INJECTION 1 G/40 ML 1	PEMETREXED INJECTION 1 G/40 ML 1	TEVA	\$6,849.33	1 G / 40 ML	No	116	1	40	\$171.23
69238142401	Vigabatrin	Vigabatrin 500mg Tablets	AMNEAL PHARMACEUTICALS	\$10,511.89	Please refer to dosing and administration section of the full Prescribing Information found on our corporate website and/or DailyMed.	No	133	1	100	\$105.12
00378120178	Sorafenib Tosylate Tablet 200 mg	Sorafenib Tosylate Tablet 200 mg	MYLAN PHARMACEUTICALS INC	\$20,239.83	The dosage differs based on patient and therefore may vary. See Section 2 "DOSAGE AND ADMINISTRATION" of the attached prescribing information for specific dosage information.	No	159,934	1	120	\$168.67
00781351990	PEMETREXED	PEMETREXED	FOUGERA PHARMACEUTICALS INC	\$3,369.17	Carton containing one (1) single-dose vial 500 mg/20 ml	No	2,396	1	20	\$168.46

NDC	Trade name	Chemical name	Manufacturer name	Drug price	Drug dosage	FDA priority	Patients per month	Package quantity	Package size	Price per unit
00781351876	PEMETREXED	PEMETREXED	FOUGERA PHARMACEUTICALS INC	\$673.84	Carton containing one (1) single-dose vial 100 mg/4 ml	No	2,396	1	4	\$168.46
16729024438	Pemetrexed Disodium	Pemetrexed Disodium	ACCORD HEALTHCARE, INC.	\$1,044.50	1G Lyophilized Powder for Injection.	No	1	1	1	\$1,044.50
70505020260	NITISINONE capsules, for oral use 2 mg.	NITISINONE	ANALOG PHARMA, INC	\$4,360.00	60	No	1	1	60	\$72.67
43598045804	Sorafenib Tablets 200mg 120s HDPE US	Sorafenib	DR. REDDY'S LABORATORIES, INC	\$15,534.96	200 mg, 120s	No	70,000	1	120	\$129.46
60505431800	TOLVAPTAN TABLET	TOLVAPTAN	APOTEX CORP	\$4,687.19	6 blister packs	No	2,985	1	10	\$468.72
16729046785	Pirfenidone 267 mg tablet 3 Bottles	Pirfenidone	ACCORD HEALTHCARE, INC.	\$7,147.41	267mg	No	1	3	90	\$26.47
16729046815	Pirfenidone 801 mg tablet 1 Bottle	Pirfenidone	ACCORD HEALTHCARE, INC.	\$7,147.41	801mg	No	1	1	90	\$79.42
71336100301	AMVUTTRA	Vutrisiran	ALNYLAM PHARMACEUTICALS INC	\$115,875.00	25 mg/0.5 mL in a single-dose pre-filled syringe; Recommended dosage every 3 months (quarterly)	No	1,000	1	0.5	\$231,750.00
70510232102	Radicava ORS Starter Kit	Edaravone	MITSUBISHI TANABE PHARMA AMERICA, INC.	\$17,807.02	2 bottles x 35mL	Yes	TS	2	35	\$254.39
70510232201	Radicava ORS Kit	Edaravone	MITSUBISHI TANABE PHARMA AMERICA, INC.	\$12,719.30	1 bottle x 50mL	Yes	TS	1	50	\$254.39
70505020560	NITISINONE capsules, for oral use 5 mg.	NITISINONE	ANALOG PHARMA, INC	\$10,899.00	60	No	1	1	60	\$181.65
70505021060	NITISINONE capsules, for oral use 10 mg.	NITISINONE	ANALOG PHARMA, INC	\$21,797.00	60	No	1	1	60	\$363.28
55150037125	Vasopressin Injection USP, SDV 20 units/1mL - 25s	Vasopressin	EUGIA US LLC (FKA AUROMEDICS PHARMA LLC)	\$3,753.64	Dilute Vasostrict® with normal saline (0.9% sodium chloride) or 5% dextrose in water (D5W) to either 0.1 units/mL or 1 unit/mL for intravenous administration. Discard unused diluted solution after 18 hours at room temperature or 24 hours under refrigeration. ( 2-2.1) Post-cardiotomy shock: 0.03 to 0.1 units/minute ( 2-2.2) Septic shock: 0.01 to 0.07 units/minute ( 2-2.2)	No	10,000	25	1	\$150.15
70710183908	Nelarabine Inj 250mg/50ml Nova+ (6x5ml)	Nelarabine Inj 250mg/50ml	ZYDUS PHARMACEUTICALS USA INC	\$3,966.00	As noted in Product Insert. Zydus is not responsible for the dosage prescribed to patients and does not suggest any specific dosage amounts. For this product, Zydus has calculated the 30 day course of treatment dosage at 50 vials, however, the dosing depends patient to patient.	No	1	6	50	\$13.22
66794024042	Zinc Sulfate injection	Zinc Sulfate	PIRAMAL CRITICAL CARE, INC.	\$1,100.00	1 box of 25 vials	No	TS	25	10	\$4.40
70954025510	Methyltestosterone Capsules, USP 10mg	Methyltestosterone	ANI PHARMACEUTICALS INC	\$6,213.88	Methyltestosterone capsules are administered orally. The suggested dosage for androgens varies depending on the age, sex, and diagnosis of the individual patient. Dosage is adjusted according to the patient's response and the appearance of adverse reactions.	No	100	1	100	\$62.14
00574020101	Vigabatrin Tablets, USP 500 mg 100 Tablets	Vigabatrin Tablets, USP 500 mg 100 Tablets	PADAGIS US LLC	\$10,511.89	See Attached	No	661	1	100	\$105.12
00173090442	NUCALA 40MG/0.4ML	mepolizumab 40MG/0.4ML	GLAXOSMITHKLINE LLC (AKA GSK)	\$1,330.14	NUCALA (NDC: 00173090442) is indicated for add-on maintenance treatment of patients with severe asthma aged 6 years to 11 years. Severe asthma in patients aged 6 to 11 years: 40 mg administered subcutaneously once every 4 weeks.	No	5,000	1	0.4	\$3,325.35
66302064803	Tyvaso DPI	Treprostinil Powder	UNITED THERAPEUTICS CORPORATION	\$20,906.09	112 cartridges of 48 MCG 5 inhalers per prescription	Yes	TS	1	112	\$186.66
66302066403	Tyvaso DPI	Treprostinil Powder	UNITED THERAPEUTICS CORPORATION	\$20,906.09	112 cartridges of 64 MCG 5 inhalers per prescription	Yes	TS	1	112	\$186.66
66302063203	Tyvaso DPI	Treprostinil Powder	UNITED THERAPEUTICS CORPORATION	\$20,906.09	112 cartridges of 32 MCG 5 inhalers per prescription	Yes	TS	1	112	\$186.66
66794023942	Zinc Sulfate injection	Zinc Sulfate	PIRAMAL CRITICAL CARE, INC.	\$950.00	1 box of 25 vials	No	TS	25	5	\$7.60
00074501501	SKYRIZI	risankizumab-rzaa	ABBVIE INC.	\$9,136.40	600 mg/10 ml vial	Yes	1,000	1	10	\$913.64
00409353201	pemetrexed	pemetrexed	PFIZER	\$900.00	1gm per day for a 2 day treatment	No	130,000	1	40	\$22.50

NDC	Trade name	Chemical name	Manufacturer name	Drug price	Drug dosage	FDA priority	Patients per month	Package quantity	Package size	Price per unit
81643927001	Floxuridine	5-fluorodeoxyuridine	CERONA THERAPEUTICS, INC.	\$3,350.00	1 vial (500 mg of floxuridine to be reconstituted with 5 mL of sterile water for injection)	No	80			
64406001901	Byooviz	ranibizumab-nuna	BIOGEN INC	\$1,130.00	BYOOVIZ 0.5 mg (0.05 mL) is recommended to be administered by intravitreal injection once a month (approximately 28 days).	No	1	1	0.05	\$22,600.00
76282071690	Pirfenidone 801mg	Pirfenidone 801mg	EXELAN PHARMACEUTICALS, INC	\$6,281.05	801mg three times daily over a 14 day period	No	41	1	90	\$69.79
76282071727	Pirfenidone 267mg	Pirfenidone 267mg	EXELAN PHARMACEUTICALS, INC	\$6,292.70	801mg three times daily over a 14 day period	No	41	1	270	\$23.31
50268068312	POSACONAZOLE DR TAB 100MG 2X10 CT	POSACONAZOLE DR TAB 100MG 2X10 CT	AVKARE, INC (AKA AVPAK)	\$850.00	3 tabs daily (300mg)	No	1,450	1	20	\$42.50
00781349895	ARSENIC TRIOXIDE	ARSENIC TRIOXIDE	FOUGERA PHARMACEUTICALS INC	\$4,784.40	Carton containing (10) single-dose vial 12 mg/6 ml	No	86	10	6	\$79.74
70121164205	Vasopressin Injection	Vasopressin Injection 20 units/mL (1 mL)	AMNEAL PHARMACEUTICALS	\$2,627.63	Please refer to dosing and administration section of the full Prescribing Information found on our corporate website and/or DailyMed.	No	372	25	1	\$105.11
65219038370	Iodixanol	Iodixanol	FRESENIUS KABI USA LLC	\$1,930.00	320 MG/ML	No	479,000	10	200	\$0.97
65219038350	Iodixanol	Iodixanol	FRESENIUS KABI USA LLC	\$1,566.70	320 MG/ML	No	479,000	10	150	\$1.04
65219038310	Iodixanol	Iodixanol	FRESENIUS KABI USA LLC	\$1,134.90	320 MG/ML	No	479,000	10	100	\$1.13
65219038150	Iodixanol	Iodixanol	FRESENIUS KABI USA LLC	\$1,489.60	270 MG/ML	No	479,000	10	150	\$0.99
65219038110	Iodixanol	Iodixanol	FRESENIUS KABI USA LLC	\$1,021.30	270 MG/ML	No	479,000	10	100	\$1.02
72512092901	Qutenza	Capsaicin	AVERITAS PHARMA, INC.	\$1,675.02	2 patches	No	10	1	1	\$1,675.02
72512092801	Qutenza	Capsaicin	AVERITAS PHARMA, INC.	\$837.51	1 patch	No	10	1	1	\$837.51
72512093001	Qutenza	Capsaicin	AVERITAS PHARMA, INC.	\$3,433.80	4 patches	No	58	1	1	\$3,433.80
81092112001	Igalmi	Dexmedetomidine Hydrochloride	BIOXCEL THERAPEUTICS, INC.	\$1,050.00	Sublingual or Buccal Film	Yes	TS	1	10	\$105.00
81092118001	Igalmi	Dexmedetomidine Hydrochloride	BIOXCEL THERAPEUTICS, INC.	\$1,050.00	Sublingual or Buccal Film	Yes	TS	1	10	\$105.00
74695082318	VIVJOA	oteseconazole	MYCOVIA PHARMACEUTICALS, INC.	\$2,700.00		18 Yes	1,950	1	18	\$150.00
00406771160	Noxafil (posaconazole)	triazole	SPECGX LLC	\$970.00	Posaconazole Delayed-Release Tablets: Loading dose: 300 mg (three 100 mg delayed-release tablets) twice a day on the first day. Maintenance dose: 300 mg (three 100 mg delayed-release tablets) once a day, starting on the second day.	No	TS	1	60	\$16.17
69097098793	Pirfenidone 267mg	Pirfenidone 267mg	CIPLA USA, INC	\$1,800.00	Days 1 through 7 :267 mg three times daily (801 mg/day) Days 8 through 14:534 mg three times daily (1602 mg/day) Days 15 onward :801 mg three times daily (2403 mg/day)	Yes	6,250	1	270	\$6.67
69097098805	Pirfenidone 801mg	Pirfenidone 801mg	CIPLA USA, INC	\$1,800.00	Days 1 through 7 :267 mg three times daily (801 mg/day) Days 8 through 14:534 mg three times daily (1602 mg/day) Days 15 onward :801 mg three times daily (2403 mg/day)	Yes	6,250	1	90	\$20.00
72647033003	Pyrimethamine	Pyrimethamine	OAKRUM PHARMA, LLC	\$9,653.00	50 mg/day	No	14	1	30	\$321.77
72647090001	Betaine Anhydrous for Oral Solution	Betaine Anhydrous for Oral Solution	OAKRUM PHARMA, LLC	\$1,578.00	6 g/day	No	15	1	180	\$8.77
72647037130	Deferasirox Oral Granules	Deferasirox Oral Granules	OAKRUM PHARMA, LLC	\$1,025.01	28 mg/kg/day	No	6	1	30	\$34.17
72647033001	Pyrimethamine	Pyrimethamine	OAKRUM PHARMA, LLC	\$32,175.00	50 mg	No	57	1	100	\$321.75
72647037230	Deferasirox Oral Granules	Deferasirox Oral Granules	OAKRUM PHARMA, LLC	\$2,049.98	28 mg/kg/day	No	6	1	30	\$68.33
72647037330	Deferasirox Oral Granules	Deferasirox Oral Granules	OAKRUM PHARMA, LLC	\$4,099.87	28 mg/kg/day	No	15	1	30	\$136.66
65219002920	Thiotepa	Thiotepa	FRESENIUS KABI USA LLC	\$3,000.00	100 MG	No	60,000	1	1	\$3,000.00
66302060002	Tyvaso DPI Titration Kit Inhalation Powder 112 cartridges of 16 MCG and 84 cartridges of 32 MCG with 5 inhalers per box	Treprostinil Powder	UNITED THERAPEUTICS CORPORATION	\$20,906.09	112 cartridges of 16 MCG and 84 cartridges of 32 MCG 5 inhalers per prescription	Yes	TS	1	196	\$106.66
62332047964	Pirfenidone Tablet, 267mg	Pirfenidone Tablet, 267mg	ALEMBIC PHARMACEUTICALS INC	\$5,360.55	Days 1-7 267mg three times daily (801mg/day); Days 8-14 534mg(1602mg/day), Days 15 onward 801mg (2403 mg/day)	No	100,000	3	90	\$19.85

NDC	Trade name	Chemical name	Manufacturer name	Drug price	Drug dosage	FDA priority	Patients per month	Package quantity	Package size	Price per unit
66302061603	Tyvaso DPI Maintenance Kit Inhalation Powder 112 cartridges of 16 MCG with 5 inhalers per box	Treprostinil Powder	UNITED THERAPEUTICS CORPORATION	\$20,906.09	112 cartridges of 16 MCG 5 inhalers per prescription	Yes	TS	1	112	\$186.66
66302061002	Tyvaso DPI Titration Kit Inhalation Powder 112 cartridges of 16 MCG and 112 cartridges of 32 MCG and 28 cartridges of 48 MCG with 5 inhalers per box	Treprostinil Powder	UNITED THERAPEUTICS CORPORATION	\$20,906.09	112 cartridges of 16 MCG and 112 cartridges of 32 MCG and 28 cartridges of 48 MCG 5 inhalers per prescription	Yes	TS	1	252	\$82.96
47335017795	Ilumya Subcutaneous Solution Prefilled Syringe 100 MG/ML	Tildrakizumab	SUN PHARMACEUTICAL INDUSTRIES INC	\$13,256.00	100 MG/ML, 1 ML, Unit-Dose, Syringe	No	1	1	1	\$13,256.00
47335030588	metFORMIN HCl ER (MOD) Oral Tablet Extended Release 24 Hour 500 MG	Metformin	SUN PHARMACEUTICAL INDUSTRIES INC	\$1,615.00	500 MG, 100 Each, Bottle	No	1	1	100	\$16.15
47335030688	metFORMIN HCl ER (MOD) Oral Tablet Extended Release 24 Hour 1000 MG	Metformin	SUN PHARMACEUTICAL INDUSTRIES INC	\$2,625.00	1000 MG, 100 Each, Bottle	No	1	1	100	\$26.25
47335040181	Yonsa Oral Tablet 125 MG	Abiraterone	SUN PHARMACEUTICAL INDUSTRIES INC	\$9,209.00	125 MG, 120 Each, Bottle	No	1	1	120	\$76.74
47335041022	SUMatriptan-Naproxen Sodium Oral Tablet 85-500 MG	Sumatriptan-Naproxen Sodium	SUN PHARMACEUTICAL INDUSTRIES INC	\$750.76	Initial dose: 1 tablet orally once; Maximum dose: 2 tablets in a 24-hour period taken at least 2 hours apart	No	1	1	9	\$83.42
47335074483	Paliperidone ER Oral Tablet Extended Release 24 Hour 1.5 MG	Paliperidone	SUN PHARMACEUTICAL INDUSTRIES INC	\$733.49	24HR 1.5 MG, 30 Each, Bottle	No	1	1	30	\$24.45
47335076583	Paliperidone ER Oral Tablet Extended Release 24 Hour 3 MG	Paliperidone	SUN PHARMACEUTICAL INDUSTRIES INC	\$733.49	24 Hour 3 MG	No	1	1	30	\$24.45
47335076683	Paliperidone ER Oral Tablet Extended Release 24 Hour 6 MG	Paliperidone	SUN PHARMACEUTICAL INDUSTRIES INC	\$733.49	24 Hour 6 MG	No	1	1	30	\$24.45
47335076783	Paliperidone ER Oral Tablet Extended Release 24 Hour 9 MG	Paliperidone	SUN PHARMACEUTICAL INDUSTRIES INC	\$1,100.23	24 Hour 9 MG	No	1	1	30	\$36.67
47335089272	Temozolomide Oral Capsule 100 MG	Temozolomide	SUN PHARMACEUTICAL INDUSTRIES INC	\$3,027.45	100 MG	No	1	1	15	\$201.83
47335089274	Temozolomide Oral Capsule 100 MG	Temozolomide	SUN PHARMACEUTICAL INDUSTRIES INC	\$1,009.15	100	No	1	1	5	\$201.83
47335089374	Temozolomide Oral Capsule 250 MG	Temozolomide	SUN PHARMACEUTICAL INDUSTRIES INC	\$2,523.60	250 MG	No	1	1	5	\$504.72
47335092972	Temozolomide Oral Capsule 140 MG	Temozolomide	SUN PHARMACEUTICAL INDUSTRIES INC	\$4,238.55	140 MG	No	1	1	15	\$282.57
47335092974	Temozolomide Oral Capsule 140 MG	Temozolomide	SUN PHARMACEUTICAL INDUSTRIES INC	\$1,412.85	140 MG	No	1	1	5	\$282.57
47335093072	Temozolomide Oral Capsule 180 MG	Temozolomide	SUN PHARMACEUTICAL INDUSTRIES INC	\$5,449.50	180 MG	No	1	1	15	\$363.30
47335093074	Temozolomide Oral Capsule 180 MG	Temozolomide	SUN PHARMACEUTICAL INDUSTRIES INC	\$1,816.50	180 MG	No	1	1	5	\$363.30
57664076288	Levorphanol Tartrate Oral Tablet 2 MG	Levorphanol	SUN PHARMACEUTICAL INDUSTRIES INC	\$3,337.50	Initial dose: 1 to 2 mg orally every 6 to 8 hours - more dosage information in correspondence	No	1	1	100	\$33.38
62756053360	Infugem Intravenous Solution 1800-0.9 MG/180ML-%	Gemcitabine	SUN PHARMACEUTICAL INDUSTRIES INC	\$684.00	1800 MG/180ML-0.9%, 180 ML, Unit-Dose, Flex Cont	No	1	1	180	\$3.80
62756061460	Infugem Intravenous Solution 1900-0.9 MG/190ML-%	Gemcitabine	SUN PHARMACEUTICAL INDUSTRIES INC	\$722.00	1900 MG/190ML-0.9%, 190 ML, Unit-Dose, Flex Cont	No	70,000	1	190	\$3.80
62756074660	Infugem Intravenous Solution 2000-0.9 MG/200ML-%	Gemcitabine	SUN PHARMACEUTICAL INDUSTRIES INC	\$760.00	2000-0.9 MG/200ML-%	No	1	1	200	\$3.80
62756097460	Infugem Intravenous Solution 2200-0.9 MG/220ML-%	Gemcitabine	SUN PHARMACEUTICAL INDUSTRIES INC	\$836.00	2200-0.9 MG/220ML-%	No	1	1	220	\$3.80
63304008310	chlorproMAZINE HCl Oral Tablet 200 MG	Chlorpromazine	SUN PHARMACEUTICAL INDUSTRIES INC	\$3,952.40	200 MG, 1000 Each, Bottle	No	1	1	1000	\$3.95
63304011410	chlorproMAZINE HCl Oral Tablet 100 MG	Chlorpromazine	SUN PHARMACEUTICAL INDUSTRIES INC	\$2,661.30	Oral Tablet 100 MG	No	1	1	1000	\$2.66
63304012210	chlorproMAZINE HCl Oral Tablet 50 MG	Chlorpromazine	SUN PHARMACEUTICAL INDUSTRIES INC	\$1,880.60	50 MG, 1000 Each, Bottle	No	1	1	1000	\$1.88
63304014310	chlorproMAZINE HCl Oral Tablet 25 MG	Chlorpromazine	SUN PHARMACEUTICAL INDUSTRIES INC	\$1,002.80	Oral Tablet 25 MG	No	1	1	1000	\$1.00
63304058360	Fosamprenavir Calcium Oral Tablet 700 MG	Fosamprenavir	SUN PHARMACEUTICAL INDUSTRIES INC	\$999.89	700 MG (Base Equiv), 60 Each, Bottle - more dosage information in correspondence	No	1	1	60	\$16.66
63304072290	diltiazem HCl ER Coated Beads Oral Capsule Extended Release 24 Hour 360 MG	Diltiazem	SUN PHARMACEUTICAL INDUSTRIES INC	\$736.88	1 capsule (300 mg) by oral route once daily	No	1	1	90	\$8.19
51672140204	Calcipotriene-Betameth Diprop External Suspension 0.005-0.064 %	Calcipotriene-Betamethasone Dipropionate	TARO PHARMACEUTICAL USA INC.	\$834.96	Injectable 30 mg/5 mL suspension - more dosage information in correspondence	No	1	1	60	\$13.92
51672140208	Calcipotriene-Betameth Diprop External Suspension 0.005-0.064 %	Calcipotriene-Betameth	TARO PHARMACEUTICAL USA INC.	\$1,669.92	Injectable 30 mg/5 mL suspension - more dosage information in correspondence	No	1	2	60	\$13.92

NDC	Trade name	Chemical name	Manufacturer name	Drug price	Drug dosage	FDA priority	Patients per month	Package quantity	Package size	Price per unit
51672417409	Imiquimod Pump External Cream 3.75 %	Imiquimod	TARO PHARMACEUTICAL USA INC.	\$1,064.58	Apply a thin layer once a day to the external genital/perianal warts until total clearance or up to 8 weeks	No	1	1	7.5	\$141.94
51672419601	Deferiprone Oral Tablet 500 MG	Deferiprone	TARO PHARMACEUTICAL USA INC.	\$6,148.08	Initial dose: 25 mg/kg, orally, 3 times a day (total daily dose: 75 mg/kg) - more info in correspondence	No	1	1	100	\$61.48
43598016001	Potassium Chloride Solution 10% 40MEQ/30ML 100CT	Potassium Chloride	DR. REDDY'S LABORATORIES, INC	\$1,260.00	40MEQ/30ML	No	44,000	100	30	\$0.42
60505453302	Lenalidomide Capsules	Lenalidomide	APOTEX CORP	\$20,157.36	0	No	11,065	1	28	\$719.91
60505453402	Lenalidomide Capsules	Lenalidomide	APOTEX CORP	\$20,157.36	0	No	11,065	1	28	\$719.91
60505453502	Lenalidomide Capsules	Lenalidomide	APOTEX CORP	\$15,118.04	0	No	11,065	1	21	\$719.91
60505453702	Lenalidomide Capsules	Lenalidomide	APOTEX CORP	\$15,118.04	0	No	11,065	1	21	\$719.91
69097038173	Lenalidomide Capsules 5mg 28's	Lenalidomide Capsules 5mg 28's	CIPLA USA, INC	\$20,157.36	a) Multiple myeloma combination therapy: 25 mg once daily orally on Days 1-21 of repeated 28-day cycles b) Multiple myeloma maintenance therapy following auto-HSCT: 10 mg once daily continuously on Days 1-28 of repeated 28-day cycles c) myelodysplastic syndromes: 10 mg once daily d) Mantle cell lymphoma: 25 mg once daily orally on Days 1-21 of repeated 28-day cycles e) follicular lymphoma or marginal zone lymphoma: 20 mg once daily orally on Days 1-21 of repeated 28-day cycles for up to 12 cycl	Yes	34,000	1	28	\$719.91
69097038273	Lenalidomide Capsules 10mg 28's	Lenalidomide Capsules 10mg 28's	CIPLA USA, INC	\$20,157.36	a) Multiple myeloma combination therapy: 25 mg once daily orally on Days 1-21 of repeated 28-day cycles b) Multiple myeloma maintenance therapy following auto-HSCT: 10 mg once daily continuously on Days 1-28 of repeated 28-day cycles c) myelodysplastic syndromes: 10 mg once daily d) Mantle cell lymphoma: 25 mg once daily orally on Days 1-21 of repeated 28-day cycles e) follicular lymphoma or marginal zone lymphoma: 20 mg once daily orally on Days 1-21 of repeated 28-day cycles for up to 12 cycl	Yes	34,000	1	28	\$719.91
69097038381	Lenalidomide Capsules 15 mg 21's	Lenalidomide Capsules 15 mg 21's	CIPLA USA, INC	\$15,118.04	a) Multiple myeloma combination therapy: 25 mg once daily orally on Days 1-21 of repeated 28-day cycles b) Multiple myeloma maintenance therapy following auto-HSCT: 10 mg once daily continuously on Days 1-28 of repeated 28-day cycles c) myelodysplastic syndromes: 10 mg once daily d) Mantle cell lymphoma: 25 mg once daily orally on Days 1-21 of repeated 28-day cycles e) follicular lymphoma or marginal zone lymphoma: 20 mg once daily orally on Days 1-21 of repeated 28-day cycles for up to 12 cycl	Yes	34,000	1	21	\$719.91

NDC	Trade name	Chemical name	Manufacturer name	Drug price	Drug dosage	FDA priority	Patients per month	Package quantity	Package size	Price per unit
69097038581	Lenalidomide Capsules 25mg 21's	Lenalidomide Capsules 25mg 21's	CIPLA USA, INC	\$15,118.04	a) Multiple myeloma combination therapy: 25 mg once daily orally on Days 1-21 of repeated 28-day cycles b) Multiple myeloma maintenance therapy following auto-HSCT: 10 mg once daily continuously on Days 1-28 of repeated 28-day cycles c) myelodysplastic syndromes: 10 mg once daily d) Mantle cell lymphoma: 25 mg once daily orally on Days 1-21 of repeated 28-day cycles e) follicular lymphoma or marginal zone lymphoma: 20 mg once daily orally on Days 1-21 of repeated 28-day cycles for up to 12 cycl	Yes	34,000	1	21	\$719.91
70121164207	Vasopressin Injection	Vasopressin Injection	AMNEAL PHARMACEUTICALS	\$1,051.05	Please refer to dosing and administration section of the full Prescribing Information found on our corporate website and/or DailyMed.	No	3,020	10	1	\$105.11
82293000210	ABIRATERONE ACETATE 500MG	ABIRATERONE ACETATE 500MG	NOVUGEN PHARMA USA LLC	\$4,219.54	100mg daily	No	350	1	60	\$70.33
62332048090	Pirfenidone Tablet, 801mg	Pirfenidone Tablet, 801mg	ALEMBIC PHARMACEUTICALS INC	\$5,360.55	Days 1-7 267mg three times daily (801mg/day); Days 8-14 534mg(1602mg/day), Days 15 onward 801mg (2403 mg/day)	No	100,000	1	90	\$59.56
55150042010	Esmolol Hydrochloride in Sodium Chloride Injection SD Bags 2	esmolol hydrochloride in sodium chloride	EUGIA US LLC (FKA AUROMEDICS PHARMA LLC)	\$1,398.00	2,500 mg/250 mL 10 mg/mL 250 mL Bag	No	1,000	10	250	\$0.56
55150042110	Esmolol Hydrochloride in Sodium Chloride Injection SD Bags 2	esmolol hydrochloride in sodium chloride	EUGIA US LLC (FKA AUROMEDICS PHARMA LLC)	\$1,595.00	2,000 mg/100 mL, 20 mg/mL, 100 mL Bag	No	1,000	10	100	\$1.60
00597003510	Spevigo	Spesolimab-sbzo	BOEHRINGER INGELHEIM PHARMACEUTICALS INC	\$51,133.00	900 mg (2 vials consisting of 450mg per 7.5 mL)	Yes	15	2	7.5	\$3,408.87
81583010001	ZTALMY	ganaxolone	MARINUS PHARMACEUTICALS, INC.	\$2,425.00	9.16667	Yes	9	1	110	\$22.05
81583010005	ZTALMY	ganaxolone	MARINUS PHARMACEUTICALS, INC.	\$12,125.00	45.83333	Yes	9	5	110	\$22.05
00074107001	SKYRIZI	risankizumab-rzaa	ABBVIE INC.	\$18,272.79	360 mg/2.4 mL single dose prefilled cartridge	Yes	1,000	1	2.4	\$7,613.66
74676590201	Trelstar	Triptorelin Pamoate	VERITY PHARMACEUTICALS INC.	\$813.24	3.75 mg	No	1	1	1	\$813.24
60505455203	Ambrisentan	Letairis	APOTEX CORP	\$5,533.61	A dosage of 5 mg once a day was estimated as the course of treatment. This corresponds with 1 bottle in 30 days. Apotex does not recommend this particular dosage and the dosage should be determined by the health care provider	No	1,000	1	30	\$184.45
60505455303	Ambrisentan	Letairis	APOTEX CORP	\$5,533.61	A dosage of 10 mg once a day was estimated as the course of treatment. This corresponds with 2 bottles in 30 days. Apotex does not recommend this particular dosage and the dosage should be determined by the health care provider	No	1,000	1	30	\$184.45
62332054460	Asenapine Sublingual Tablets 2.5mg	Asenapine	ALEMBIC PHARMACEUTICALS INC	\$720.49	The recommended dose of asenapine is 2.5 mg to 10 mg twice daily in pediatric patients 10 to 17 years of age, and dose may be adjusted for individual response and tolerability. The starting dose of asenapine is 2.5 mg twice daily. After 3 days, the dose can be increased to 5 mg twice daily, and from 5 mg to 10 mg twice daily after 3 additional days.	No	136	6	10	\$12.01

NDC	Trade name	Chemical name	Manufacturer name	Drug price	Drug dosage	FDA priority	Patients per month	Package quantity	Package size	Price per unit
70756061756	Tobramycin Inhalation Solution, USP 300mg/4ml	Tobramycin Inhalation Solution, USP 300mg/4ml	LIFESTAR PHARMA, LLC	\$2,350.00	administer one single-use ampule (300 mg/4 mL) twice daily by oral inhalation in repeated cycles of 28 days on drug, followed by 28 days off drug. The doses should be taken as close to 12 hours apart as possible and not less than 6 hours apart.	No	8,000	56	4	\$10.49
70710103107	Lenalidomide Capsule	Lenalidomide	ZYDUS PHARMACEUTICALS USA INC	\$20,157.36	As noted in Product Insert. Zydus is not responsible for the dosage prescribed to patients and does not suggest any specific dosage amounts. For this product, Zydus has calculated the course of treatment dosage at 28 capsules, however, the dosing depends patient to patient.	No	1	1	28	\$719.91
70710103207	Lenalidomide Capsule 10mg	Lenalidomide	ZYDUS PHARMACEUTICALS USA INC	\$20,157.36	As noted in Product Insert. Zydus is not responsible for the dosage prescribed to patients and does not suggest any specific dosage amounts. For this product, Zydus has calculated the course of treatment dosage at 28 capsules, however, the dosing depends patient to patient.	No	1	1	28	\$719.91
70710103308	Lenalidomide Capsule 15mg	Lenalidomide	ZYDUS PHARMACEUTICALS USA INC	\$15,118.04	As noted in Product Insert. Zydus is not responsible for the dosage prescribed to patients and does not suggest any specific dosage amounts. For this product, Zydus has calculated the course of treatment dosage at 21 capsules, however, the dosing depends patient to patient.	No	1	1	21	\$719.91
70710103508	Lenalidomide Capsule 25mg	Lenalidomide	ZYDUS PHARMACEUTICALS USA INC	\$15,118.04	As noted in Product Insert. Zydus is not responsible for the dosage prescribed to patients and does not suggest any specific dosage amounts. For this product, Zydus has calculated the course of treatment dosage at 21 capsules, however, the dosing depends patient to patient.	No	1	1	21	\$719.91
71770020010	PHEBURANE	sodium phenylbutyrate	MEDUNIK USA, INC.	\$4,375.00	Oral pellets: 84 g of sodium phenylbutyrate per PHEBURANE bottle as white to off-white coated pellets	No	7	1	174	\$25.14
74676590401	Trelstar	Triptorelin Pamoate	VERITY PHARMACEUTICALS INC.	\$2,439.72	11.25 mg	No	30	1	1	\$2,439.72
74676590601	Trelstar	Triptorelin Pamoate	VERITY PHARMACEUTICALS INC.	\$4,879.44	22.5 mg	No	35	1	1	\$4,879.44
67877063502	Tolvaptan 15 mg Tablets	Tolvaptan 15 mg Tablets	ASCEND LABORATORIES LLC	\$4,630.10	15mg	No	1	1	10	\$463.01
67877063533	Tolvaptan 15 mg Tabs 1x10	Tolvaptan 15 mg Tabs 1x10	ASCEND LABORATORIES LLC	\$4,630.10	15mg	No	1	1	10	\$463.01
70121162701	Fylnetra® (pegfilgrastim-pbbk) Injection	Fylnetra 6mg/0.6mL Injection single dose	AMNEAL PHARMACEUTICALS	\$2,500.00	The recommended dosage of FYLNETRA is a single subcutaneous injection of 6 mg administered once per chemotherapy cycle. For dosing in pediatric patients weighing less than 45 kg, refer to Table 1. Do not administer FYLNETRA between 14 days before and 24 hours after administration of cytotoxic chemotherapy.	No	2,087	1	0.6	\$4,166.67
43598051663	Lenalidomide Capsules 2.5 mg, 28 ct	Lenalidomide	DR. REDDY'S LABORATORIES, INC	\$20,157.36	2.5 mg	No	200,000	1	28	\$719.91
43598051163	Lenalidomide Capsules 5 mg, 28 ct	Lenalidomide	DR. REDDY'S LABORATORIES, INC	\$20,157.36	5mg	No	200,000	1	28	\$719.91
43598051263	Lenalidomide Capsules 10 mg, 28 ct	Lenalidomide	DR. REDDY'S LABORATORIES, INC	\$20,157.36	10mg	No	200,000	1	28	\$719.91
43598051321	Lenalidomide Capsules 15 mg, 21 ct	Lenalidomide	DR. REDDY'S LABORATORIES, INC	\$15,118.04	15mg	No	200,000	1	21	\$719.91
43598051421	Lenalidomide Capsules 20 mg, 21 ct	Lenalidomide	DR. REDDY'S LABORATORIES, INC	\$15,118.04	20mg	No	200,000	1	21	\$719.91
43598051521	Lenalidomide Capsules 25 mg, 21 ct	Lenalidomide	DR. REDDY'S LABORATORIES, INC	\$15,118.04	25mg	No	200,000	1	21	\$719.91
73683010110	HYFTOR	sirolimus topical gel	NOBELPHARMA AMERICA, LLC	\$1,750.00	0.2% Topical Gel	Yes	600	1	10	\$175.00
00310351260	CALQUENCE	acalabrutinib maleate	ASTRAZENECA PHARMACEUTICALS LP	\$14,485.92	Tablet	No	11,500	1	60	\$241.43

NDC	Trade name	Chemical name	Manufacturer name	Drug price	Drug dosage	FDA priority	Patients per month	Package quantity	Package size	Price per unit
00378193601	Lenalidomide 5mg Oral capsule, 100	Lenalidomide 5mg Oral capsule, 100	MYLAN PHARMACEUTICALS INC	\$71,990.62	The dosage differs based on patient and therefore may vary. See Section 2 "DOSAGE AND ADMINISTRATION" of the attached prescribing information for specific dosage information.	No	70,792	1	100	\$719.91
00378193628	Lenalidomide 5mg Oral capsule, 28	Lenalidomide 5mg Oral capsule, 28	MYLAN PHARMACEUTICALS INC	\$20,157.36	The dosage differs based on patient and therefore may vary. See Section 2 "DOSAGE AND ADMINISTRATION" of the attached prescribing information for specific dosage information.	No	70,792	1	28	\$719.91
00378193701	Lenalidomide 10mg Oral capsule, 100	Lenalidomide 10mg Oral capsule, 100	MYLAN PHARMACEUTICALS INC	\$71,990.62	The dosage differs based on patient and therefore may vary. See Section 2 "DOSAGE AND ADMINISTRATION" of the attached prescribing information for specific dosage information.	No	70,792	1	100	\$719.91
00378193728	Lenalidomide 10mg Oral capsule, 28	Lenalidomide 10mg Oral capsule, 28	MYLAN PHARMACEUTICALS INC	\$20,157.36	The dosage differs based on patient and therefore may vary. See Section 2 "DOSAGE AND ADMINISTRATION" of the attached prescribing information for specific dosage information.	No	70,792	1	28	\$719.91
00378194101	Lenalidomide 15mg Oral capsule, 100	Lenalidomide 15mg Oral capsule, 100	MYLAN PHARMACEUTICALS INC	\$71,990.62	The dosage differs based on patient and therefore may vary. See Section 2 "DOSAGE AND ADMINISTRATION" of the attached prescribing information for specific dosage information.	No	70,792	1	100	\$719.91
00378194121	Lenalidomide 15mg Oral capsule, 21	Lenalidomide 15mg Oral capsule, 21	MYLAN PHARMACEUTICALS INC	\$15,118.04	The dosage differs based on patient and therefore may vary. See Section 2 "DOSAGE AND ADMINISTRATION" of the attached prescribing information for specific dosage information.	No	70,792	1	21	\$719.91
00378194001	Lenalidomide 25mg Oral capsule, 100	Lenalidomide 25mg Oral capsule, 100	MYLAN PHARMACEUTICALS INC	\$71,990.62	The dosage differs based on patient and therefore may vary. See Section 2 "DOSAGE AND ADMINISTRATION" of the attached prescribing information for specific dosage information.	No	70,792	1	100	\$719.91
00378194021	Lenalidomide 25mg Oral capsule, 21	Lenalidomide 25mg Oral capsule, 21	MYLAN PHARMACEUTICALS INC	\$15,118.04	The dosage differs based on patient and therefore may vary. See Section 2 "DOSAGE AND ADMINISTRATION" of the attached prescribing information for specific dosage information.	No	70,792	1	21	\$719.91
67877047630	FINGOLIMOD 0.5MG CAPSULE	FINGOLIMOD 0.5MG CAPSULE	ASCEND LABORATORIES LLC	\$8,279.94	0.5mg	No	1	1	30	\$276.00
00003089511	SOTYKTU	deucravacitinib	BRISTOL-MYERS SQUIBB, INC	\$6,164.38	6 mg	No	900	1	30	\$205.48
58468005001	XENPOZYME™	olipudase alfa-rpcp	GENZYME CORPORATION	\$7,142.00	US list price (WAC) is \$7,142 per 20 mg single-dose vial. XENPOZYME™ is administered as a monotherapy ERT every two weeks. Recommended dose is based on body weight and is administered incrementally via IV infusion. Based on the median patient (US), the cost per infusion is approximately \$30,000 every other week. Actual patient out-of-pocket costs may be lower, as WAC does not reflect insurance coverage, co-pay support for eligible patients, or financial assistance from patient support programs.	Yes	120	1	1	\$7,142.00
57962000712	Imbruvica	ibrutinib	PHARMACYCLICS LLC	\$9,614.63	70 mg/mL	No	20	1	108	\$89.02
43598009730	Sapropterin Dihydrochloride Sachets, 100 mg (Javygtor), 30s	Sapropterin Dihydrochloride	DR. REDDY'S LABORATORIES, INC	\$1,260.00	100mg	No	19,000	1	30	\$42.00

NDC	Trade name	Chemical name	Manufacturer name	Drug price	Drug dosage	FDA priority	Patients per month	Package quantity	Package size	Price per unit
00378452593	Fingolimod Capsules, 0.5mg	Fingolimod Capsules, 0.5mg	MYLAN PHARMACEUTICALS INC	\$8,883.89	The dosage differs based on patient and therefore may vary. See Section 2 "DOSAGE AND ADMINISTRATION" of the attached prescribing information for specific dosage information.	Yes	830,000	1	30	\$296.13
68382091206	Fingolimod 0.5mg Capsule	Fingolimod Capsule	ZYDUS PHARMACEUTICALS USA INC	\$2,220.97	As noted in Product Insert. Zydus is not responsible for the dosage prescribed to patients and does not suggest any specific dosage amounts. For this product, Zydus has calculated the course of treatment dosage at 30 capsules, however, the dosing depends patient to patient.	No	1	1	30	\$74.03
43598037074	Pemetrexed for Injection 1000mg/Vial USA 1's	Pemetrexed	DR. REDDY'S LABORATORIES, INC	\$1,586.00	1000mg/vial	No	541,000	1	1	\$1,586.00
69784061025	Leukeran® Tablets, 2mg	chlorambucil	WOODWARD PHARMA SERVICES LLC	\$6,009.15	2mg Tablet	No	1,000	1	25	\$240.37
69784062025	Myleran® Tablets, 2mg	busulfan	WOODWARD PHARMA SERVICES LLC	\$3,125.00	2mg Tablets	No	1,000	1	25	\$125.00
69784063025	Tabloid® Tablets, 40mg	thioguanine	WOODWARD PHARMA SERVICES LLC	\$5,624.50	40mg Tablets	No	1,000	1	25	\$224.98
70377010311	Aminocaproic Acid Tablets	Aminocaproic Acid Tablets	BIOCON LIMITED	\$1,008.11	1000mg	No	1,667	1	30	\$33.60
70377010411	Aminocaproic Acid Oral Solution	Aminocaproic Acid Oral Solution	BIOCON LIMITED	\$1,100.00	0.25gm/ml	No	5,738	1	236.5	\$4.65
43598009604	Sapropterin DiHCL Tablets (Javygtor) 100 mg, 120s	Sapropterin DiHCL	DR. REDDY'S LABORATORIES, INC	\$5,040.00	100mg	No	19,000	1	120	\$42.00
73554311101	ZYNTEGLO	betibeglogene autotemcel	BLUEBIRD BIO, INC.	TS	TS	Yes	TS	1	1	
68462016630	Fingolimod Capsules 0.5 mg, 30	Fingolimod Capsules 0.5 mg, 30	GLENMARK PHARMACEUTICALS INC., USA	\$1,000.00	0.5 mg orally once daily	No	1	1	30	\$33.33
69087015812	Jatenzo	testosterone undecanoate	TOLMAR PHARMACEUTICALS, INC.	\$962.64	typically 2 tablets a day. WAC price is for 120 tablets.	No	2	1	120	\$8.02
69087019812	Jatenzo	testosterone undecanoate	TOLMAR PHARMACEUTICALS, INC.	\$962.64	typically 2 tablets a day, WAC price is for 120 tablets	No	1	1	120	\$8.02
69087023712	Jatenzo	testosterone undecanoate	TOLMAR PHARMACEUTICALS, INC.	\$1,925.26	237 mg	No	1	1	120	\$16.04
70114044101	CIMERLI	Ranibizumab-eqrn	COHERUS BIOSCIENCE, INC.	\$1,360.00	0.5 mg carton containing a single-dose, 2-mL glass vial with a BLUE CAP designed to deliver 0.05 mL of 10 mg/mL ranibizumab-eqrn solution	No	135,133	1	0.05	\$27,200.00
70114044001	CIMERLI	Ranibizumab-eqrn	COHERUS BIOSCIENCE, INC.	\$816.00	0.3 mg carton containing a single-dose, 2-mL glass vial with a WHITE CAP designed to deliver 0.05 mL of 6 mg/mL ranibizumab-eqrn solution	No	135,133	1	0.05	\$16,320.00
73063003503	Relyvrio	Sodium Phenylbutyrate - Taurursodiol	AMLYX PHARMACEUTICALS, INC.	\$12,504.24	Relyvrio Oral Packet 3-1 GM	No	TS	1	56	\$223.29
73063003504	Relyvrio	Sodium Phenylbutyrate - Taurursodiol	AMLYX PHARMACEUTICALS, INC.	\$1,563.03	Relyvrio Oral Packet 3-1 GM	No	TS	1	7	\$223.29
73077001001	PEDMARK	sodium thiosulfate injection	FENNEC PHARMACEUTICALS INC.	\$11,417.09	Pedmark dosing is based on surface area according to actual body weight. Pedmark maximum dose for patients over 10kg is 20g/m2	Yes	290	1	100	\$114.17
43825020001	Terlivaz	Terlipressin acetate	MALLINCKRODT HOSPITAL PRODUCTS INC	\$950.00	The recommended starting dosage is 0.85 mg terlipressin every 6 hours by slow intravenous bolus injection (over 2 minutes) on days 1 through 3. Adjust the dose based on changes from baseline SCr on day 4.	No	35,000	1	1	\$950.00
43598028530	Fingolimod 0.5mg 30s capsules	Fingolimod	DR. REDDY'S LABORATORIES, INC	\$4,140.00	.5mg	No	1,000,000	1	30	\$138.00
43598017111	Thiotepa for injection, 100mg/Vial	Thiotepa	DR. REDDY'S LABORATORIES, INC	\$2,995.00	100mg	No	300,000	1	1	\$2,995.00
65162068312	Diclofenac Sodium 2% Topical Gel	Diclofenac Sodium 2% Topical Gel	AMNEAL PHARMACEUTICALS	\$1,616.82	Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals. The recommended dosage is 2 pump actuations on each painful knee , 2 times a day.	No	448,815	1	112	\$14.44
76961010101	Rolvedon	Eflapegrastim-xnst	SPECTRUM PHARMACEUTICALS, INC.	\$4,500.00	13.2 mg per 0.6mL syringe	No	12,500	1	0.6	\$7,500.00
16729034210	Fingolimod	Fingolimod HCl	ACCORD HEALTHCARE, INC.	\$4,870.56	0.5 mg	No	1	1	30	\$162.35

NDC	Trade name	Chemical name	Manufacturer name	Drug price	Drug dosage	FDA priority	Patients per month	Package quantity	Package size	Price per unit
60505433203	Fingolimod 0.5 mg Capsules	Fingolimod	APOTEX CORP	\$4,870.56	0.5 mg capsules taken orally, once-daily. The correct dosage should be determined by the health care provider.	No	15,000	1	30	\$162.35
25021019011	Micafungin Injection	Micafungin Sodium	SAGENT PHARMACEUTICALS, INC	\$935.00	Recommended dosage for adult patients based on indications is 50 mg-150mg daily for a mean duration of treatment of 15-19 days	No	1	10	1	\$93.50
57237000114	AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE	AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE	CASPER PHARMA	\$887.49	CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS 112 (size) and case pack is 24	Yes	1	1	112	\$7.92
64980045001	TRIENTINE HYDROCHLORIDE	TRIENTINE HYDROCHLORIDE	CASPER PHARMA	\$998.00	Capsule 100 (size) 6 (case pack)	No	1	1	100	\$9.98
64980020612	ZILEUTON	ZILEUTON ER ORAL TABLET ER 12 HOUR 600 MG	CASPER PHARMA	\$1,500.00	TABLET, EXTENDED RELEASE 600mg	No	1	1	120	\$12.50
64980052621	NITAZOXANIDE	NITAZOXANIDE	CASPER PHARMA	\$1,561.10	500mg	No	1	1	12	\$130.09
64980052603	NITAZOXANIDE	NITAZOXANIDE	CASPER PHARMA	\$3,625.81	500mg	No	1	1	30	\$120.86
16571074024	NITROFURANTOIN	NITROFURANTOIN	CASPER PHARMA	\$2,198.00	25mg/5ml	No	1	1	230	\$9.56
25021019111	Micafungin Injection	Micafungin Sodium	SAGENT PHARMACEUTICALS, INC	\$1,870.00	Recommended dosage for adult patients based on indications is 50 mg-150mg daily for a mean duration of treatment of 15-19 days	No	1	10	1	\$187.00
62756006483	Fingolimod	Fingolimod	SUN PHARMACEUTICAL INDUSTRIES INC	\$2,220.97	30 Oral Capsules	No	296,700	1	30	\$74.03
57894044901	TECVAYLI™	teclistamab-cqyv	JANSSEN BIOTECH	\$1,770.00	Injection -30 mg/3 mL (10 mg/mL)	Yes	TS	1	3	\$590.00
57894045001	TECVAYLI™	teclistamab-cqyv	JANSSEN BIOTECH	\$9,027.00	Injection -153 mg/1.7 mL (90 mg/mL)	Yes	TS	1	1.7	\$5,310.00
68462085320	Sodium Phenylbutyrate Tablets 500mg, 250	Sodium Phenylbutyrate Tablets 500mg, 250	GLENMARK PHARMACEUTICALS INC., USA	\$3,000.00	13 mg/sq m/day or 26 tablets/day	No	1	1	250	\$12.00
65219008850	Gadoterate Meglumine	Gadoterate Meglumine	FRESENIUS KABI USA LLC	\$1,084.98	50 MMOL/100ML	No	4,165	6	100	\$1.81
69097090950	Leuprolide acetate suspension 22.5mg	Leuprolide acetate suspension 22.5mg	CIPLA USA, INC	\$1,355.07	22.5 mg for 3 months administration, given as a single intramuscular injection every 12 weeks.	No	22,500	1	1	\$1,355.07
00085222402	NOXAFIL PowderMix	posaconazole	MERCK SHARP & DOHME LLC	\$1,644.72	Pediatric patients weighing at least 10kg: Weight-based dosing of the oral suspension twice daily on the first day and once daily for 20 days	No	17	1	8	\$205.59
42385093412	Lopinavir and Ritonavir Tablets USP	Lopinavir and Ritonavir Tablets USP	LAURUS GENERICS INC.	\$884.76	4 tablets per day	No	1,333	1	120	\$7.37
72903085301	ELAHERE	mirvetuximab soravtansine-gynx	IMMUNOGEN, INC.	\$6,220.00	The recommended dose of ELAHERE is 6 mg/kg adjusted ideal body weight (AIBW) administered once every 3 weeks (21-day cycle) as an intravenous infusion until disease progression or unacceptable toxicity	Yes	150	1	20	\$311.00
67877072031	Everolimus Tablets 0.75mg 6X10	Everolimus Tablets 0.75mg 6X10	ASCEND LABORATORIES LLC	\$750.00	0.75mg	No	1	1	60	\$12.50
67877072131	Everolimus Tablets 1mg 6X10	Everolimus Tablets 1mg 6X10	ASCEND LABORATORIES LLC	\$2,047.50	1mg	No	1	1	60	\$34.13
67877067784	Deferasirox Oral Gran 360mg- 0.620x30's	Deferasirox Oral Gran 360mg- 0.620x30's	ASCEND LABORATORIES LLC	\$4,307.12	360mg	No	1	1	30	\$143.57
42799095001	Vigabatrin Tablets	Vigabatrin Tablets	EDENBRIDGE PHARMACEUTICALS INC	\$10,511.89	Max dosage for adults is 3000mg per day	No	12	1	100	\$105.12
00378089655	Penciclovir 1% Topical Cream	Penciclovir 1% Topical Cream	MYLAN PHARMACEUTICALS INC	\$700.78	The dosage differs based on patient and therefore may vary. See Section 2 "DOSAGE AND ADMINISTRATION" of the attached prescribing information for specific dosage information.	No	101,692,098	1	5	\$140.16
42291047312	Etravirine 100mg	Etravirine 100mg	AVKARE, INC (AKA AVPAK)	\$929.36	Adults – 400mg a day	No	100	1	120	\$7.74
42291047460	Etravirine 200mg	Etravirine 200mg	AVKARE, INC (AKA AVPAK)	\$929.36	Adults – 400mg a day	No	100	1	60	\$15.49
00310450525	IMJUDO 25mg vial	tremelimumab-actl	ASTRAZENECA PHARMACEUTICALS LP	\$3,250.00	25MG/1.25M injection	Yes	1,250	1	1.25	\$2,600.00
00310453530	IMJUDO 300mg vial	tremelimumab-actl	ASTRAZENECA PHARMACEUTICALS LP	\$39,000.00	300MG/15ML injection	Yes	1,250	1	15	\$2,600.00
00574016712	Diclofenac Sodium Topical Solution 2%	Diclofenac Sodium Topical Solution 2%	PADAGIS US LLC	\$1,616.82	The recommended dose is 40mg of diclofenac sodium (2 pump activations) on each painful knee, 2 times a day.?	No	268,000	1	112	\$14.44
73650031601	TZIELD	teplizumab-mzvw	PROVENTION BIO, INC.	\$13,850.00	1 dose(s) per package	Yes	1	1	2	\$6,925.00
73650031610	TZIELD	teplizumab-mzvw	PROVENTION BIO, INC.	\$138,500.00	10 dose(s) per package	Yes	1	10	2	\$6,925.00
73650031614	TZIELD	teplizumab-mzvw	PROVENTION BIO, INC.	\$193,900.00	14 dose(s) per package	Yes	TS	14	2	\$6,925.00

NDC	Trade name	Chemical name	Manufacturer name	Drug price	Drug dosage	FDA priority	Patients per month	Package quantity	Package size	Price per unit
24979071544	Sorafenib Tablets 200mg	Sorafenib Tablets 200mg	TWI PHARMACEUTICALS, USA	\$15,000.00	400mg 2x per day	No	46	1	120	\$125.00
49884012891	Everolimus	Everolimus	PAR PHARMACEUTICAL	\$1,272.17	10mg	No	1	1	28	\$45.43
46287004515	TADLIQ	Tadalafil	CMP PHARMA, INC.	\$1,895.00	40 mg (10 mL) once daily	No	186	1	150	\$12.63

### Number of new specialty drug NDCs reported in 2022 by manufacturer

Manufacturer name	New NDCs reported
SUN PHARMACEUTICAL INDUSTRIES INC	28
TEVA	16
DR. REDDY'S LABORATORIES, INC	16
MYLAN PHARMACEUTICALS INC	15
AMNEAL PHARMACEUTICALS	14
APOTEX CORP	14
FRESENIUS KABI USA LLC	11
CIPLA USA, INC	11
ZYDUS PHARMACEUTICALS USA INC	9
PAR PHARMACEUTICAL	7
ANI PHARMACEUTICALS INC	7
BRISTOL-MYERS SQUIBB, INC	7
RECORDATI RARE DISEASES, INC.	7
AGIOS PHARMACEUTICAL INC.	6
PFIZER	6
UNITED THERAPEUTICS CORPORATION	6
LILLY USA, LLC	6
ASCEND LABORATORIES LLC	6
CASPER PHARMA	6
OAKRUM PHARMA, LLC	6
EUGIA US LLC (FKA AUROMEDICS PHARMA LLC)	5
NOVARTIS	4
ACCORD HEALTHCARE, INC.	4
ALEMBIC PHARMACEUTICALS INC	4
JANSSEN BIOTECH	4
TARO PHARMACEUTICAL USA INC.	4
AVKARE, INC (AKA AVPAK)	4
ABBVIE INC.	4
WOODWARD PHARMA SERVICES LLC	3
VERITY PHARMACEUTICALS INC.	3
ASTRAZENECA PHARMACEUTICALS LP	3
AVERITAS PHARMA, INC.	3
HIKMA PHARMACEUTICALS	3
INGENUS PHARMACEUTICALS, LLC	3
TOLMAR PHARMACEUTICALS, INC.	3
PROVENTION BIO, INC.	3

### Number of new specialty drug NDCs reported in 2022 by manufacturer

Manufacturer name	New NDCs reported
ANALOG PHARMA, INC	3
BIOMARIN PHARMACEUTICAL	3
FOUGERA PHARMACEUTICALS INC	3
GLENMARK PHARMACEUTICALS INC., USA	3
AMERICAN REGENT INC	2
MARINUS PHARMACEUTICALS, INC.	2
EXELAN PHARMACEUTICALS, INC	2
HERITAGE PHARMACEUTICALS INC DBA AVET PHARMACEUTICALS INC	2
TWI PHARMACEUTICALS, USA	2
COHERUS BIOSCIENCE, INC.	2
BIOCON LIMITED	2
PIRAMAL CRITICAL CARE, INC.	2
TELIX PHARMACEUTICALS US INC.	2
AUROBINDO PHARMA USA	2
MITSUBISHI TANABE PHARMA AMERICA, INC.	2
BIOXCEL THERAPEUTICS, INC.	2
AMYLYX PHARMACEUTICALS, INC.	2
SAGENT PHARMACEUTICALS, INC	2
VIIV HEALTHCARE	2
SANDOZ INC	2
PADAGIS US LLC	2
LEO PHARMA INC	2
GLOBAL BLOOD THERAPEUTICS, INC.	2
PRIMUS PHARMACEUTICALS INC	1
TRUPHARMA LLC	1
SOLARIS PHARMA CORP	1
BLUEBIRD BIO, INC.	1
GRANULES PHARMACEUTICALS INC.	1
IMMUNOCORE COMMERCIAL LLC	1
EPIC PHARMA LLC	1
IMMUNOGEN, INC.	1
BIODELIVERY SCIENCES INTERNATIONAL	1
BOEHRINGER INGELHEIM PHARMACEUTICALS INC	1
VIFOR (INTERNATIONAL) INC.	1
ALNYLAM PHARMACEUTICALS INC	1
PHARMAESSENTIA USA CORPORATION	1

### Number of new specialty drug NDCs reported in 2022 by manufacturer

Manufacturer name	New NDCs reported
KEDRION BIOPHARMA INC	1
AMGEN	1
LANTHEUS MEDICAL IMAGING, INC	1
SANTEN USA	1
LAURUS GENERICS INC.	1
SPECTRUM PHARMACEUTICALS, INC.	1
CALLIDITAS THERAPEUTICS US INC.	1
BIOGEN INC	1
LIFESTAR PHARMA, LLC	1
GENZYME CORPORATION	1
ACCORD BIOPHARMA, INC.	1
AADI BIOSCIENCE, INC.	1
MALLINCKRODT HOSPITAL PRODUCTS INC	1
PHARMACYCLICS LLC	1
CERONA THERAPEUTICS, INC.	1
DERMAVANT SCIENCES, INC.	1
MEDUNIK USA, INC.	1
PROGENICS PHARMACEUTICALS INC	1
MERCK SHARP & DOHME LLC	1
EDENBRIDGE PHARMACEUTICALS INC	1
MIRUM PHARMACEUTICALS	1
ETON PHARMACEUTICALS, INC.	1
CHIESI USA, INC.	1
SCIEGEN PHARMACEUTICALS INC	1
MYCOVIA PHARMACEUTICALS, INC.	1
SPECGX LLC	1
CINTEX SERVICES, LLC	1
ARDELYX, INC.	1
NOBELPHARMA AMERICA, LLC	1
FENNEC PHARMACEUTICALS INC.	1
NOSTRUM LABORATORIES, INC.	1
ARGENX US, INC.	1
AMERISOURCE HEALTH SERVICES, LLC	1
GENENTECH INC	1
NOVUGEN PHARMA USA LLC	1
GLAXOSMITHKLINE LLC (AKA GSK)	1

**Number of new specialty drug NDCs reported in 2022 by manufacturer**

<b>Manufacturer name</b>	<b>New NDCs reported</b>
CMP PHARMA, INC.	1
BIOVERATIV US LLC	1
AVION PHARMACEUTICALS, LLC	1
XERIS PHARMACEUTICALS	1
CTI BIOPHARMA CORP	1
ADMA BIOLOGICS, INC.	1
DASH PHARMACEUTICALS, LLC	1
<b>Grand Total</b>	<b>367</b>

### Top 10 new specialty drugs by highest package price

NDC	Trade name	Manufacturer name	Package price
57894011102	CARVYKTI™	JANSSEN BIOTECH	\$465,000.00
57894011101	CARVYKTI™	JANSSEN BIOTECH	\$465,000.00
73650031614	TZIELD	PROVENTION BIO, INC.	\$193,900.00
73650031610	TZIELD	PROVENTION BIO, INC.	\$138,500.00
71336100301	AMVUTTRA	ALNYLAM PHARMACEUTICALS INC	\$115,875.00
00378193701	Lenalidomide 10mg Oral capsule, 100	MYLAN PHARMACEUTICALS INC	\$71,990.62
00378194001	Lenalidomide 25mg Oral capsule, 100	MYLAN PHARMACEUTICALS INC	\$71,990.62
00378194101	Lenalidomide 15mg Oral capsule, 100	MYLAN PHARMACEUTICALS INC	\$71,990.62
00378193601	Lenalidomide 5mg Oral capsule, 100	MYLAN PHARMACEUTICALS INC	\$71,990.62
00597003510	Spevigo	BOEHRINGER INGELHEIM PHARMACEUTICALS INC	\$51,133.00

### Top 10 new specialty drugs by highest price per unit

NDC	Trade name	Manufacturer name	Unit price
57894011102	CARVYKTI™	JANSSEN BIOTECH	\$465,000.00
57894011101	CARVYKTI™	JANSSEN BIOTECH	\$465,000.00
71336100301	AMVUTTRA	ALNYLAM PHARMACEUTICALS INC	\$231,750.00
50242009601	Vabysmo 6mg/0.05ml Vial	GENENTECH INC	\$43,800.00
80446040101	KIMMTRAK	IMMUNOCORE COMMERCIAL LLC	\$37,520.00
70114044101	CIMERLI	COHERUS BIOSCIENCE, INC.	\$27,200.00
64406001901	Byooviz	BIOGEN INC	\$22,600.00
69097087067	Lanreotide Injection 120mg/0.5ml	CIPLA USA, INC	\$17,785.32
70114044001	CIMERLI	COHERUS BIOSCIENCE, INC.	\$16,320.00
47335017795	Ilumya Subcutaneous Solution Prefilled Syringe 100 MG/ML	SUN PHARMACEUTICAL INDUSTRIES INC	\$13,256.00

**Top new specialty drugs by estimated patients per month**

<b>NDC</b>	<b>Trade name</b>	<b>Manufacturer name</b>	<b>Estimated patients per month</b>
00378089655	Penciclovir 1% Topical Cream	MYLAN PHARMACEUTICALS INC	101,692,098
00002149580	Mounjaro	LILLY USA, LLC	34,500,000
00002148480	Mounjaro	LILLY USA, LLC	34,500,000
00002146080	Mounjaro	LILLY USA, LLC	34,500,000
00002145780	Mounjaro	LILLY USA, LLC	34,500,000
00002147180	Mounjaro	LILLY USA, LLC	34,500,000
00002150680	Mounjaro	LILLY USA, LLC	34,500,000
49702026423	APRETUDE 600 mg/3 mL Kit	VIIV HEALTHCARE	1,200,000
00069023530	CIBINQO®	PFIZER	1,200,000
00069033530	CIBINQO®	PFIZER	1,200,000
00069043530	CIBINQO®	PFIZER	1,200,000

## APAC insulin data 2021-2022 by total annual cost per person

<b>Data source:</b>	The Oregon All Payer All Claims (APAC) database*
<b>Date range:</b>	2021-2022 claims data
<b>Payer types:</b>	Commercial insurance. Includes PEBB, OEBC, and self-insured
<b>Demographic notes:</b>	Data is Oregon specific and excludes out-of-state claims
<b>Drug class:</b>	Insulin

### Additional data notes:

The total annual cost per person was calculated by dividing the total annual cost (payer paid and expected patient paid) by the number of claimants.

The "expected patient paid" is the sum of the copay, co-insurance, and other patients cost.

Patient cost data was summed together in the APAC data provided by the Oregon Health Authority (OHA) but could be separated in future requests to see what percentage of individual cost types make up the total cost to the patient.

2021 numbers may be impacted by COVID. 2022 data is 99.9% final but not officially approved until year end.

\*For additional information about Oregon APAC data, please visit the official website:


<https://www.oregon.gov/oha/HPA/ANALYTICS/Pages/All-Payer-All-Claims.aspx>



## Top 10 insulin drugs with the highest total annual cost per person by drug

Year(s): 2021, 2022

Drug class: Insulin




Non-proprietary name / drug	2021	2021	2022	2022
	Total claimants	Total cost per person	Total claimants	Total cost per person
Insulin Glulisine	32	\$5,438	23	\$5,868
Insulin Lispro Protamine & Lispro	105	\$4,928	83	\$5,156
Insulin Aspart (with Niacinamide)	258	\$3,774	287	\$4,606
Insulin Degludec	2,287	\$3,932	2,355	\$3,968
Insulin Lispro-aabc	131	\$3,131	165	\$4,420
Insulin Aspart Protamine & Aspart (Human)	268	\$3,583	197	\$2,630
Insulin Detemir	852	\$3,236	808	\$2,844
Insulin Aspart	4,817	\$2,935	4,545	\$3,128
Insulin Lispro	9,563	\$2,643	9,423	\$2,532
Insulin Glargine	14,437	\$2,486	11,905	\$2,355



## Top 10 insulin drugs with the highest total annual cost per person by proprietary name level

Year(s): 2021, 2022

Drug class: Insulin



	2021	2021	2022	2022
Proprietary name	Total claimants	Total cost per person	Total claimants	Total cost per person
HumuLIN R U-500 KwikPen	152	\$12,386	157	\$12,064
HumuLIN R U-500 (CONCENTRATED)	116	\$12,605	115	\$10,695
Afrezza	15	\$10,013	9	\$11,480
HumaLOG Mix 75/25	11	\$7,626	9	\$7,439
HumaLOG Mix 75/25 KwikPen	59	\$6,008	49	\$6,512
Apidra SoloStar	22	\$5,891	14	\$6,744
NovoLOG	856	\$5,434	863	\$6,210
Toujeo Max SoloStar	408	\$5,574	483	\$5,488
NovoLOG Mix 70/30 FlexPen	124	\$5,177	44	\$5,595
Fiasp	101	\$4,686	108	\$4,934



## Top 10 insulin drugs with the highest total annual cost per person by NDC level

Year(s): 2021, 2022

Drug class: Insulin



11-Digit NDC	Proprietary name	Non-proprietary name / drug	2021 Total claimants	2021 Total cost per person	2022 Total claimants	2022 Total cost per person
47918090218	Afrezza	Insulin Regular (Human)	3	\$25,810	2	\$25,865
47918087890	Afrezza	Insulin Regular (Human)	1	\$24,157	1	\$21,307
00002882427	HumuLIN R U-500 KwikPen	Insulin Regular (Human)	152	\$12,386	157	\$12,064
00002850101	HumuLIN R U-500 (CONCENTRATED)	Insulin Regular (Human)	116	\$12,605	115	\$10,695
00002771227	HumaLOG KwikPen	Insulin Lispro	197	\$7,215	173	\$7,931
00002751101	HumaLOG Mix 75/25	Insulin Lispro Protamine & Lispro	11	\$7,626	9	\$7,439
47918088018	Afrezza	Insulin Regular (Human)	4	\$6,724	2	\$7,980
00002879759	HumaLOG Mix 75/25 KwikPen	Insulin Lispro Protamine & Lispro	59	\$6,008	49	\$6,512
00088250205	Apidra SoloStar	Insulin Glulisine	22	\$5,891	14	\$6,744
00002822827	Lyumjev KwikPen	Insulin Lispro-aabc	6	\$3,703	10	\$7,643



## APAC insulin data 2021-2022 by annual patient cost

<b>Data source:</b>	The Oregon All Payer All Claims (APAC) database*
<b>Date range:</b>	2021-2022 claims data
<b>Payer types:</b>	Commercial insurance. Includes PEBB, OEBC, and self-insured
<b>Demographic notes:</b>	Data is Oregon specific and excludes out-of-state claims
<b>Drug class:</b>	Insulin

### Additional data notes:

The annual patient cost was calculated by dividing the annual "Expected patient paid" by the number of claimants.

The "Expected patient paid" is the sum of the copay, co-insurance, and other patients cost.

Patient cost data was summed together in the APAC data provided by the Oregon Health Authority (OHA) but could be separated in future requests to see what percentage of individual cost types make up the total cost to the patient.

2021 numbers may be impacted by COVID. 2022 data is 99.9% final but not officially approved until year end.

\*For additional information about Oregon APAC data, please visit the official website:


<https://www.oregon.gov/oha/HPA/ANALYTICS/Pages/All-Payer-All-Claims.aspx>



## Top 10 insulin drugs with the highest annual patient cost by drug

Year(s): 2021, 2022

Drug class: Insulin




Non-proprietary name / drug	2021	2021	2022	2022
	Total claimants	Annual patient cost	Total claimants	Annual patient cost
Insulin Glulisine	32	\$813	23	\$273
Insulin Lispro-aabc	131	\$625	165	\$334
Insulin Aspart (with Niacinamide)	258	\$279	287	\$274
Insulin Detemir	852	\$257	808	\$194
Insulin Lispro Protamine & Lispro	105	\$217	83	\$224
Insulin Glargine	14,437	\$227	11,905	\$163
Insulin Degludec	2,287	\$192	2,355	\$165
Insulin Aspart	4,817	\$188	4,545	\$150
Insulin Lispro	9,563	\$151	9,423	\$128
Insulin Aspart Protamine & Aspart (Human)	268	\$136	197	\$75



## Top 10 insulin drugs with the highest annual patient cost by proprietary name level

Year(s): 2021, 2022

Drug class: Insulin




	2021	2021	2022	2022
Proprietary name	Total claimants	Annual patient cost	Total claimants	Annual patient cost
Afrezza	15	\$1,258	9	\$1,094
Apidra SoloStar	22	\$1,043	14	\$158
Lyumjev	60	\$656	76	\$376
Lyumjev KwikPen	71	\$600	89	\$299
Toujeo SoloStar	784	\$487	776	\$347
Apidra	10	\$308	9	\$453
NovoLOG	856	\$406	863	\$323
Toujeo Max SoloStar	408	\$377	483	\$316
Fiasp	101	\$393	108	\$295
HumaLOG Mix 75/25	11	\$326	9	\$239



## Top 10 insulin drugs with the highest annual cost per person by NDC level

Year(s): 2021, 2022

Drug class: Insulin



11-Digit NDC	Proprietary name	Non-proprietary name / drug	2021 Total claimants	2021 Annual patient cost	2022 Total claimants	2022 Annual patient cost
47918087890	Afrezza	Insulin Regular (Human)	1	\$7,948	1	\$3,372
47918089818	Afrezza	Insulin Regular (Human)	1	\$3,728	0	N/A
47918090218	Afrezza	Insulin Regular (Human)	3	\$1,293	2	\$1,673
00088250205	Apidra SoloStar	Insulin Glulisine	22	\$1,043	14	\$158
00002772801	Lyumjev	Insulin Lispro-aabc	60	\$656	76	\$376
00002820705	Lyumjev KwikPen	Insulin Lispro-aabc	65	\$650	79	\$273
47918087490	Afrezza	Insulin Regular (Human)	6	\$334	4	\$596
00024586903	Toujeo SoloStar	Insulin Glargine	784	\$487	776	\$347
00088250033	Apidra	Insulin Glulisine	10	\$308	9	\$453
00169750111	NovoLOG	Insulin Aspart	856	\$406	863	\$323

